{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import uuid\n",
    "import base64\n",
    "from IPython import display\n",
    "from unstructured.partition.pdf import partition_pdf\n",
    "# from langchain.chat_models import ChatOpenAI\n",
    "from langchain_community.chat_models import ChatOllama\n",
    "from langchain_community import embeddings\n",
    "\n",
    "# from langchain.embeddings import OpenAIEmbeddings\n",
    "from langchain.chains import LLMChain\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.schema.messages import HumanMessage, SystemMessage\n",
    "from langchain.schema.document import Document\n",
    "from langchain.vectorstores import FAISS\n",
    "from langchain.retrievers.multi_vector import MultiVectorRetriever"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "output_path = \"./fivedrung_images\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "This function will be deprecated in a future release and `unstructured` will simply use the DEFAULT_MODEL from `unstructured_inference.model.base` to set default model name\n",
      "Some weights of the model checkpoint at microsoft/table-transformer-structure-recognition were not used when initializing TableTransformerForObjectDetection: ['model.backbone.conv_encoder.model.layer2.0.downsample.1.num_batches_tracked', 'model.backbone.conv_encoder.model.layer3.0.downsample.1.num_batches_tracked', 'model.backbone.conv_encoder.model.layer4.0.downsample.1.num_batches_tracked']\n",
      "- This IS expected if you are initializing TableTransformerForObjectDetection from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
      "- This IS NOT expected if you are initializing TableTransformerForObjectDetection from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n"
     ]
    }
   ],
   "source": [
    "raw_pdf_elements = partition_pdf(\n",
    "    filename=r\"C:\\Users\\RAHUL\\Desktop\\chatbot_new\\chatbot\\drug5_refined_scraped.pdf\",\n",
    "    extract_images_in_pdf=True,\n",
    "    infer_table_structure=True,\n",
    "    chunking_strategy=\"by_title\",\n",
    "    max_characters=4000,\n",
    "    new_after_n_chars=3800,\n",
    "    combine_text_under_n_chars=2000,\n",
    "    extract_image_block_output_dir=output_path,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "list"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(raw_pdf_elements)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1156"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(raw_pdf_elements)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<unstructured.documents.elements.CompositeElement at 0x1afd6a633d0>"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "raw_pdf_elements[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<unstructured.documents.elements.CompositeElement at 0x1afcda96dd0>"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "raw_pdf_elements[1100]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/1156 [00:00<?, ?it/s]c:\\Users\\RAHUL\\Desktop\\chatbot_new\\chatbot\\multimodel\\Lib\\site-packages\\langchain_core\\_api\\deprecation.py:117: LangChainDeprecationWarning: The function `run` was deprecated in LangChain 0.1.0 and will be removed in 0.2.0. Use invoke instead.\n",
      "  warn_deprecated(\n",
      "100%|██████████| 1156/1156 [9:27:47<00:00, 29.47s/it]  \n",
      "Processing images: 100%|██████████| 76/76 [1:05:00<00:00, 51.32s/it]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[' The image appears to be a screenshot from an electronic medical record (EMR) system or a similar software interface. It displays what seems to be a clinical lab report, possibly for a patient or sample numbered \"093.\"\\n\\nAt the top of the screen, there are text labels that might represent different sections or options within the EMR: \"PATIENT LIST,\" \"CUSTOMER SERVICE,\" and \"LOGOUT.\" These are likely drop-down menus or tabs for navigating within the system.\\n\\nThe central portion of the image shows a table with columns and rows that could represent various parameters or data points associated with the lab report. The visible text in these cells includes:\\n\\n1. \"093\" which might be the patient number, case number, or sample identifier.\\n2. A date/time stamp that reads \"16/07/2021 15:34,\" indicating when the lab report was generated or accessed.\\n3. Various test results, such as:\\n   - \"CBC w/ Diff\" which stands for Complete Blood Count with Differential (a type of blood cell count), showing numerical values and percentages for different types of cells like white blood cells (WBCs) and red blood cells (RBCs).\\n   - \"Platelets\" followed by a number, likely the platelet count.\\n4. Other test results that are partially obscured due to the resolution or cropping of the image. These may include measurements for hemoglobin (HGB), hematocrit (HCT), and other parameters related to blood cell counts and differential.\\n\\nThe bottom part of the screenshot shows a section titled \"COMMENTS,\" which is often used by healthcare providers to record notes or observations about a patient\\'s test results, medical history, or treatment plan. The visible text in this field is too small and blurry to read accurately.\\n\\nThe color scheme of the interface is neutral with shades of gray and beige, typical for many EMR systems to maintain a professional look. The overall style of the image is utilitarian, focusing on information presentation over aesthetic design. ', ' This image appears to be a graphical representation of data, likely from a scientific or medical study. It is a line graph with a combination of text and numerical values.\\n\\nOn the x-axis, there are specific time points indicated by the letters \\'A\\', \\'B\\', \\'C\\', and \\'D\\'. These labels are not described in terms of units of measurement or scales.\\n\\nThe y-axis represents some sort of metric or measurement, which could be related to biological parameters such as gene expression levels, percentages, or any other variable that is being measured over time. However, without specific labels for the axes, the exact nature of these measurements is not clear.\\n\\nThere are three lines on the graph:\\n\\n1. The line in blue represents a \\'Baseline\\' or control group, which is likely to represent the average or expected value for the measurement over time.\\n2. The dashed line in orange represents the \\'Vehicle\\' or placebo control in a study, often indicating what happens when no treatment or intervention is given.\\n3. The solid line in black represents the group receiving some form of intervention or treatment, which could be an experimental drug or another type of manipulation.\\n\\nThe vertical dashed lines at points \\'A\\', \\'B\\', \\'C\\', and \\'D\\' may indicate significant changes in the measurement over time. These could represent specific events or conditions in the study, such as timepoints where the treatment group deviates significantly from the control or vehicle group.\\n\\nAdditionally, there is a text box on the top left corner of the graph that reads: \"Vehicle - 31.2% (n=76)\". This indicates that at baseline or before any intervention, the vehicle-treated group had an average value for the measured parameter of 31.2%, with a sample size of 76 observations.\\n\\nBelow this text box is another line graph, which includes three lines: \\'Baseline\\', \\'Vehicle\\', and \\'Treatment\\'. This graph shows the mean values over time for each group. The dotted black horizontal line represents the average value from the baseline or control group.\\n\\nThe bottom of the image contains a legend that explains the symbols used to represent the vehicle-treated group, the treated group, and the standard error bars associated with each group\\'s data points. The legend also includes a note indicating that the graph is \\'Probability specified\\' and specifies a \\'2-tailed analysis\\'. This suggests that statistical tests were conducted to determine whether the difference in means between groups was significant at a given probability level (often 5% or 10%).\\n\\nIn summary, the image seems to be from a study comparing the effect of an experimental intervention on a certain measured parameter over time, with a control group and a vehicle-treated group as comparisons. The statistical analysis indicates that the differences observed between the groups were significant at a specified probability level. ', \" The image appears to be a medical scan, specifically an X-ray. It's a lateral chest X-ray, as indicated by the text label in the top right corner. The X-ray shows the lungs and heart area with bones and soft tissues visible. The patient's spine is aligned vertically along the center of the image. There are no visible texts or labels within the image itself that provide additional information about the patient or the medical condition being depicted. \", \" The image you've provided appears to be a medical imaging study, specifically an MRI (Magnetic Resonance Imaging) scan. It shows a cross-sectional view of what seems to be the head and neck region. Here are some observations and interpretations in medical terms:\\n\\n1. **Bone Structures**: We can observe various bones within the skull, including the frontal bone, parietal bones, occipital bone, and the vertebrae of the cervical spine.\\n\\n2. **Soft Tissues**: There are soft tissues present as well, such as muscles and ligaments, which appear to be in their normal anatomical positions relative to the bones.\\n\\n3. **Brain**: The gray matter within the skull is likely brain tissue, including the cerebrum (the large mass of tissue that forms the major part of the brain), which is seen here as a series of darker areas separated by lighter areas, indicating different functional regions of the brain.\\n\\n4. **Fluid-Filled Spaces**: The spaces filled with fluid are likely to be the cerebrospinal fluid (CSF) found within the skull. This fluid helps protect and cushion the brain, as well as facilitate its function.\\n\\n5. **Air Filling**: The areas without dense tissue appear to be air-filled spaces such as the nasopharynx (the part of the pharynx that extends from the nasal cavity into the oral cavity) and possibly parts of the respiratory tract, which are expected to contain air within an MRI scan.\\n\\n6. **Artifacts**: There may be artifacts present due to the imaging process or the presence of metallic implants or foreign bodies, which would appear as dark or bright areas that are not typical tissue.\\n\\n7. **Technical Details**: The scan is likely a T1-weighted sequence, which typically shows more contrast between tissues of different fat content (such as white matter and gray matter) than other weighting schemes.\\n\\n8. **Quality of the Scan**: Without further context or expertise in radiology, it's not possible to determine the quality of the scan or the presence of any abnormalities. The scan appears to be of standard resolution for clinical imaging.\\n\\nPlease note that without a medical license and access to patient information, I can only describe what is visible in the image in general terms. Any interpretation of this image for medical purposes would require the expertise of a qualified healthcare professional. \", \" The image you've provided appears to be a medical-related diagram or graph. It shows a plot with multiple lines, which could represent various parameters over time. These lines might represent different conditions, treatments, or outcomes related to a specific clinical study or case report.\\n\\nHowever, due to the low resolution and lack of context, it is not possible for me to provide detailed text labels on this image that accurately describe each line or the axes' labels, which would be necessary to understand the medical significance of the graph. Moreover, without additional information, I am unable to provide a diagnosis or discuss the content in terms of any specific diseases or conditions.\\n\\nIf you have more context or higher-resolution imagery, I can attempt to provide a more detailed analysis using standard medical terminology. \", ' The image you\\'ve provided appears to be a screenshot of a computer interface, likely related to medical or scientific research given the text present on it. However, due to the limitations of interpreting images without specific context or knowledge about the software being used, I can only describe what is visible:\\n\\n- At the top, there\\'s a graph with multiple lines and markers, suggesting a plot that might represent data over time. The labels \"X\" and \"Y\" indicate the axes of this graph, which are common in scientific plots to denote the independent and dependent variables. However, without specific legends or labels for the axes, it\\'s not possible to determine what the axes represent.\\n\\n- Below the graph, there is a table with several columns and rows. The columns seem to contain headings that could be related to data points or categories, such as \"TIME\" or \"VARIABLE\". Each row likely represents a specific observation or measurement, but without clearer text labels or a context for the data, it\\'s not possible to provide detailed information about this table.\\n\\n- The left side of the interface includes various buttons and icons, which could be used to manipulate the graph or interact with the software. These are typical for software interfaces designed for data analysis and plotting in a scientific or medical context.\\n\\n- The text visible on the image reads \"ERROR - The file is missing\". This suggests that there has been an issue with opening a file, which might be associated with the data being plotted or the settings of the software.\\n\\nThis description is based on the visual content and standard elements found in computer interfaces for scientific or medical analysis software. Without additional context or information about the specific software or the nature of the data, a more detailed interpretation would not be possible. ', ' The image appears to be a graphical representation of medical data, possibly from an electronic health record (EHR) or a clinical study. It displays various pieces of information that seem relevant to the healthcare setting. Here\\'s a description in medical terms:\\n\\n- There are multiple rows, each representing different subjects, with columns for various measurements or parameters.\\n- The rows are labeled with patient ID numbers, and there is a header row at the top which includes \"Patient,\" \"Age,\" \"Sex,\" \"BMI,\" \"Medication,\" and other categories that might be relevant to the medical context.\\n- The age of the subjects is listed in years, and they seem to be adults, as indicated by the \"Age\" column.\\n- The \"Sex\" column indicates either male (M) or female (F), which is standard for demographic data in healthcare settings.\\n- The BMI (Body Mass Index) is a measure of body fat based on height and weight that is commonly used to assess health. It\\'s indicated by the acronym \"BMI\" followed by numerical values.\\n- The \"Medication\" column lists various medications, possibly prescribed to the patients for treatment or prevention of certain conditions.\\n- There are columns labeled with numerical values ranging from 0 to 12. These could represent various measurements or scales used in healthcare, such as blood pressure (BP), heart rate (HR), temperature, etc., but without specific labels, their exact meaning is unclear.\\n\\nPlease note that due to the nature of medical data, it\\'s essential to maintain patient privacy and confidentiality. This image should not be shared or analyzed in a way that could potentially compromise individual patient information. ', ' The image appears to be a screenshot of a computer interface, possibly from a medical imaging or analysis software. However, due to the resolution and angle of the photo, it\\'s difficult to make out specific details about the software or its features. From what can be discerned, there are several elements in the image:\\n\\n1. At the top left corner, there is a text label \"12\" which might indicate a case number or an index within a dataset.\\n\\n2. To the right of this number, there is a column header that reads \"Measures,\" suggesting that data measurements are being displayed.\\n\\n3. There is another column header to the left, but it\\'s not clearly visible due to the resolution.\\n\\n4. The main part of the image shows a table with rows and columns filled with numerical values and possibly some additional information such as dates or other data points.\\n\\n5. In the bottom right corner, there is a partial view of another screen, showing a blurred list with column headers such as \"Date,\" \"Site,\" and \"Measure.\" This suggests that the software might be used for tracking and analyzing measurements over time across different sites.\\n\\n6. There\\'s a button in the bottom left corner labeled \"Add\" which is likely used to input new data into the system.\\n\\n7. The background of the image is gray, providing a neutral backdrop for the text and numerical values displayed on the software interface.\\n\\nThe image does not contain any medical terminology or specific details that are typically associated with medical imaging or analysis. It\\'s more likely that this image represents a generic spreadsheet or data management tool rather than a specialized medical device or software. ', ' The image displays a line graph with text labels. The title of the graph is \"Bone marrow suppression in patients receiving subcutaneous zoledronate 3 mg/kg/day\".\\n\\nOn the x-axis, labeled as \"Days on treatment\", there are time points ranging from 1 to 56 days. On the y-axis, labeled as \"% of bone marrow cells recovered\", there is a range from 0 to 80%.\\n\\nThere are three lines representing different groups of patients: one receiving zoledronate, another receiving no treatment (control), and a third group with a missing label indicating a different drug or intervention. Each line represents the percentage of bone marrow cells recovered over time. The graph shows that all groups have an initial decline in bone marrow cell recovery, but the line representing patients receiving zoledronate has a more gradual decline compared to the control and the group with the missing label.\\n\\nBelow the graph, there is text indicating the \"95% confidence interval\" for the percentage of bone marrow cells recovered on day 40, which is 63 (18) to 72 (21). The asterisk indicates statistical significance between the zoledronate group and the control/missing label group.\\n\\nThe image also contains text labels: \"P value < 0.001\" with an asterisk symbolizing highly significant p-values, and \"Cox model hazard ratio 0.97 (0.86 - 1.08)\" indicating the hazard ratio for a Cox proportional hazards model comparing the zoledronate group to the control/missing label group.\\n\\nThe graph is from a scientific publication or study, which uses statistical methods to compare the bone marrow cell recovery between different treatment groups over time. The asterisk symbolizes statistical significance at p < 0.001, which means there is less than a 0.001 chance that the observed difference in bone marrow cell recovery is due to random variation alone. The Cox model hazard ratio indicates that patients receiving zoledronate have a slightly lower risk of having low bone marrow cell recovery compared to those in the control/missing label group. ', ' The image appears to be a screenshot of a software interface used for medical imaging analysis. The central part of the screen displays a grayscale image that seems to be an MRI (Magnetic Resonance Imaging) scan, which is a type of diagnostic imaging used by radiologists.\\n\\nOn the right side of the image, there is a column with plots and data points, likely representing quantitative analysis results. The plots are labeled \"X Axis\" at the bottom and \"Y Axis,\" indicating the axes for the graph. Additionally, there are numerical values on the left side of each plot, which could be measurements or other analytical data related to the MRI scan.\\n\\nAt the top of the screen, there is a menu bar with text labels such as \"File,\" \"Edit,\" and other options typically found in software applications used for medical analysis. The specific details of the software interface are not visible due to the cropping of the image.\\n\\nThe bottom part of the image shows a watermark or an overlaid pattern, which is common in digital images to prevent unauthorized use. The exact nature of the pattern or text is not clearly visible due to the angle and resolution of the image.\\n\\nPlease note that this description is based on the available visual information and does not include any speculative or imaginary content. ', ' The image shows a graph plotting the relationship between two variables, labeled as \"Average Time to Treatment\" and \"Days on Treatment\". The x-axis represents the average time to treat in hours (Hours), while the y-axis indicates the number of days spent on treatment. There are three data points represented by three distinct markers: a diamond, a circle, and a square, each corresponding to different days on treatment.\\n\\nThe graph is overlaid on top of a beige background and includes grid lines that assist in reading the values for both axes. The title \"Average Time to Treatment\" appears at the top left corner of the image.\\n\\nIn the bottom right corner, there\\'s text providing additional information about the data: \"N = 10\", indicating that the graph is based on a sample size of ten, and \"R2 = 0.93\", which suggests that the fitted curve explains approximately 93% of the variation in the observed data.\\n\\nThe image seems to be from a medical or health-related study, where the average time to treatment is being evaluated for its impact on the duration of therapy. The R-squared value is typically used to evaluate the goodness of fit of a model, with higher values indicating that the model explains more of the observed data. In this case, the R-squared value of 0.93 suggests a strong positive correlation between the average time to treatment and the days spent on treatment. ', ' The image displays a graphical representation of data, which appears to be from a medical or clinical study. Specifically, the image shows a bar chart with several horizontal bars, each representing a specific value within the dataset.\\n\\nAt the top, there is a title that reads \"SCORE OF PATIENTS\". This suggests that the data pertains to some form of scoring system applied to patients, possibly related to health outcomes or clinical measures.\\n\\nEach bar is labeled with a numerical value, ranging from 0 to what seems to be 200, though the actual values are not clearly visible due to the image\\'s resolution and size. The bars appear to be evenly spaced along a horizontal axis that extends across the entire width of the chart.\\n\\nBelow the bars, there is a numerical sequence indicating some form of measurement or scale. This could represent scores for different conditions or variables within the study.\\n\\nOn the right side of the image, there are additional numbers listed without context, which might be related to the data in the bars. These numbers vary from 0 to approximately 85, again with a step value that is not clearly defined.\\n\\nThe bottom part of the image shows what appears to be a color-coded map or a representation of different groups or categories. Each area on this map is filled with a solid color and numbered accordingly. The colors and numbers do not appear to have any labels or legends that provide context for their meaning within the study.\\n\\nThe style of the image suggests it is a screenshot from a presentation or a report, rather than an original artwork or photograph. The background of the image shows a typical computer interface with a menu bar at the top and other software elements, indicating that this is a digital document being viewed on a computer screen. ', ' The image is a digital rendering or a photograph of a sign with text. The text on the sign reads \"SORCERUS\" in large white letters against a blue background at the top of the sign. Below this, there are three lines of smaller white text, which appear to be in Latin. The first line starts with \"COSTUS,\" followed by \"INVESTITATIS,\" and ends with \"EXPEDIVS.\" There is an arrow pointing downwards from the bottom right corner of the sign towards the lower left corner. The arrow has a black outline and a white arrowhead.\\n\\nThe style of the image is informational, with a focus on conveying information about medical costs or investment in healthcare. The Latin text suggests that the content may be related to legal or financial aspects of medicine, such as costs or investments. However, without additional context, it is not possible to provide further details about the specific meaning or purpose of the sign. ', ' The image shows a logo with the text \"Genentech\" prominently displayed. Below the brand name, there is additional text that reads \"A Member of the Roche Group.\" This suggests that Genentech is a subsidiary company within the Roche group.\\n\\nIn terms of medical context, Genentech is a biotechnology company known for its research and development in the field of genetics and human health. The logo itself does not provide any specific information about the company\\'s products or services. However, based on the text \"Genentech,\" we can infer that the company is likely involved in the creation, production, and distribution of therapeutic products designed to improve human health, which could include biologics, vaccines, diagnostic tools, and other healthcare solutions.\\n\\nWithout additional context or details visible in the image, it\\'s difficult to provide more specific information about Genentech\\'s areas of focus, research pipelines, or any particular product or service. The logo serves as a visual representation of the company, indicating its identity within the Roche Group and potentially providing a sense of its commitment to advancing healthcare through genetics. ', ' The image is a scatter plot graph with a title. It appears to be related to medical data, possibly representing the relationship between two variables over time.\\n\\nThe x-axis of the graph is labeled \"months,\" ranging from 0 to 12 months. The y-axis is labeled \"Total WBC (10^3) / MMV,\" indicating that it represents the total white blood cell count per month divided by the mean monthly value over a two-year period.\\n\\nOn the scatter plot, there are several data points, each represented as a small circle. These circles are connected by a line that represents the trend in the ratio of total white blood cell count to mean monthly values over time.\\n\\nAt the top left of the graph, there is a legend with the text \"EVVSD,\" which likely stands for a specific condition or treatment protocol related to oncology. The data points are color-coded and marked by a diamond symbol, indicating different groups or stages within the EVVSD dataset.\\n\\nThe line of best fit (in red) is drawn through the data points, suggesting a relationship between the two variables being measured.\\n\\nBelow the scatter plot, there are two additional lines with the text \"change in WBC (10^3)\" and \"mean line,\" respectively. These likely represent the expected change in white blood cell count over time based on the initial values and the overall trend within the dataset.\\n\\nThe graph includes a shaded area with the title \"95% CI.\" This indicates that there is a confidence interval around the observed data points, which represents the range of values where one could expect to find approximately 95% of the observations if the true underlying population distribution were known.\\n\\nThe overall style and presentation of the image suggest it is part of a medical study or report, possibly related to oncology due to the reference to \"EVVSD.\" The specifics of the study or context are not provided in the image. ', ' The image appears to be a screenshot from a website or digital advertisement related to medical products or information. There are several elements present in the image:\\n\\n1. **Logo and Brand Name**: At the top left, there is a logo with a stylized \\'O\\' that contains a partial depiction of a molecule, suggesting it may be associated with biology, chemistry, or pharmacology. The brand name \"FARMECOS\" is prominently displayed above this logo in bold capital letters.\\n\\n2. **Medical Information**: On the right side of the image, there\\'s a large block of text written in Spanish that seems to be related to medical information or health-related content. The text includes words like \"Dieta,\" which translates to \"diet\" and \"Baja caloria,\" meaning \"low-calorie diet.\"\\n\\n3. **Product Name**: In the center, there is a product name \"FARMECOS\" prominently displayed in larger font size than the surrounding text. This suggests that the product named \\'Farmecos\\' is being promoted or advertised on this website.\\n\\n4. **Medical Advertisement**: The overall style of the image, including the use of colors and layout, resembles a typical medical advertisement or promotional material for health products or services.\\n\\n5. **Visual Representation**: There\\'s an abstract visual representation that includes shapes and lines resembling cells or molecules in the bottom left corner, which could be related to the scientific nature of the product being advertised.\\n\\n6. **Website Information**: At the bottom of the image, there is a URL \"FARMECOS.com.br\" which indicates the website address for this company or product information page. The \".com.br\" extension suggests that the site may be based in Brazil, as it\\'s not a standard top-level domain (TLD).\\n\\n7. **Color Scheme**: The image uses a color scheme primarily composed of shades of gray and beige, with accents of red and green in the text, which could be used to highlight important information or keywords.\\n\\n8. **Text Formatting**: The text within the image varies in size and boldness, suggesting a level of importance or emphasis for certain words or phrases. For example, \"FARMECOS\" is much larger than the surrounding text, making it the focal point of the advertisement.\\n\\n9. **Call to Action (CTA)**: The text \"Baja caloria\" could be interpreted as a CTA for viewers who are interested in weight management or low-calorie options, inviting them to explore more information about the product.\\n\\nThe image is designed to convey information about the brand \\'FARMECOS\\' and its products, likely aiming at potential consumers interested in health or dietary supplements. ', ' The image displays a diagrammatic representation of cellular structures, specifically focusing on the microarchitecture of cells. On the left side of the image is a schematic representation of a typical eukaryotic cell, which includes a nucleus (n), cytoplasm (cy), and cell membrane (m). The nucleus appears to have internal structures, such as chromosomes (ch) and possibly other organelles.\\n\\nThe right side of the image features a zoomed-in view of specific cellular components. This section is labeled \"HE1+,\" which could indicate cells that express protein H (HE1). It shows the following parts:\\n\\n1. Nucleus (n) - The central part of the cell containing DNA and other genetic material.\\n2. Chromatin (ch) - The condensed material found within a nucleus.\\n3. Cytoskeleton (csk) - A network of fibrous proteins that forms in eukaryotic cells.\\n4. Nucleolus (nucl) - A small, dense structure located near the center of the nucleus and contains genetic material.\\n5. Cell membrane (m) - The plasma membrane that encloses all the contents of a cell.\\n\\nBelow these structures is a label \"HE1+,\" which might indicate that the cells express the H protein, although without context, it\\'s unclear what \"HE1+\" refers to in this specific image.\\n\\nIn addition, there is a text box on the left side with a chemical structure diagram (a circular topology), possibly representing a molecule of interest or a pharmaceutical compound being studied. The chemical structure appears to be that of a cyclic peptide.\\n\\nThe overall style of the image is clinical and educational, likely used in a scientific or medical context to illustrate cellular components and molecular structures relevant to cell biology or pharmacology. ', ' The image depicts a scientific illustration and a schematic representation of the molecular structure of a biomolecule, in this case, HER2.\\n\\nStarting with the top left, labeled \"HER2\", we see a detailed 3D model of the HER2 protein, which is a receptor tyrosine kinase (RTK) that plays a key role in the pathophysiology of several cancers. The HER2 molecule is composed of an extracellular domain (ECD), a transmembrane domain (TMD), and an intracellular kinase domain (KD).\\n\\nThe extracellular domain is shown in green, indicating the color for this part of the protein. The transmembrane domain is depicted as the darker green regions, while the intracellular kinase domain is represented by the purple area, showing the different colors used to illustrate the molecular structure.\\n\\nOn the bottom right of the image, there is a schematic diagram with text labels that explain the process of HER2-mediated signaling. The diagram shows HER2 as a dimer (two units linked together), which can then bind to other molecules such as EGFR (depicted in red) and Akt (in purple).\\n\\nThe process starts with ligand binding, where an external signal activates the HER2 receptors. Following this, HER2 undergoes a conformational change that leads to dimerization. The dimer then transphosphorylates each other\\'s intracellular domains, resulting in the activation of downstream signaling pathways such as the PI3K/AKT pathway and MAPK/ERK pathway. This activation ultimately leads to cell proliferation, survival, and resistance to chemotherapy.\\n\\nThe text labels on the diagram are as follows:\\n- \"HER2\" – indicating the name of the protein.\\n- \"Ligand binding\" – showing where the initial interaction occurs.\\n- \"Conformational change leading to dimerization.\"\\n- \"Transphosphorylation\" – illustrating the activation process.\\n- \"PI3K/AKT pathway\" and \"MAPK/ERK pathway\" – indicating the downstream signaling pathways activated by HER2.\\n\\nThis image is educational, likely used in a medical or biology textbook or lecture to explain the molecular mechanisms of HER2 function and its role in cancer development and progression. ', ' The image appears to be an illustration or diagram of the human torso, with a focus on the breast area. It shows a lateral view of the thoracic cage and part of the ribcage. There are texts overlaid on the image.\\n\\nAt the top of the image, there is text that reads \"DON\\'T DRAW ON THE BREASTS,\" suggesting a reminder about not making marks or writing on the breast area of the medical illustration.\\n\\nBelow this, there is an instructional text that says \"Draw on the ribcage to help identify what you are looking for.\" This indicates that the viewer should draw on the ribcage instead of the breasts to aid in understanding or identifying certain structures.\\n\\nThere are also labels on the image:\\n- To the left, under the ribs, there is a label pointing towards the spleen, which appears to be labeled as \"spleen.\"\\n- To the right of this, there is another label indicating \"liver.\"\\n- At the bottom of the image, under the ribcage, there is a label pointing towards the stomach area with the text \"stomach.\"\\n\\nThe image seems to serve an educational purpose, possibly for medical students or individuals learning about human anatomy. The labels are meant to help in identifying different organs within the thoracic cavity. ', ' The image illustrates a concept related to personalized medicine and precision therapies. Here\\'s the breakdown in medical terms:\\n\\n1. **Pharmaceutical Compound**: This is represented by a yellow pill with an \"N\" on it, symbolizing a medication. It is often used in scientific contexts to represent a drug or active substance within a medication.\\n\\n2. **Disease State**: This is depicted as a grey bubble with a cross inside, representing the condition or disease state that the pharmaceutical compound is intended to address.\\n\\n3. **Biological Sample**: The blue bubble with a test tube in it symbolizes a biological sample, commonly used for diagnostic testing or research purposes. It represents the starting point from which information about an individual\\'s health status can be obtained.\\n\\n4. **Genetic Sequencing (DNA)**: This is represented by the helix structure typically associated with DNA. Genetic sequencing is a key component of precision medicine, as it allows for the identification of genetic variations that may play a role in disease or drug response.\\n\\n5. **Computational Analysis**: The red cloud surrounding the genetic sequencing represents computational analysis, which would be used to interpret the results of the genetic sequencing. This process is crucial for understanding the genetic information and how it relates to the individual\\'s health.\\n\\n6. **Pharmacogenomic Testing**: The green bubble with a checkmark in it signifies pharmacogenomic testing, which involves analyzing an individual\\'s genetic material to determine how they might respond to certain medications. This type of test is particularly useful in personalized medicine as it can help in selecting the most effective and safe medication for each individual based on their unique genetic makeup.\\n\\n7. **Personalized Medicine**: The overall concept illustrated here is that of personalized medicine, which takes into account an individual\\'s unique genetic profile, disease state, and other factors to tailor treatment plans specifically for them. This approach has the potential to significantly improve patient outcomes by ensuring that each person receives the most effective care based on their specific needs.\\n\\nThe image also includes text labels:\\n- **PEREIA**: A term that may be specific to a certain field or study, but without additional context, its exact meaning in this image is unclear.\\n- **HEREPITAM & TRANSPORTUM**: These terms are likely referring to two different proteins or molecules (Hererepitam and Transportum) that are relevant in the context of the image. However, without specific knowledge about these substances or their relevance in this context, their exact meaning is unclear.\\n\\nIn summary, the image represents a process where an individual\\'s biological sample undergoes genetic sequencing and computational analysis to identify relevant genetic variations. Based on this information, pharmacogenomic testing is performed to predict how the person will respond to certain medications. The end goal is personalized medicine, which utilizes these findings to tailor treatment plans for each individual based on their unique biological profile and disease state. ', ' The image depicts a stylized icon of a healthcare professional, specifically a nurse or nurse practitioner. This is indicated by the attire and tools typically associated with nursing, such as the stethoscope around the neck, which suggests auscultation skills often required in patient care. The background is minimalistic, featuring shades of gray, which could represent an electronic health record or a digital medical platform interface. There are no texts present on the image itself. ', ' The image appears to be a screenshot of a medical or scientific article with text and graphs overlaid on a plain background. The top part of the image displays a graphic with two timelines, labeled \"6 hours\" and \"1 hour,\" indicating different time intervals for the data presented.\\n\\nThe left timeline shows three horizontal bars, each representing a specific value. At the bottom of this timeline, there is text that reads \"Período de 5h vs. 6h.\" Below this, there are two bars, one labeled with a number and the other with a letter (P), possibly indicating percentages or proportions. The numbers above these bars are not fully visible, but we can see that the left bar is approximately 6 times larger than the right bar.\\n\\nThe right timeline also features three horizontal bars. Each bar is labeled with a number and a corresponding letter (A). These bars represent values similar to those on the left timeline, with the numbers being much smaller in comparison. The bars are approximately half the size of those on the left, as indicated by the text \"6h: 100% vs. 6h: 50%.\"\\n\\nBelow the graphic, there is additional text that reads \"Perojeta PERIODOS DE 5H VS 6H,\" which translates to \"Periods of 5h vs. 6h Project.\" This suggests that the graphic is comparing data across different time periods (5 hours and 6 hours).\\n\\nThe image\\'s content is not specific enough to provide medical or scientific details, but it seems to be a visual representation of some kind of research or study comparing two periods of time (5 hours and 6 hours) in a clinical or experimental context. The exact nature of the data represented by these timelines (e.g., blood pressure, medication administration intervals, patient recovery rates, etc.) is not clear from this image alone. ', ' This image appears to be a screenshot of a product or drug information page from a website or digital platform. The text in the image is partially obscured, but it seems to contain information related to a medication. Here\\'s an attempt at interpreting the visible text:\\n\\n- \"Morphine\" - This could be the name of the active ingredient in the product, which is a strong opioid used for pain relief.\\n- \"1 mg\" - This likely indicates the dosage strength of the medication.\\n- The barcode on the right side typically contains information that can be scanned by pharmacists to verify the product\\'s authenticity and expiration date.\\n- There are several pieces of text in different languages, suggesting that this page is intended for a multilingual audience or is accessible from multiple countries.\\n- The logo \"PHARMA\" with the subtext \"Pharmaceutical Industry\" could indicate the company or the industry group responsible for producing or distributing the medication.\\n- \"Morphine\" - Repeated again, possibly as the name of the product itself or as a brand name associated with the product.\\n- \"5ml\" - This might refer to the volume of the solution in the syringe (which is typically used for injection), indicating that it contains 5 milliliters of morphine.\\n- \"Dosage form: Morphine hydrochloride.\" - This line provides information about the chemical form of the medication, which is a salt of morphine with hydrochloric acid.\\n- \"For subcutaneous injection\" - This sentence informs that this specific dosage form is intended for subcutaneous (under the skin) injection use.\\n- There are additional pieces of text that are too small to be legible, but they likely contain important information about the product\\'s usage instructions, side effects, storage conditions, and other details relevant to the medication.\\n\\nThe overall layout suggests a professional context for providing healthcare or pharmaceutical information to consumers or medical professionals. The design is clean and simple, with a focus on conveying essential product-related data clearly and efficiently. ', ' The image presents a side-by-side comparison of two different vaccines, each represented by an icon and labeled with their names. \\n\\nOn the left, there is a vaccine icon accompanied by text that reads \"PERJETA.\" This likely refers to Perjeta, which is a brand name for bictegrat, a monoclonal antibody medication used to treat certain types of breast cancer. The label on the left also mentions \"HEREPIN,\" suggesting that Herceptin, another monoclonal antibody drug, may be involved in the mechanism or effectiveness of Perjeta.\\n\\nOn the right, there is a vaccine icon labeled with \"PERTUSUMAB.\" This is a brand name for Pertuzumab, which is an anti-HER2 therapy used to treat advanced breast cancers and other HER2-positive tumors. The label on the right also indicates that this drug has been developed by a company called \"PERJETA.\"\\n\\nThe background of the image features a gradient from light to darker tones, providing a contrasting backdrop for the icons and text. The style of the image is informative and educational, designed to compare two vaccines in a visual format that might be used in medical literature or educational materials. ', \" The image provided appears to be a scientific or medical illustration, possibly depicting a cross-section of a biological structure or a schematic diagram related to anatomy. There are no visible texts or labels that can provide specific information about the image.\\n\\nThe central feature seems to represent a circular structure with concentric layers or compartments. The innermost layer is light blue, and it has three distinct circles around it—a light green one at the top, a darker teal-blue circle in the middle, and another light green circle at the bottom. These concentric circles are connected to each other by thin lines that suggest fluid or material movement between them.\\n\\nThe outermost layer is a darker shade of blue and surrounds the central structure, indicating some sort of protective sheath or outer boundary. The layers appear to be cylindrical in shape, with the top and bottom edges of the cross-section visible as well.\\n\\nWithout additional context or information, it's not possible to provide a detailed interpretation or identification of what this image represents. It could be a model of cells within an organelle, a representation of the layers in a specific biological structure, or even an abstract concept from a scientific or medical field. \", ' The image displays a pie chart with a legend and a title. The chart is superimposed on a light grey background. At the top of the image, there\\'s a title that reads \"85%\" in bold black text, which appears to be a percentage value associated with the chart.\\n\\nThe pie chart itself shows three distinct segments. Starting from the bottom right and moving clockwise, we see:\\n\\n1. The smallest segment is labeled as \"14%\" and is colored in blue. This piece represents 14% of the whole.\\n2. The middle segment is larger than the first but smaller than the third and has a label that reads \"85%,\" indicating this segment constitutes 85%. It\\'s depicted with a shade of green.\\n3. The largest segment is at the top left and is labeled as \"1%.\" This segment represents only 1% of the whole, being significantly smaller than the other two segments.\\n\\nTo the right of the pie chart, there is a legend that explains the colors and their corresponding percentages:\\n\\n- Blue corresponds to 14%.\\n- Green corresponds to 85%.\\n- Black text indicates \"1%,\" although no area of color on the pie chart matches this label. This discrepancy might be an error in the image or could represent a data point not shown visually.\\n\\nThe style of the image is informative and appears to be a screenshot from a presentation or an article related to statistics or medical research, given the context of percentages that are typically associated with quantitative analysis in health sciences. The text \"85%\" at the top suggests the pie chart represents a large majority or dominant group in comparison to the smaller segments. ', ' The image is a digital illustration that features a stylized graphic of a clock with the time \"3:10\" visible on its face. Superimposed on this clock are two thumbs-up symbols, one on each side. To the right of the clock, there\\'s a small icon that resembles a mobile phone. The style of the illustration is flat and uses limited colors, which gives it a modern, minimalist aesthetic. There are no texts or labels present in the image. ', ' The image appears to be a screenshot of a webpage or advertisement featuring medical products. At the top, there\\'s a logo with a stylized letter \"G\" and below it is the name \"THE GIGA,\" which could suggest a brand or company name. The text \"HARMONIZED WATER INJECTION 70ml\" is prominently displayed in a white rectangular background, indicating that the product is harmonized water for injection, and the volume is 70 milliliters.\\n\\nIn the upper portion of the image, there\\'s additional text that is partially obscured; however, the visible part reads \"BIBLIOTECA DE CONTENIDOS,\" which translates to a \"content library\" in English. This suggests that the webpage may provide more information or resources related to the product or health topics.\\n\\nBelow the logo and brand name, there\\'s another block of text that is too small to read clearly from this image. However, it seems to contain additional information about the product or company.\\n\\nThe bottom right corner features a QR code, which is typically used to link to more detailed information about the product when scanned with a smartphone camera. There are also two small icons or symbols that might represent social media platforms, but they are too small and blurred to discern their exact purpose or function.\\n\\nThe image is taken from a computer monitor displaying a webpage, as indicated by the pixelated quality of the text and the overall layout of the webpage. The style of the image is digital, likely representing an online presence for medical products or information. ', ' This image is a medical illustration that depicts a side view of the human lower limb and torso. The upper part of the image shows the waist, abdomen, and upper legs, which includes the hip, thighs, and a portion of the buttocks with what appears to be a silhouette of a person standing.\\n\\nOn the right side of the lower limb, there are two green rectangles that represent different levels of muscular development. The one on the left is labeled \"Frail,\" indicating a less developed muscle group, and the one on the right is labeled \"Fit,\" suggesting a more toned muscle structure.\\n\\nThe image also includes a small inset image at the top left, which seems to be showing an MRI (magnetic resonance imaging) scan of the lower back region with a focus on the spinal column and lumbar area. The inset is labeled \"LUMBAR SPINE,\" with an arrow pointing at a specific area on the scan, but without context or more information, it\\'s difficult to provide details about this inset.\\n\\nThe overall style of the image is clinical and educational, designed to illustrate differences in physical fitness levels in a medical setting. ', ' The image depicts a graphical representation of the duration of various injections. At the top of the image, there is a title that reads \"8 minutes vs 5 minutes\". The two main timelines are labeled \"1st Injection\" and \"Future Injections\", which visually represent a comparison between these two types of injection processes.\\n\\nOn the left side of the image, labeled \"1st Injection\", we see a timeline indicating that this injection process takes 8 minutes to complete. On the right side, labeled \"Future Injections\", the duration has been reduced from 8 minutes to 5 minutes. This implies a significant improvement in the administration time for future injections.\\n\\nIn the bottom left corner of the image, there is a note stating that it took 30 minutes to prepare the first injection. This suggests that the preparation process was quite lengthy for the initial injection but has since been streamlined.\\n\\nOverall, the image conveys a message of efficiency improvement in medical procedures, particularly with regards to injection administration times. The use of a timeline format effectively communicates the time-saving aspect of the change from the first injection to future injections. ', ' The image appears to be a diagram or illustration related to the COVID-19 pandemic, specifically focusing on the use of therapeutic agents in the treatment and management of severe cases.\\n\\nAt the top left corner, there is a blue rectangular label with white text that reads \"PHASE 2: MANAGEMENT.\" This label likely refers to a second phase or stage in managing COVID-19 patients, which could include hospitalization or intensive care treatment.\\n\\nBelow this, on the right side of the image, there is an injection syringe labeled \"OXYGEN SUPPORT.\" This suggests that oxygen therapy is part of the management phase for severe cases of COVID-19.\\n\\nTo the left, there is a black arrow pointing from the syringe to the text label \"HEPARIN THERAPY.\" This implies that heparin therapy is also included in the management phase. Heparin is an anticoagulant drug used to prevent blood clots and is commonly administered via injection.\\n\\nThe bottom right corner of the image shows a diagram of a syringe with a needle connected to a clear plastic tube, labeled \"SURGERY.\" This indicates that surgery might be part of the treatment process for severe COVID-19 cases, although the specific type of surgery is not specified within the visible text.\\n\\nThe background of the image is plain white, which helps focus attention on the medical items and labels. The overall style of the image is informational or instructional, aiming to convey the types of treatments and interventions that might be considered in the management of severe COVID-19 cases. ', ' The image depicts a medical infographic with a cartoon illustration style. On the left side of the image, there is a visual representation of a surgical instrument and a syringe labeled \"Surgery.\" A dashed arrow pointing from the surgery icon to the syringe icon suggests a relationship between the two procedures.\\n\\nOn the right side, there are two additional icons with accompanying text labels. The first icon shows a pair of scissors with a label that reads \"Phesgo,\" indicating this could be a specific medication or treatment associated with the surgery. Below the pair of scissors, another dashed arrow points to a syringe labeled \"Phsesgo,\" suggesting that the same medication is given via an intravenous route.\\n\\nBelow these icons, there\\'s a caption in bold text that states, \"1 year later...\" followed by a bullet point explaining, \"I\\'m up to 10 cycles.\" This caption implies that the patient has been on treatment for one year and has completed ten cycles of therapy.\\n\\nThe overall message conveyed by the image is a visual timeline or progression from surgery to ongoing medical care involving the use of Phesgo, which seems to be an intravenous medication associated with the surgical procedure. The caption suggests that this treatment process has been ongoing for a significant period, as indicated by the completed \"cycles.\" ', ' The image appears to be a humorous or satirical depiction of the concept of \"PHESGO\" and its relation to COVID-19 (COVID) vaccinations. On the left side, there is an illustration of a syringe with the label \"DOCETAXEL,\" which is a chemotherapeutic drug often used in cancer treatment. On the right side, there\\'s a depiction of the COVID-19 vaccine vial, indicating that both drugs are related to treatments for different diseases.\\n\\nThe word \"PHESGO\" is written at the top left corner, suggesting it might be a term or an acronym relevant to this context. However, without additional information, the specific meaning of \"PHESGO\" in this image is unclear. The text \"continue until the side effects become too difficult to manage\" is adjacent to \"DOCETAXEL,\" humorously suggesting that one should continue with a treatment (such as a vaccine) even when side effects are severe.\\n\\nThe text \"minimum of 6 cycles\" is positioned between \"PHESGO\" and \"DOCETAXEL,\" which in a medical context likely refers to the number of cycles or rounds of chemotherapy that an individual undergoes before deciding if additional treatment is necessary. The word \"COVID\" is placed next to the illustration of the vaccine vial, directly associating the COVID-19 vaccine with \"PHESGO.\"\\n\\nThe image seems to be a play on the idea of \"PHESGO\" as being related to or associated with the need for multiple doses of the COVID-19 vaccine. The humor arises from the juxtaposition of the serious and potentially dangerous nature of chemotherapy (represented by \"DOCETAXEL\") with the more routine and generally less severe side effects typically experienced after receiving COVID-19 vaccinations.\\n\\nPlease note that this description is based on the visual content and text provided in the image, and interpretations may vary depending on the context in which the term \"PHESGO\" was originally used or intended. ', ' The image shows a logo with the text \"ALEXANDRIA\" prominently displayed at the top. Below this, there is a subtitle that reads \"Hepatitis C\", indicating that the logo might be related to a brand or product associated with treatments or management of Hepatitis C.\\n\\nThe main visual element of the logo is a stylized representation of a molecule, which could symbolize a medical, pharmaceutical, or biological context. This molecule graphic features a central structure that resembles a spheroid with various arms and appendages that branch outward. The colors used in the logo are primarily shades of gray, black, and white, with hints of green and blue that might suggest natural elements or the environment within which Hepatitis C occurs.\\n\\nIn the upper right corner of the image, there is a small icon that looks like a shield with three arrows pointing outward, possibly representing some form of protection or defense against the effects of Hepatitis C. This could be interpreted as a visual metaphor for the brand\\'s commitment to safety, health, or wellness.\\n\\nThe overall style of the logo is modern and minimalist, with clean lines and a lack of clutter. The use of negative space around the central graphic suggests a focus on simplicity and elegance in design. ', ' The image appears to be a graphical representation of clinical trial data. It\\'s a scatter plot with x-axis labeled \"Response,\" which could represent the level or duration of response to treatment, and y-axis labeled \"Toxicity,\" which likely represents the severity or frequency of adverse events or toxicities in the study. The horizontal line at the top indicates that there is no response (possibly an absence of efficacy) below this threshold.\\n\\nThe vertical dashed lines represent specific thresholds, such as the 10% and 30% thresholds for response rate. These lines seem to be used to define different groups or categories based on the response rates observed within the trial. For example, \"95% Confidence Interval\" suggests that this plot is intended to indicate a statistical range within which the true response rate is believed to lie with 95% confidence.\\n\\nThe x-axis shows numerical values ranging from -1 to about 3. These numbers could represent ordinal or categorical variables, such as stages of disease progression or levels of therapeutic efficacy, rather than continuous measurements.\\n\\nThe graph includes a legend indicating that the data points are color-coded based on specific criteria, although the exact nature of these criteria is not explained in the image. The legend suggests that there are two categories represented by different symbols: \"Best Supportive Care\" and another category that seems to be a combination of supportive care with something else, which could possibly refer to an intervention or control arm in a clinical trial.\\n\\nThe text labels and the format of the data suggest that this image is likely from a medical journal or report describing a clinical trial for a disease or condition. The specific terms used here are \"Best Supportive Care,\" which implies a standard treatment approach without a new experimental therapy, and another category that seems to be related to the use of the drug or intervention being tested in the trial.\\n\\nThe image is not high-resolution, but the text labels and symbols for the data points can be discerned with clarity. The overall impression is that of an academic paper or presentation slide summarizing the results of a clinical trial, specifically focusing on the efficacy and toxicity profile of a particular intervention in the treatment of a certain disease or condition. ', ' This image appears to be a graph from a medical or health-related study. The graph is a plot of two variables, with one on the x-axis and the other on the y-axis, indicating a scatterplot.\\n\\nThe x-axis is labeled \"Months,\" suggesting that the data points represent values measured over time in months. There are numerical values at each month marking the timeline, which start from \"1\" and end with \"17.\"\\n\\nThe y-axis is labeled \"Death rate per 100 population,\" indicating that the vertical axis represents a measure of mortality or fatalities per unit population. The scale on the y-axis shows values ranging from \"0.125\" to \"0.869.\"\\n\\nOn the graph, there are several data points that represent specific months and corresponding death rates per 100 population. These points show a general increasing trend from left to right, with some fluctuations in the death rate over time.\\n\\nThere is a legend in the upper left corner of the image that provides context for the data points: \"Death rate per 100 population,\" \"95% confidence interval,\" and \"Observed number of events.\" These labels indicate that the graph represents a statistical analysis of mortality rates, with error bars indicating the uncertainty or variability in the observed death rates.\\n\\nAdditionally, there are two lines on the graph: one solid line and one dashed line. The solid line seems to represent the actual measured data points, while the dashed line appears to be a smoothed curve that might represent a trend or model fitted to the data.\\n\\nThere is also a small text label in the lower left corner of the image stating \"N = 100,\" which suggests that the observed number of events (deaths) is based on a sample size of 100 observations. This implies that the graph is likely from a statistical analysis with a relatively small dataset.\\n\\nThe overall style of the image is clinical and academic, consistent with scientific research in fields like public health or epidemiology. The text labels and the scatterplot itself are standard elements of a graphical representation of data from a study or a report. ', ' The image appears to be a scatter plot graph, possibly from a medical or scientific study. On the x-axis, there is a variable labeled as \"Cumulative Survival,\" which indicates the proportion of individuals who are still alive at different time points (marked by the ticks on the horizontal axis). The y-axis is labeled \"Tecentin,\" suggesting that this may be related to data collected using Tecentin, which could be a specific type of monitoring or measurement.\\n\\nThe graph itself shows a series of scattered dots, indicating various time points at which individuals were still alive. There is a line drawn through these dots with an irregular shape, which represents the trend in survival over time. The line seems to show that survival rates initially increase and then decrease as time progresses.\\n\\nIn the lower left corner of the image, there\\'s a text label \"Fit Survival Model\" followed by \"Y = 1 - EXP(-X/T),\" which suggests that an exponential decay model has been used to fit the observed survival data. This is a common method in survival analysis to estimate long-term survival rates based on shorter periods of observation.\\n\\nIn addition, there\\'s a text label \"Deviation from Tecentin,\" indicating that the y-axis values are relative to what would be expected under the assumed Tecentin model, assuming there is a baseline expectation for survival over time. This could mean that the actual survival rates deviate from what was predicted by the Tecentin model in some cases.\\n\\nThe image has been edited to include a large red arrow pointing diagonally downwards and then horizontally, which seems to be an anomaly or an outlier in the data set. This could represent an individual whose survival rates do not follow the general trend indicated by the line.\\n\\nOverall, the graph is a visual representation of how survival rates change over time for individuals being monitored by Tecentin, with the red arrow highlighting an unusual pattern that deviates from what might be expected based on the assumed model. ', ' This image is a graphical representation of clinical trial data. It shows a line graph with the x-axis labeled \"Months\" and the y-axis labeled \"% of subjects available for follow-up.\" The line represents the percentage of subjects at different time points in a study, ranging from 1 to 24 months post-treatment.\\n\\nAt the bottom of the image, there\\'s a text label that reads \"Survival (%) vs. Time (months).\" This indicates that the graph is comparing the survival percentage over time.\\n\\nThe title at the top left corner states, \"SURVIVAL OF 89 PATIENTS WITH PRIMARY TUMOR COMPARING FOLLOW-UP OF CHEMOTHERAPY AND NO FOLLOW-UP.\" This suggests that the graph is comparing survival rates between patients who received chemotherapy (with follow-up) and those who did not receive it.\\n\\nThe y-axis scale ranges from 0 to 1, indicating a 100% survival rate, with increments of 10%. The x-axis scale ranges from -1 to 24, which could be the number of months after treatment or another measure of time.\\n\\nThere are several data points on the graph that represent different time intervals and the corresponding percentage of subjects who were available for follow-up. However, without additional context, it is not possible to provide specific values for each data point. ', ' The image appears to be a scatter plot graph from a medical study, specifically showing the relationship between two variables: \"Level of Protein\" on the x-axis and \"Disease Prevalence\" on the y-axis.\\n\\nThe title of the graph is not visible in this crop of the image. The horizontal axis is labeled with the \"Level of Protein,\" ranging from 0 to 1, while the vertical axis indicates the \"Disease Prevalence,\" measured as a percentage.\\n\\nOn the right side of the graph, there are two distinct trends represented by dotted lines connecting individual data points:\\n- The solid line with filled circles represents the data for one group or category.\\n- The dashed line with open circles represents the data for another group or category.\\n\\nThe data points and the lines connecting them show a general increase in disease prevalence as protein levels increase, with the trend being steeper for the dashed line than the solid line. This could imply that there is a stronger association between protein level and disease prevalence for the group represented by the dashed line. The graph does not include any text labels indicating the specifics of the study such as the name of the protein, the type of disease, or the significance of the observed trend.\\n\\nThe image is cropped in such a way that the top left corner where the title and possibly additional information about the study would be located is cut off. This leaves the exact context or purpose of the graph unclear without further data. ', ' The image shows a scatter plot with a logarithmic scale on the x-axis, representing survival time in months. On the y-axis is the cumulative probability of survival, which appears to be falling over time. The plot includes a dashed line that likely represents the upper bound for the survival rate, suggesting that a higher proportion of patients survived up until this point and then starts to decline.\\n\\nAt the top left corner of the image, there\\'s a label indicating \"100%,\" which is presumably the initial survival rate at the beginning of the study or observation period. This baseline indicates 100% survival probability for all patients. The plot shows that as time progresses, the number of patients who are still alive decreases and their cumulative probability of survival drops below this line, indicating a decline in the survival rate over time.\\n\\nThere\\'s also a horizontal axis labeled \"Months,\" with numbers ranging from 0 to 26 months after some initial point, though it is not clear what this point represents (e.g., the start date of the study). The vertical axis on the right side of the image has numerical values ranging from 1 to 100, but without a specific scale provided in the text or labels within the image, it\\'s difficult to determine the exact meaning or interpretation of these numbers.\\n\\nThe image is typical of medical plots used to visually present survival data from clinical trials or observational studies, with a focus on how patient outcomes change over time. The decline in the line suggests that the proportion of patients surviving decreases as time passes, which could indicate worsening disease conditions or treatment failure. ', ' The image appears to be a scatter plot graph, which is commonly used in medical research and statistics to visualize the relationship between two variables. Here\\'s a breakdown of the elements present:\\n\\n1. **Title**: At the top left corner, there is a title \"Cox proportional hazards regression,\" which suggests that the graph represents the results of a Cox proportional hazards model, a statistical method used to analyze time-to-event data in medical research.\\n\\n2. **X and Y Axes**: The graph has two axes, one vertical (Y) and one horizontal (X). However, without specific labels, it\\'s not possible to determine what the axes represent. They could be variables such as time of an event or a patient characteristic, but this would require context that is not provided in the image.\\n\\n3. **Data Points**: There are several dots scattered across the graph, which likely represent individual data points from the dataset being analyzed. Each dot represents an observation in the dataset, with the location on the graph indicating the values of the two variables for that particular observation.\\n\\n4. **Regression Line**: A straight line is overlaid on the graph, which serves as a model fit for the data. The slope and intercept of this line can provide information about the hazard rate and its association with the predictor variable.\\n\\n5. **Residual Error Bars**: To the right of each dot, there are horizontal bars labeled \"Residual error.\" These represent the difference between the observed event time for an individual and the expected event time based on the Cox proportional hazards model. A smaller residual indicates that the model is better at predicting the event time for that particular observation.\\n\\n6. **Statistical Significance Indicators**: There are three asterisks present on the graph: one to the left of the line, another in the middle, and a third to the right. These typically indicate statistical significance levels (e.g., p < 0.05) for the hazard ratio associated with each predictor variable. The presence of these stars suggests that the researchers have performed a regression analysis and are reporting on the statistical significance of their findings.\\n\\n7. **Predictor Variables**: There is no text within the image to identify what the predictor variables (independent variables) might be, so it\\'s not possible to provide details about them.\\n\\nThe specific context, such as the nature of the event being analyzed or the significance of the observed relationships, would require additional information that is not provided in the image. ', ' The image is a medical chart with graphical and numerical data. It appears to be a scatter plot or time series plot showing changes in the levels of something over time, represented on the y-axis by a line graph that seems to decrease from left to right. The x-axis represents time, but the specific time points are not labeled.\\n\\nThe title \"Tecentro\" is present at the top left corner, suggesting that this chart may be related to Tecentro, which could be a drug or therapeutic regimen. Below the title, there are three labels:\\n\\n1. \"TECENTRO\"\\n2. \"Cardiopulmonary\"\\n3. \"Plasma\"\\n\\nThe label \"Cardiopulmonary\" may refer to cardiovascular and pulmonary effects or measurements, while \"Plasma\" could indicate the presence of something in the bloodstream.\\n\\nIn addition to the graph, there are numerical values indicated by dots along the y-axis. These appear to be concentration levels measured in nanograms per milliliter (ng/mL) for the \"Cardiopulmonary\" and \"Plasma\" categories. However, without a clear legend or additional context, it is not possible to determine what these values represent precisely.\\n\\nThe chart also includes a vertical dashed line with numerical values from 0 to 100, which might indicate some sort of threshold or range of interest for the data being presented. There are no visible annotations on this line.\\n\\nBelow the main graph, there is another smaller graph showing a similar trend as the main graph but with different symbols and additional numerical values along the y-axis that seem to correspond to specific time points. This could represent a secondary parameter or a comparison between two measurements over time.\\n\\nThe overall style of the image suggests it may be from a scientific study or clinical trial, used to present data in a clear, visual format for analysis and discussion. ', ' The image appears to be a graphical representation of medical data, likely from a clinical study or a similar research context. It is a line chart with a title and axis labels which provide information about the data being presented.\\n\\nTitle: \"Average Risk of Mortality in Patients on TPI Antagonist Therapy\"\\n\\nAxes Labels:\\n- X-axis: \"Days Post-Transplantation\" - Indicates the time elapsed since the transplant operation.\\n- Y-axis: \"Mortality Rate\" - Represents the percentage of patients who have died during that period of time.\\n\\nThe chart shows a line graph with two lines, each representing a different group of patients:\\n1. The solid line represents the average risk of mortality for patients receiving TPI antagonist therapy.\\n2. The dashed line represents the average risk of mortality for patients not receiving TPI antagonist therapy.\\n\\nBelow the chart is a watermark text \"GREYSCALE\" which seems to indicate that the image may be a screenshot from a presentation software or a digital document where the color palette has been set to grayscale.\\n\\nThe purpose of this chart is to compare the mortality rates between patients on TPI antagonist therapy and those not receiving it, over time after transplantation. ', ' The image appears to be a graph or a chart, which is likely used in a medical or scientific context. It shows a plot with two y-axes and one x-axis, indicating that it\\'s a three-dimensional graph (3D).\\n\\nOn the left y-axis, there is a numerical scale from 0 to 968, though no specific values are labeled within this range. On the right y-axis, there is a categorical scale with five labels: \"TETRAC,\" \"BEZPEĆNA,\" \"BELAJNIK,\" \"NAPOJ,\" and \"NEPRAK.\" These terms suggest that they may refer to different types of patients or groups, possibly indicating the nature of the medical study.\\n\\nThe x-axis is labeled with \"Time (months),\" indicating that this graph represents data collected over time in months. The axis has numerical values ranging from 0 to around 142.\\n\\nThere are two plots on this graph: a black plot and a white plot. These plots likely represent different types of data or different groups of patients, as suggested by the labels on the right y-axis. The black plot is labeled \"TETRAC,\" while the white plot is labeled \"NAPOJ.\"\\n\\nThe x-axis values are not explicitly labeled, but they range from 0 to just above 142. This suggests a time span of several months.\\n\\nThere is a legend on the left side of the image that appears to provide information about the data represented in the graph. The legend uses a combination of colors (black and white) to differentiate between different types of data or patient groups, which are likely related to the terms on the right y-axis. However, the text in the legend is not fully legible due to the image\\'s resolution.\\n\\nThe image itself has a watermark that reads \"TETRAC,\" and there appears to be an overlay or annotation that says \"BEZPEČNA\" at the top left corner. This could indicate that this graph was produced by or for the Tetrac group, possibly related to a study or clinical trial involving patient groups labeled \"TETRAC,\" \"BEZPEČNA,\" \"BELAJNIK,\" \"NAPOJ,\" and \"NEPRAK.\"\\n\\nThe watermark suggests that the image might be associated with a research paper or presentation, where such terminology would be part of the study design. The overall style of the image is that of an academic or clinical publication, with a focus on quantitative data representation. ', ' This image appears to be a grayscale photograph of a medical document or chart. It shows a graph with various lines, each representing different data points, likely related to patient monitoring or clinical trial results. The graph includes labels indicating time in hours (e.g., \"0.25\", \"0.49\", and \"0.73\"). There are also numerical values alongside the time axis, which might represent specific measurements or observations at those times.\\n\\nThe chart contains a grid that helps to visually organize the data points. There is a line with dots labeled \"SENSOR,\" which suggests that this line represents some form of continuous measurement, perhaps physiological parameters, over time. Another line, marked as \"ACTUATOR,\" appears to follow a different trend or pattern compared to the sensor line, indicating some sort of intervention or manipulation over the same time period.\\n\\nOn the right side of the image, there is additional numerical data presented in a tabular format. The table seems to include rows with timestamps and columns with numerical values that could be related to the data points on the graph. However, without specific labels for the columns or context for their significance, it\\'s difficult to provide a precise interpretation of this table.\\n\\nThe overall style of the image is utilitarian and clinical, with a focus on presenting data in a structured and analytical manner that is typical of medical records or scientific research reports. The grayscale nature of the image may suggest that it was taken from an electronic device displaying the graph and table as part of a larger system for patient care, medical research, or educational purposes. ', ' The image displays a line graph with a title and axes labels. The graph is a plot of a longitudinal study or a time series analysis, as indicated by the \"Time (months)\" horizontal axis. It appears to track some sort of data over a period of time, which is not specified in the visible part of the image.\\n\\nThe vertical axis is labeled \"Cumulative incidence,\" suggesting that the graph represents the cumulative number or percentage of cases occurring over the time period. The y-axis ranges from 0 to approximately 200, although the specific units (such as cases, events, etc.) are not provided in the visible part of the image.\\n\\nThe line representing the data is plotted with a few small peaks and valleys, indicating periods of higher and lower incidence rates. The peaks suggest there may have been increases in the cumulative incidence over time at certain points, while the valleys indicate periods of decreasing incidence.\\n\\nAt the top left corner of the image, there is a legend or a key with text that reads \"Trend 45678.\" The number \"45678\" could possibly refer to a specific trend line on this graph, as it suggests a categorization of data points according to different trends.\\n\\nThe background is plain white, which contrasts with the black and gray lines and grid that represent the graph. There are no visible texts other than those associated with the graph, and the style of the image is typical for scientific or medical presentations, where graphs are used to visually represent data over time. ', ' This image shows two diagrams of the human lung, illustrating different states or processes. The left side of the image features a \"Healthy Lung\" with annotations pointing to various structures and their functions within the respiratory system. It highlights the bronchial tree, which includes the trachea, bronchi, and smaller bronchioles leading to terminal bronchioles where gas exchange occurs. The lung parenchyma is also labeled, indicating the spongy tissue that helps in gas exchange.\\n\\nOn the right side, there\\'s a \"Diseased Lung\" diagram, which appears to show what happens to the lungs when they are affected by emphysema or chronic obstructive pulmonary disease (COPD). The main differences from the healthy lung include thickened bronchial walls and inflammatory cell infiltration, suggesting airway obstruction. There are also annotations pointing to the increased size of airspaces and decreased efficiency of gas exchange, as well as possible accumulation of mucus in the airways, which is a common symptom in COPD patients.\\n\\nThe text labels on both diagrams provide educational context about the anatomical structures depicted, such as \"Trachea\" and \"Bronchioles,\" as well as functional aspects like \"Gas exchange.\" The label \"Mucus accumulation\" points to the increased presence of mucus in the affected lung.\\n\\nThe image is likely used for educational purposes to help people understand what happens to the lungs when diseases such as COPD or emphysema affect them, leading to reduced lung function and the symptoms associated with these conditions. ', ' The image appears to be a medical illustration or diagram, possibly from an educational material such as a textbook, journal article, or patient information brochure. It depicts a detailed cross-sectional view of the human thorax and lungs, focusing on the respiratory system and its function in breathing.\\n\\nThe image is labeled with various text labels that provide information about the anatomy depicted:\\n\\n1. At the top, there is a label \"Non-small cell lung cancer,\" indicating that this diagram may be discussing the impact of cancer on lung tissue.\\n2. Below this title, there\\'s a smaller subtitle that reads \"Primary tumor,\" pointing to the area within the lungs where the primary tumor resides.\\n3. There is an inset image with a marker labeled \"Lymph node,\" which is typically part of the immune system and helps filter out bacteria and viruses.\\n4. The main body of the image shows the trachea, bronchial tree, alveoli, and pleura (the lining that covers the lungs).\\n5. The label \"Breathing\" points to the overall process of breathing, emphasizing the role of the respiratory system in this physiological function.\\n6. The diagram also mentions \"Stem cells,\" which are not visible but may be related to the regeneration or repair of lung tissue.\\n7. A small label with a star indicates \"Mesothelium,\" which is the membrane lining the pleural cavity and surrounding the lungs, heart, and diaphragm.\\n8. The image also mentions \"Primary tumor,\" indicating where the cancerous cells have originated in this illustration.\\n9. There are labels that point to the \"Trachea,\" \"Bronchial tree,\" and \"Alveoli,\" which are part of the anatomical structure that allows for gas exchange during breathing.\\n10. The diagram also shows the \"Pleura\" and \"Lymph node,\" which are involved in immune function and protection against infections.\\n11. At the bottom, there\\'s a label indicating \"Myastasis,\" which is an autoimmune disease that causes inflammation and damage to the skeletal muscles.\\n\\nThe image is a composite of photographs and diagrammatic representations, intended to educate viewers about the structure of the respiratory system and its role in health and disease, particularly in relation to lung cancer. ', ' The image provided appears to be a screenshot of an interface that simulates the use of medical equipment or devices, possibly for training purposes. It is divided into three sections:\\n\\n1. **Top Section**: This shows a circular symbol with an arrow pointing outwards from the center towards the direction \"NORTH\" and includes a timer set at 30 minutes. The purpose of this symbol might be to indicate the duration or operation of the equipment in the \\'North\\' direction.\\n\\n2. **Middle Section**: This area has two arrows pointing upwards, suggesting an upward movement or action, possibly related to the use of the device. There is a button labeled \"START,\" which could initiate the process or function of the equipment being simulated.\\n\\n3. **Bottom Section**: This part of the interface features three buttons aligned horizontally, each labeled with different verbs: \"STOP,\" \"PAUSE,\" and \"RESUME.\" These indicate the ability to stop, pause, and resume the operation of the device or process in question. The labels are clear and straightforward, providing an intuitive user experience for simulating medical equipment use.\\n\\nThe overall design is simple and utilitarian, focusing on functionality rather than aesthetics. It\\'s a typical representation of a graphical user interface (GUI) that one might encounter in a medical simulation software or training tool. The interface could be used to teach healthcare professionals about proper usage of medical devices or equipment, ensuring standardization across different healthcare settings. ', ' The image appears to be a screenshot of a document with medical content. It shows a diagrammatic representation of a surgical or medical procedure, accompanied by a written text explanation.\\n\\nAt the top left corner of the image, there is a label \"DIAGRAM OF THE PROCEDURE\" which implies that the following images illustrate the steps involved in a specific medical process. The central part of the image contains an instruction: \"to carry out the preparation of the instrument\". This suggests that before commencing any surgical or medical intervention, there is a preparatory step involving an instrument.\\n\\nBelow this text is a graphic illustration of a human eye and what appears to be a small jar with a dropper cap, commonly used for ophthalmic medications. The image also includes two smaller images or icons that are not clearly labeled but could represent additional instruments or steps in the procedure.\\n\\nOn the right side of the image, there is text that reads \"SURGERY GUIDE TO CARRY OUT THE PREPARATION OF THE INSTRUMENT\". This reinforces the theme of the document and provides a clear purpose for the diagrams and explanations provided. The overall layout suggests an educational or instructional context, likely intended for medical professionals or students learning about surgical or ophthalmic procedures. ', ' The image depicts an instructional graphic that illustrates the steps for using eye drops. The text labels on the image provide a detailed guide for administering the drops. Here\\'s the transcription of the visible parts:\\n\\n1. \"EXP\" - likely stands for \"expired,\" indicating that the medication is no longer effective or safe to use.\\n2. \"Figure A\" - suggests that this image represents a visual aid, possibly a step-by-step guide or an example for how to properly administer eye drops.\\n3. The graphic shows the process of applying eye drops in the following order:\\n    - A hand holds the bottle with the medication.\\n    - The eyedropper is positioned over the eye to be dropped.\\n    - The medication is dispensed from the bottle into the eye.\\n4. There are two small icons labeled \"EXP,\" which might represent the expiration of the medication, emphasizing that it should no longer be used.\\n5. The image does not provide specific details about the medication or its indication for use.\\n\\nThe graphic is designed to be educational and instructive, guiding the viewer through the correct process for applying eye drops, with a particular emphasis on the expiration status of the medication in question. ', ' The image depicts three panels, each illustrating a different step in a process. It appears to be a flowchart or instructional sequence, with text labels and symbols indicating actions or steps to follow.\\n\\nIn the first panel, labeled \"A\", there is a person seated on a chair at a table. A green checkmark next to this panel suggests that this step has been completed successfully. The second panel, labeled \"B\", shows the same person standing up and walking away from the chair and table. This implies movement or transition following the action in panel A.\\n\\nThe third panel, labeled \"C\", features an empty chair at a desk with a piece of paper on it. There is also a jar marked with a plus sign over the lid, possibly indicating an action related to adding something to the jar. The jar could represent a medicine bottle or another kind of container that requires contents to be added.\\n\\nThe text \"FIGURE B\" and \"FIGURE C\" are present in the image, suggesting that these steps are part of a sequence described in a document titled \"FIGURE B\". The overall context is unclear without additional information, but it seems to relate to some sort of clinical or medical procedure or protocol. ', ' The image depicts two steps in the process of creating a wound care solution.\\n\\nOn the left, labeled \"Figure D,\" we see a hand pouring a transparent liquid from one container to another. This step involves transferring the contents of the bottle with the dropper into another bottle.\\n\\nOn the right, labeled \"Figure E,\" the same hand is seen placing the cap on the bottle after the solution has been poured. The image does not provide specific medical terms or text labels for these steps, but in general, this process can be related to preparing a wound care solution, possibly involving antiseptics or other medicated substances.\\n\\nThe exact nature of the contents being transferred and their intended use are not clear from the image alone without additional context. ', \" This image depicts a hands-on demonstration of the administration of an injection into an upper extremity, likely for educational or training purposes. The following medical terms and text labels can be observed:\\n\\n1. Syringe: The instrument being used to deliver the medication or fluid.\\n2. Needle: The sharp point at the end of the syringe that penetrates the skin to deliver the contents.\\n3. Skin: The outer protective layer covering the body.\\n4. Injection site: The specific location on the body where the injection is being administered, which appears to be in the upper arm or shoulder area.\\n5. Muscle mass: The dense tissue beneath the skin that provides strength and support for the body.\\n6. Veins: Blood vessels carrying blood away from the heart.\\n7. Tissue layers: Various layers of fat, muscle, and connective tissue that envelop the bones and provide insulation and protection.\\n8. Subcutaneous tissue: The layer of fat just beneath the skin.\\n9. Fascia: A tough, white membrane that covers and protects the muscles, organs, and bones in the body.\\n10. Bone: The hard, dense structure that provides support and protection for the body's internal structures.\\n11. Joint or elbow: The point of articulation where two bones meet, allowing for movement at that point.\\n\\nThe image is presented in a simplified and stylized manner to facilitate understanding of the injection process without unnecessary distractions or anatomical complexity. \", ' The image illustrates a medical procedure involving an intravenous (IV) needle and a syringe. Here\\'s the description in medical terms:\\n\\n- An **intravenous (IV) needle** is being inserted into a vein of a patient, presumably for administration of medication or fluids.\\n- A **syringe**, which is commonly used to deliver drugs or fluids, is connected to the IV needle by a flexible tubing known as an extension set.\\n- The **extension set** allows the syringe to be filled with fluid or medication and then transferred through the IV needle into the patient\\'s vein.\\n- A **filter**, which is not explicitly labeled in the image, is placed between the needle and the syringe. This filter is typically used to prevent air bubbles from entering the patient\\'s bloodstream and to protect against possible contamination of the infused fluid or medication.\\n- The syringe is being filled with a solution, presumably medication or fluid, which will be injected through the IV needle.\\n\\nText labels on this image:\\n- \"PUSH THE TRANSFUSER FILTER INTO THE VEIN\" - This text label indicates that the individual performing the procedure should carefully insert the filter into the vein to prevent air bubbles or contamination.\\n- \"TILT THE SYRINGE TO THE EDGE OF THE VIAL\" - This text label instructs on the proper technique for filling the syringe with medication or fluid, ensuring that all air pockets are removed from the syringe and the plunger is not dislodged before inserting it into the patient\\'s vein.\\n- \"SEE FIGURE H\" - This text label directs the viewer to consult additional information or a diagram (Figure H) for further guidance on this procedure. ', ' The image depicts a schematic representation of an intra-arterial (IA) catheterization procedure, specifically focusing on the initial stages. It illustrates a step-by-step process that involves three distinct actions:\\n\\n1. **Preparation**: This stage is represented by an empty syringe with a needle attached to it. The needle is shown entering the skin, simulating the process of percutaneous puncture.\\n\\n2. **Insertion**: The second part of the image shows the needle and syringe now inserted into a blood vessel, as indicated by the arrows pointing towards the target catheterization site. The label \"Fineline g\" points to this stage, suggesting that it is a critical point in the procedure where a guidewire must be advanced through the needle.\\n\\n3. **Advancement**: The third image demonstrates the final step of the procedure, where the guidewire has been advanced into the vessel, and a catheter has now been introduced over the wire. This stage is labeled \"H\", which could stand for an abbreviation or code within the medical context.\\n\\nEach image is accompanied by a label that provides a textual explanation of the action depicted. The labels are \"Preparation,\" \"Insertion,\" and \"Advancement,\" respectively, reinforcing the narrative provided by the images. ', ' The image depicts a syringe being filled with a substance. The syringe has a needle attached to its plunger, indicating that it is ready for use. A hand holds the needle and plunger assembly of the syringe. The person\\'s hand is visible, but no further details about the individual are provided.\\n\\nThe substance inside the syringe appears to be in liquid form, suggesting it could be an injectable medication or solution. However, without additional context, it is not possible to identify the specific nature of the substance.\\n\\nIn the bottom right corner of the image, there is a text label that reads \"DIAMAGENTE,\" which translates from French as \"DIAGENITIC.\" This label is likely present because the substance being injected may be part of diagnostic testing or could be used in a medical diagnostic context.\\n\\nThe text on the image is also noteworthy: \"Figure 1.\" This suggests that this image may be part of a series or a larger presentation, possibly within a scientific or medical paper. The text does not provide any additional information or context about what Figure 1 represents in the context of the source material from which it is drawn.\\n\\nOverall, the image provides a visual representation of an injection being prepared, with an emphasis on the diagnostic nature of the substance involved. However, without more context, no further conclusions can be drawn regarding the specific medical procedures or practices depicted here. ', ' The image depicts a hand holding up a syringe, which is being used to give an injection. On the right side of the syringe, there\\'s a figure labeled \"Figure K.\" Below the figure, there is text that reads \"Tapeworm infestation.\"\\n\\nThe syringe in the foreground contains what appears to be medicine for tapeworm infestation, as indicated by the labeling the medicine and the accompanying text. The person\\'s hand holding up the syringe has a red checkmark, suggesting that this is a correct or recommended method of administering medication for tapeworms.\\n\\nThe background of the image contains another syringe with a similar mechanism for injecting a needle into a vein, but without the additional context provided by the figure and text, it\\'s unclear what this syringe represents. The focus of the image is on the act of giving an injection to combat tapeworm infestation, emphasizing the correct method or dosage. ', ' The image presents a line graph, which is a type of plot used to display data over a continuous variable. There are two lines on the graph, each representing a different set of data points. The x-axis of the graph represents time, marked in days from 9/1 to 9/30, with increments of approximately one week per interval.\\n\\nThe y-axis indicates the number of new COVID-19 cases reported daily, measured in thousands. There is a legend on the top left corner that distinguishes between \"New Cases,\" \"Cumulative Weekly,\" and \"Vaccinations.\" These labels suggest that the graph plots both the current daily count of new COVID-19 cases as well as cumulative weekly case counts and the number of vaccinations administered.\\n\\nThe graph is overlaid with a scatter plot, which shows data points representing weekly COVID-19 test positivity rates. The title \"COVID-19 Testing\" suggests that these data points represent the percentage of tests conducted for COVID-19 that have returned positive results.\\n\\nAt the top right corner, there is a table with two columns: \"Weekly Cases/Tests,\" which likely represents the number of new cases per test conducted, and \"Vaccinations.\" The values in this table are as follows:\\n- Weekly Cases/Tests: 9.63\\n- Vaccinations: 1058\\n\\nThe background of the image is plain white, and there is no additional context provided about the source or purpose of the graph. The style of the image suggests it may be from a medical report or presentation, as indicated by the technical terminology and the formatting of the data table. The overall focus of the graph seems to be on tracking and analyzing COVID-19 infection rates in conjunction with testing and vaccination efforts over time. ', ' The image appears to be a graph, which is commonly used in medical research or healthcare data analysis. Here\\'s a description using medical terminology and text labels:\\n\\n- **X-axis (Horizontal): Age** - This axis represents the age groups of the patients being analyzed.\\n- **Y-axis (Vertical): Mean Cognitive Score (MCSS)** - This axis represents the cognitive scores averaged across all subjects in each age group.\\n- **Data Points:** - The data points represent individual cognitive scores for each patient within their respective age groups, which are then used to calculate the mean for that group.\\n- **Title Text:** - \"Mean Cognitive Score by Age\" - This label indicates that the graph is plotting the average cognitive score across different age groups.\\n- **Subtitle Text:** - \"Cognitive scores range from 0 to 100, with higher scores indicating better cognitive function.\" - This text explains the scale and interpretation of the cognitive scores plotted on the graph.\\n- **Data Labels:** - The data labels are not entirely visible or legible due to resolution, but they likely represent each individual\\'s cognitive score within their age group.\\n\\nThe image is a bar chart where each bar represents an age group and its corresponding mean cognitive score. The bars vary in height, indicating differences in cognitive scores among the different age groups. The data points are plotted over time (represented by the x-axis), showing how cognitive scores change with age.\\n\\nThis kind of graph is often used in clinical trials or observational studies to visualize changes in cognitive function across different age groups. The purpose could be to assess the impact of aging on cognitive health, to evaluate the effectiveness of an intervention aimed at improving cognition, or to identify trends and patterns in cognitive performance over time. ', ' The image shows a table, which appears to be from a medical or scientific report or article. The title at the top of the image reads \"Effectiveness results year 1 and year 2 in yosemite and rine studies.\" This suggests that the data presented is related to studies conducted at Yosemite and Rine locations over two years.\\n\\nBelow the title, there are three columns labeled \"Site,\" \"Year 1,\" and \"Year 2,\" indicating the respective results for each year. The \"Site\" column lists two locations: \"YOSEMITE\" and \"RINE.\" There are two rows in the table, one for each site.\\n\\nThe numbers under \"Year 1\" and \"Year 2\" likely represent some form of measurement or data point related to the study\\'s outcomes or effectiveness at each location. However, without specific labels on the axes, it is not clear what these numbers represent, such as a percentage increase, a raw score, or another unit of measurement.\\n\\nThe text \"YOSEMITE and RINE studies\" implies that this image is part of a report comparing the effectiveness of something at Yosemite and Rine over two years. The specific context of what is being studied (e.g., a clinical trial, an observational study, or another type of research) is not provided in the image itself. ', ' The image appears to be a medical-related graphic or banner, with the top half showing a grey color and the bottom half displaying a darker shade of grey. There is text on both parts of the image:\\n\\n1. Top (grey background):\\n   - This part of the image is not detailed enough to discern any specific medical terminology or text labels. The text appears to be too small for clear readability, and there are no distinctive features or symbols that would allow me to provide a more precise description.\\n\\n2. Bottom (darker grey background):\\n   - There are horizontal lines and what seems to be a representation of waves or bands on the bottom part. The image is too small for detailed analysis, and any attempt to interpret medical terminology would be speculative without clear text labels.\\n\\nThe overall style of the image suggests it could be from a presentation slide, a poster, or an informational graphic related to healthcare or medicine. However, due to the low resolution and the lack of distinguishable features, there is no specific information that can be provided about this image in medical terms. ', ' The image appears to be a graphical representation of clinical or scientific data, likely from a medical study or clinical trial. It is a scatter plot with various lines and markers representing different data sets overlaid on a time series basis.\\n\\n- The x-axis represents time in months (labeled as \"Months\").\\n- The y-axis represents some form of measurement or parameter, labeled as \"RQI\" which could stand for Relative Quantitative Index, Relative Quality Index, or another metric specific to the study.\\n- There are multiple lines and markers on the graph:\\n  - A solid line (labeled \"VASY\") likely represents a control group or a standard of reference.\\n  - Other lines represent different experimental groups or interventions over time. The labels for these lines are not fully visible, but they might indicate various treatments or conditions being compared to the VASY control.\\n\\nBelow the graph, there is a histogram that shows a distribution of RQI values at a specific time point. The histogram bars are labeled with different categories such as \"VASY\" and what appears to be different experimental groups or interventions. The histogram has a central peak indicating a concentration of data points within a certain range of the RQI value.\\n\\n- In the lower right corner, there\\'s a box plot showing a distribution of another measurement or parameter (labeled as \"VASY\").\\n- To the left and right of this box plot are two sets of data represented by dotted lines with markers, which could be additional experimental groups or interventions.\\n- The labels for the dotted lines are not fully visible, but they might indicate different conditions being compared to the VASY control.\\n\\nThe graph includes annotations for \"Months\" and \"VASY,\" indicating that the solid line represents a standardized version of the metric being measured (RQI). The box plot indicates the spread and distribution of this metric in a specific time frame, while the other lines with markers represent various experimental conditions or treatments.\\n\\nThe image does not provide enough detail to accurately interpret the nature of the clinical trial, the parameters being measured, or the exact significance of the \"RQI\" and \"VASY\" labels without additional context from a medical or scientific publication. ', ' The image appears to be a graphical representation of medical data. It shows a scatter plot with two sets of data, each represented by a different symbol: one set is represented by black dots and the other by gray squares. The x-axis is labeled \"VASYMS\", which might refer to a specific measurement or value, and it ranges from 0 to 100, indicating the scale of measurement for this variable.\\n\\nOn the y-axis, there are two lines with labels: one line has a label reading \"IQR\" and the other \"GWRM\". These labels likely refer to statistical measures related to the data: \"IQR\" could stand for \"Interquartile Range\", which is a measure of the range of a dataset that captures the variability within a sample, while \"GWRM\" might refer to \"Genetic Weighted Regression Model\", suggesting that this plot is from a study or analysis that involves genetic weighting.\\n\\nThe title of the image reads \"PLOT: IQR_vs_GWRM_with_VASYMS\". This suggests that the plot is comparing two statistical measures, Interquartile Range (IQR) and Genetic Weighted Regression Model (GWRM), in relation to the variable \"VASYMS\".\\n\\nThe dotted line above the scatter plot seems to represent a threshold or cut-off point, which could be significant for understanding the data. This is typically used to determine which values of one variable are associated with particular values of another variable in statistical analysis.\\n\\nWithout additional context or knowledge about the specific study this image represents, it\\'s not possible to provide more detailed interpretations of the data and its significance. ', ' The image appears to be a screenshot of a scientific paper or article. It is in portrait orientation and contains both text and figures.\\n\\nAt the top, there is a header with the title \"MICRONEDIA FOLLOWING VENOUS OCCULTION BY YVO SMOKE\", followed by some subtext that includes mentions of \"MACULAR EDEMA\", \"EDAMA\", \"RHEGAM\", and \"YVO\".\\n\\nThe main body of the text is too small to read clearly, but it seems to be discussing a medical study or clinical trial related to venous occlusion in micromedia. The term \"MICRONEDIA\" likely refers to the use of small particles or drug delivery systems designed for localized therapy.\\n\\nBelow the main title, there is a figure labeled as \"Fig. 1\". This figure shows a comparison of two groups with different interventions: one group received micromedia (as indicated by the inset figure), and the other received placebo treatment. The Y-axis indicates \"RHEGAM\", which is likely a clinical outcome or measurement, while the X-axis represents time in months. The graph shows that the group receiving micromedia has significantly lower levels of rhegam compared to the placebo group.\\n\\nTo the right of the main title, there is a column titled \"Statistical Analysis\", although the details are too small to read. This suggests an analysis of the data from the study, which would typically include statistical tests and results.\\n\\nThe paper also includes text at the bottom that appears to be a footnote or reference citation, mentioning a clinical trial number (NCT0215869). This is common in medical literature, as it indicates that the trial was registered with ClinicalTrials.gov, a public database of clinical studies.\\n\\nThe overall style of the image suggests an academic or scientific publication, with a focus on visual representation of data and textual descriptions of a study\\'s methods, findings, and conclusions. ', ' This image displays a statistical chart related to medical or public health data. The chart is titled \"Primary EMP results at Balaton and COMIO studies,\" indicating that it presents findings from two different studies, possibly clinical trials or observational studies, conducted in the area of Balaton and another location, COMIO.\\n\\nOn the left side of the chart, there are two columns labeled \"Balaton\" and \"COMIO.\" Both columns have numerical values ranging from 0 to 376. Each value is paired with a symbol indicating either a positive or negative result. For Balaton, the symbols are \\'+\\', \\'=\\', \\'-\\', and \\'NA\\', while for COMIO, the symbols are \\'A\\', \\'B\\', \\'C\\', and \\'D\\'.\\n\\nThe right side of the chart features a table titled \"Week 4 in the Balaton and COMIO studies.\" This table lists different variables: \\'BALATON\\' and \\'COMIO\\', which likely refer to the locations or groups being compared, followed by numerical values for each location. The variables are measured in units of BALATON/COMIO, suggesting some form of ratio or comparison between the two locations.\\n\\nThe text labels on this image provide context for the data presented:\\n- \\'Balaton\\' and \\'COMIO\\': These could be place names or codes representing different sites or populations within the studies.\\n- The numerical values are statistical results from the studies, such as counts of events, percentages, or other metrics relevant to the research question(s).\\n- The symbols in the \\'Balaton\\' and \\'COMIO\\' columns represent significance levels for the observed differences between the two locations, with positive signs indicating a higher count or rate in Balaton compared to COMIO, and negative signs indicating a higher count or rate in COMIO compared to Balaton.\\n\\nThe overall layout of the image is designed to facilitate comparison between the results obtained at Balaton and COMIO, as well as tracking changes over time (as suggested by \\'Week 4\\'). The precise nature of the studies or the significance of the data would require additional information not provided within the image. ', ' The image is a scatter plot graph with two lines, labeled \"Mean change in visual acuity from baseline to week 21\" and \"Weekly energy change (week 21).\" The x-axis of the graph is labeled \"Visual acuity,\" ranging from 0 to 6.5, while the y-axis is labeled \"Energy change (in kcal/m^2),\" ranging from -40 to 80.\\n\\nIn the upper right corner, there is a legend with two symbols. One symbol is a square, which represents the mean energy change in visual acuity over time, and another symbol is an ellipse, representing the confidence interval around the mean energy change. Both symbols are connected by a line.\\n\\nAt the bottom of the image, there is a caption that reads \"Figure 5: Mean change in visual acuity from baseline to week 21. Balaton.\"\\n\\nPlease note that this description is based on the visible elements and their typical interpretations. The specific details or significance of the image would require additional context beyond what is immediately visible. ', ' The image appears to be a screenshot of a graph from a medical study or device monitoring. It shows a line plot with two different lines and several data points.\\n\\nOn the horizontal axis, there are numbers ranging from 0 to 24, which likely represent hours of the day. On the vertical axis, there is a range of values from 5 to 100, indicating some form of measurement or scale related to the study.\\n\\nThe line on the left side of the graph represents \"Time in Seconds\" and the line on the right represents \"Power (Watts).\" These labels suggest that the data points represent the amount of time spent in a certain state (possibly an electrical or medical state, as suggested by the term \"time in seconds\") and the power output in watts.\\n\\nAdditionally, there are three horizontal bars above the lines on the right side of the graph:\\n1. A blue bar with a number 85 next to it, which could represent a count or measurement at that point in time.\\n2. A red bar with a number 93 next to it.\\n3. An orange bar with a number 74 next to it.\\n\\nThere are also three small black dots connected by lines on the left side of the graph, which seem to represent outliers or specific events in time.\\n\\nThe background is plain and does not provide additional context. The image\\'s quality is low, with a lot of pixelation, especially noticeable in the upper right corner where the image cuts off. This could be due to it being a screenshot taken from a video or a digital device displaying the graph. ', \" This image depicts a diagrammatic representation of an angiogram in medical terminology. It shows a cross-sectional view of a blood vessel within the body, which is the focus of an angiogram.\\n\\n1. **Angiogram 2**: This label likely indicates that this image is part of a series or set, possibly referring to multiple frames from a dynamic angiogram study.\\n\\n2. The central figure in the image is a blood vessel, with the lumen (inner space) filled with contrast dye, which is injected into the bloodstream during an angiogram procedure. This dye allows for visualization of the vascular system on medical imaging equipment such as X-ray machines or fluoroscopic units.\\n\\n3. **Contrast Dye**: The darker areas within the lumen are where the contrast dye has been injected, making those sections more visible against the lighter background of the blood vessel's walls.\\n\\n4. **Wall of Blood Vessel**: The outer surface of the blood vessel is its wall. In this context, it might be referring to the intimal and/or adventitial layers, depending on the specific vascular structure depicted.\\n\\n5. **Plant-like Growths**: On the wall of the blood vessel, there are small plant-like growths which could represent various cellular structures, such as smooth muscle cells or endothelial cells that line the interior surface of blood vessels.\\n\\n6. **Thrombus**: The lighter areas within the lumen might represent clots or thrombi, which can form in a variety of situations, including vascular diseases like arteriosclerosis or deep vein thrombosis.\\n\\n7. **Axons and Dendrites**: These are part of the nervous system, suggesting that the angiogram is focusing on a vessel near or within a nerve structure. This could indicate an area where blood vessels supply a nerve with nutrients.\\n\\n8. **Capsules**: The small round structures could represent capsules, which might be part of a medical intervention such as drug-eluting stents in the context of angioplasty and balloon dilatation procedures for treating vascular diseases.\\n\\nThe image is designed to provide educational information about the visualization of a blood vessel during an angiogram, likely used in a medical or educational setting to teach about the technique and what can be observed during the procedure. \", ' The image appears to be a colorful and stylized illustration of the human eye, showcasing its various components. Here\\'s an elaborate description based on medical terminology:\\n\\n- **Sclera**: This is the tough white outer coat that protects the eye.\\n- **Cornea**: The clear transparent dome at the front of the eye.\\n- **Iris**: The colored part of the eye that helps regulate the amount of light entering it.\\n- **Pupilla**: The center opening in the iris through which light passes into the eye.\\n- **Lens**: This is a flexible structure made of transparent tissue that helps to focus the light entering the eye on the retina.\\n- **Retina**: The inner layer of the eye that contains photoreceptor cells sensitive to light, and which sends electrical signals to the brain.\\n- **Choroid**: The vascular membrane between the sclera and the retina that provides nutrients to the retina.\\n- **Vitreous humor**: This is a transparent gel that fills the space between the lens and the retina, providing support to the eye\\'s structure.\\n- **Angle of intersection (angle)**: The angle at which light rays pass through the cornea, lens, and vitreous humor before reaching the retina.\\n- **Fundus**: This is the inner layer of the choroid, visible through the dilated pupil.\\n- **Aqueous humor**: A fluid that fills the space between the iris and the lens and helps maintain the shape of the cornea.\\n- **Uveos**: The vascular layer beneath the retina that contains blood vessels providing nutrients to the eye\\'s structures.\\n- **Branch vein (branch)**: One of the blood vessels that brings oxygenated blood to the retina, helping to nourish it and remove waste products.\\n- **Excess fluid**: This refers to a condition in which there is an abnormal amount of fluid inside the eye, which can cause vision loss if not treated.\\n\\nThe text labels on the image indicate the following:\\n\\n1. \"ANGLE2\" – likely referring to one of the two angles at which light enters the eye through the pupil (angle of incidence) and is refracted by the lens before being focused onto the retina.\\n2. \"BRANCH VEIN\" – indicating a blood vessel that supplies oxygenated blood to the inner layers of the eye, including the retina and choroid.\\n3. \"CENTRAL VEIN\" – presumably referring to another blood vessel that also supplies the same layers mentioned above.\\n4. \"EXCESS FLUID\" – pointing out an area where there is more fluid than normal, which could be indicative of a medical condition such as cataract or glaucoma. ', ' The image appears to be an illustration or graphic representation related to medical or biological science. It depicts a sectional view of what seems to be a cell with various organelles labeled in purple text.\\n\\nOn the left side, there is a label that reads \"VABYSMO,\" which suggests this could be the name of a molecule or substance involved in the processes depicted in the image. Below this, a label states \"Blocks ang-2 VEGF,\" indicating that the molecules shown are capable of blocking angiopoietin-2 and vascular endothelial growth factor, both of which are important for blood vessel growth and function.\\n\\nOn the right side, there\\'s another label that reads \"VEGFR-2,\" which stands for Vascular Endothelial Growth Factor Receptor 2, a protein that plays a role in angiogenesis and is a target of therapeutic agents. Below this, there are additional labels indicating the presence of other molecules or proteins: \"EGF,\" likely referring to Epidermal Growth Factor, which is involved in cell growth; \"TGF-α,\" Tissue Growth Factor alpha, known for its role in tissue repair and fibrosis; \"MMP-9,\" Metallothionein 9, a protein that helps break down the extracellular matrix during normal development, inflammation, and cancer; \"VEGFR-1,\" Vascular Endothelial Growth Factor Receptor 1, another important receptor for angiogenesis; \"VEGF,\" indicating the presence of Vascular Endothelial Growth Factor; \"Blocked Vegf-2,\" suggesting that these molecules are blocking the activity of VEGF-2; and \"Epigenetic modifier,\" which suggests a modification of the genetic material (epigenetics) is part of the image.\\n\\nThe background of the image shows a microscopic view with what appears to be cells, possibly endothelial cells given the presence of VEGF receptors, and extracellular matrix. The overall context suggests that this image is related to vascular biology or angiogenesis, which is the process by which new blood vessels are formed from pre-existing vessels. This can be important in various physiological processes, such as wound healing, tumor growth, and possibly in therapeutic development for conditions involving poor blood vessel formation or damage to existing vessels. ', ' The image shows an illustration of the human eye and its anatomy. Text labels are present, indicating the various parts and functions:\\n\\n- \"Reduced fluid\" is noted on the iris, which could refer to a condition such as uveitis or a decrease in aqueous humor.\\n- \"Reduced swelling\" is highlighted around the cornea and pupil, suggesting a reduction in inflammation or edema that can affect vision.\\n\\nThe anatomy depicted includes:\\n- The eye globe itself, which houses the lens, iris, and pupil, all of which are part of the anterior chamber.\\n- The eyelids, which provide protection to the eye.\\n- The cornea, which is transparent and forms a clear dome at the front of the eye.\\n- The pupil, the round opening in the center of the iris that controls the amount of light entering the eye.\\n- The iris, which surrounds the pupil and regulates its size through contraction and relaxation.\\n- The eyelashes, located on the eyelids and help protect the eye from dust and debris.\\n- The sclera, which is the white, firm outer layer of the eyeball that provides structural support and helps to keep the cornea in place.\\n- The eyelid and eyelashes are also visible.\\n\\nThe image does not provide any additional context or explanation for the labels \"reduced fluid\" and \"reduced swelling.\" These terms could be associated with medical conditions such as eye infections, inflammation, or allergies that affect the health of the eye. However, without more information, it is not possible to determine the exact nature of the conditions being referred to by these labels. ', ' The image you\\'ve provided appears to be a logo or emblem of some sort. It features a graphic design with elements that could represent medical services, devices, or products. Here\\'s a description in medical terms and text labels:\\n\\n- **Color Scheme**: The color scheme is primarily a gradient of purple from dark at the top to light at the bottom, with a greenish hue on the upper right side. This might suggest a focus on health, wellness, or a particular area of medicine.\\n\\n- **Symbols and Graphics**: On the left side, there\\'s a graphic resembling an atom, which could signify chemistry or biology. In the center, there\\'s a stylized representation of mountains or waves, possibly symbolizing progression, growth, or innovation. On the right, there\\'s another graphic that appears to be a stylized representation of a pillar or tower, often associated with stability, support, or strength.\\n\\n- **Text**: The main text in the image reads \"BYSMOS,\" which is not a term recognized in standard medical terminology and therefore its meaning within this context is unclear. It could be the name of the organization, service, or product represented by the logo.\\n\\n- **Additional Elements**: There are additional elements that appear to be a stylized mountain range on the upper right side and some form of geometric pattern or abstract design in the center. These might represent various aspects of health, such as wellness, health services, or the company\\'s commitment to innovation and growth.\\n\\n- **Style**: The style of the logo is modern and clean, with a focus on simplicity and elegance. It does not contain any additional text or specific medical symbols that are universally recognized in medicine.\\n\\nThe image seems to be a corporate logo rather than a piece of medical equipment or product. If you have more context about this image, such as the source or purpose, I could provide a more detailed analysis based on that information. ', ' The image appears to be a diagrammatic representation of an anatomical structure, possibly from the field of medical or biological sciences. It depicts what seems to be a cross-sectional view of an organ, which could be part of an animal or plant, but without more context, it is difficult to identify exactly which organ this is.\\n\\nThe diagram is colorful and includes various components labeled with text. There are purple structures that might represent some form of tissue or cells, and green elements that could indicate other types of cellular material or organelles. Yellow dots could signify nuclei within the cells, while blue areas may represent extracellular matrices or fluids.\\n\\nText labels in the image include:\\n- \"ANG2\" which might refer to a specific protein or molecule present in the depicted structure.\\n- \"VEGF\" which stands for Vascular Endothelial Growth Factor, a protein that promotes angiogenesis (the growth of new blood vessels).\\n- The label \"HIF1a\" could indicate the presence of Hypoxia-Inducible Factor 1 alpha, a transcription factor that regulates genes in response to oxygen availability.\\n\\nThe diagram is likely intended for educational or research purposes to illustrate the function and structure of this organ within a physiological context. Without more specific information about the organ itself, it\\'s challenging to provide a detailed analysis. ', ' The image appears to be a logo or emblem, possibly representing an organization or service. It features the word \"EYVSDI\" prominently in the center, with additional text that reads \"RIDISI DIVIDAS.\" Below this, there is smaller text that says \"KNOWLEDGE CENTRE,\" suggesting that the entity is associated with a knowledge-sharing platform.\\n\\nThe logo\\'s design incorporates a circular motif, which seems to be the central focus of the image. This circle contains a series of dots, each in a different color: blue, pink, green, and red. These colors are arranged in a pattern that does not appear to follow any specific geometric shape, but rather gives an impression of a random or abstract arrangement.\\n\\nThe color scheme is quite vibrant and attention-grabbing, with the white background serving to highlight the colored elements of the logo. The use of dots within the circle may symbolize connectivity or points of interest, which could relate to the knowledge center aspect mentioned in the text.\\n\\nWithout additional context or information, it is not possible to provide a precise interpretation of the design or its significance beyond what can be seen in the image itself. ', ' The image you\\'ve shared appears to be a scientific figure, specifically from a paper or presentation related to molecular biology or pharmacology. It depicts a chemical structure of a molecule along with its three-dimensional (3D) representation.\\n\\nOn the left side of the image is the two-dimensional (2D) diagram of a chemical structure. This structure shows the arrangement of atoms within a molecule, including the bonds between them. The text labels on this 2D diagram likely indicate different functional groups or parts of the molecule, although without specific labels, it\\'s not possible to provide detailed information about these parts.\\n\\nThe right side of the image is a 3D molecular model. This model shows how the atoms are arranged in three dimensions, giving a sense of the spatial relationships between them. The model is rendered with spheres to represent the atoms and lines to indicate the bonds between them.\\n\\nBelow the 2D diagram, there\\'s a label \"NH\" which stands for amide (nitrogen-hydrogen bond) group, a common functional group in organic chemistry that can participate in reactions like condensation or hydrolysis.\\n\\nThe chemical structure is labeled as \"Tyr1\", which suggests it is the first molecule in a series of tyrosine derivatives. Tyrosine is an amino acid that plays a key role in many biological processes, including cell signaling and neurotransmitter synthesis. The presence of nitrogen-hydrogen bonds indicates the possibility of hydrolysis or other reactions involving this functional group.\\n\\nThe image is part of scientific research, where molecules like this one are designed and studied to understand their interactions with biological systems and potentially develop drugs or treatments for various diseases. ']\n"
     ]
    }
   ],
   "source": [
    "from tqdm import tqdm\n",
    "text_elements = []\n",
    "table_elements = []\n",
    "\n",
    "text_summaries = []\n",
    "table_summaries = []\n",
    "\n",
    "summary_prompt = \"\"\"\n",
    "Summarize the following {element_type}:\n",
    "{element} in pure medical term\n",
    "\"\"\"\n",
    "summary_chain = LLMChain(\n",
    "    llm=ChatOllama(model=\"mistral\",temperature=0 ),\n",
    "    prompt=PromptTemplate.from_template(summary_prompt)\n",
    ")\n",
    "\n",
    "for e in tqdm(raw_pdf_elements):\n",
    "    if 'CompositeElement' in repr(e):\n",
    "        text_elements.append(e.text)\n",
    "        summary = summary_chain.run({'element_type': 'text', 'element': e})\n",
    "        text_summaries.append(summary)\n",
    "\n",
    "    elif 'Table' in repr(e):\n",
    "        table_elements.append(e.text)\n",
    "        summary = summary_chain.run({'element_type': 'table', 'element': e})\n",
    "        table_summaries.append(summary)\n",
    "image_elements = []\n",
    "\n",
    "def encode_image(image_path):\n",
    "    with open(image_path, \"rb\") as f:\n",
    "        return base64.b64encode(f.read()).decode('utf-8')\n",
    "for i in os.listdir(output_path):\n",
    "    if i.endswith(('.png', '.jpg', '.jpeg')):\n",
    "        image_path = os.path.join(output_path, i)\n",
    "        encoded_image = encode_image(image_path)\n",
    "        image_elements.append(encoded_image)\n",
    "import os\n",
    "import ollama\n",
    "from tqdm import tqdm\n",
    "import base64\n",
    "from PIL import Image\n",
    "from io import BytesIO\n",
    "\n",
    "# Initialize an empty list to store the results\n",
    "img_summaries = []\n",
    "\n",
    "\n",
    "# Iterate over all image strings in the list with a tqdm progress bar\n",
    "for image_string in tqdm(image_elements, desc=\"Processing images\"):\n",
    "    # Decode the image string using utf-8 encoders\n",
    "    img_data = base64.b64decode(image_string)\n",
    "    img = Image.open(BytesIO(img_data))\n",
    "    \n",
    "    # Save the image to a temporary file\n",
    "    img.save(\"temp.jpg\")\n",
    "    \n",
    "    # Call the chat function with the image file\n",
    "    res = ollama.chat(\n",
    "        model=\"llava\",\n",
    "        messages=[\n",
    "            {\n",
    "                'role':'user',\n",
    "                'content':'Describe elaboratively about this image in pure medical term and text labels on this image :',\n",
    "                'images':[\"temp.jpg\"]\n",
    "            }\n",
    "        ]\n",
    "    )\n",
    "    \n",
    "    # Append the result to the image_summary list\n",
    "    img_summaries.append(res['message']['content'])\n",
    "\n",
    "# Print the image_summary list\n",
    "print(img_summaries)\n",
    "documents = []\n",
    "retrieve_contents = []\n",
    "\n",
    "for e, s in zip(text_elements, text_summaries):\n",
    "    i = str(uuid.uuid4())\n",
    "    doc = Document(\n",
    "        page_content = s,\n",
    "        metadata = {\n",
    "            'id': i,\n",
    "            'type': 'text',\n",
    "            'original_content': e\n",
    "        }\n",
    "    )\n",
    "    retrieve_contents.append((i, e))\n",
    "    documents.append(doc)\n",
    "\n",
    "for e, s in zip(table_elements, table_summaries):\n",
    "    doc = Document(\n",
    "        page_content = s,\n",
    "        metadata = {\n",
    "            'id': i,\n",
    "            'type': 'table',\n",
    "            'original_content': e\n",
    "        }\n",
    "    )\n",
    "    retrieve_contents.append((i, e))\n",
    "    documents.append(doc)\n",
    "\n",
    "for e, s in zip(image_elements, img_summaries):\n",
    "    doc = Document(\n",
    "        page_content = s,\n",
    "        metadata = {\n",
    "            'id': i,\n",
    "            'type': 'image',\n",
    "            'original_content': e\n",
    "        }\n",
    "    )\n",
    "    retrieve_contents.append((i, s))\n",
    "    documents.append(doc)\n",
    "\n",
    "vectorstore = FAISS.from_documents(documents=documents, embedding=embeddings.OllamaEmbeddings(model='nomic-embed-text'))\n",
    "vectorstore.save_local(\"5drug_faiss\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "568"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(text_elements)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "# image_elements = []\n",
    "\n",
    "# def encode_image(image_path):\n",
    "#     with open(image_path, \"rb\") as f:\n",
    "#         return base64.b64encode(f.read()).decode('utf-8')\n",
    "# for i in os.listdir(output_path):\n",
    "#     if i.endswith(('.png', '.jpg', '.jpeg')):\n",
    "#         image_path = os.path.join(output_path, i)\n",
    "#         encoded_image = encode_image(image_path)\n",
    "#         image_elements.append(encoded_image)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "90"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(table_elements)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Processing images: 100%|██████████| 104/104 [1:08:01<00:00, 39.25s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[' The image appears to be a screenshot from a computer application displaying a graphical user interface (GUI). The GUI is designed with a monochromatic color scheme, predominantly using shades of grey.\\n\\nAt the top center of the screen, there is text that reads \"1608337\". Below this number, there are two columns labeled with text; however, the text in these columns is not visible in the image. The left column contains a series of checkboxes next to each other, but their labels are obscured and not readable.\\n\\nThe right column contains what appears to be a list or table with rows of data. Each row has multiple columns, but only one of them can be partially seen, displaying a numerical value which is also not entirely legible due to the image resolution. The bottom right corner of the screen shows a small part of another window or application that seems to have some kind of text within it, but again, the content is not clearly visible.\\n\\nThe style of the GUI suggests it might be from an enterprise resource planning (ERP) system, inventory management software, or a similar business-oriented application where users can view and manage data in structured formats. The design looks minimalistic and utilitarian, with a focus on functionality rather than aesthetic appeal. There are no visible icons or buttons that would indicate specific actions the user might take within this GUI.\\n\\nThe overall impression is that of a functional interface designed for practical use, possibly by individuals who need to manage inventory or order fulfillment within an organizational context. The precise purpose and features of the application would depend on the specific context in which it is used. ', ' The image appears to be a screenshot of a scientific paper or presentation slide. It features a graph with two lines, representing different variables over time. The x-axis is labeled \"Period and 1,\" indicating that the data is plotted as a time series with intervals between measurements.\\n\\nThe y-axis is titled \"Household Income,\" suggesting that the values on this axis represent household income levels in a certain currency, which could be US dollars, but the specific currency is not identified. The vertical line at 100% represents the baseline or average income level over time.\\n\\nAbove the graph, there is text providing context to the data represented by the lines. It reads: \"GDP per capita - Housing prices.\" This suggests that the data in the graph relate to these two variables being compared or analyzed together. The text indicates that there was a significant increase in GDP per capita from 1998 to 2017, which is associated with higher housing prices during this period.\\n\\nAt the bottom of the image, there is additional information: \"Housing price index - 1995=100.\" This indicates that the value on the y-axis represents a housing price index based on a baseline year of 1995, which has been normalized to 100 for comparison. The label \"1995=100\" suggests that the base year\\'s housing prices were arbitrarily set to 100 and all subsequent years are scaled accordingly.\\n\\nThe image also contains a text box with the title \"Predicted vs actual.\" This could imply a comparison between expected outcomes (the predicted line) and observed results (the actual line), which is typical in statistical analyses where predictions are compared against real data. The presence of error bars suggests that there is an element of uncertainty or variability associated with the data points, indicating that not every prediction will be exactly correct but should fall within certain ranges of accuracy.\\n\\nThe overall style of the image is informative and academic, designed to present complex data in a clear and structured format. The use of color coding for the predicted line differentiates it from the actual line, aiding in understanding which line represents the expected outcomes and which one reflects the actual observations. ', ' The image you\\'ve provided appears to be a photograph of a printed document, possibly a piece of academic or professional paperwork. The content on the document is partially obscured by a watermark-like pattern, which is common for documents that are intended for review or proofreading purposes before being finalized and made public.\\n\\nThe visible text seems to be a table or chart with some numerical data presented in rows and columns, although the specific details of the data are not clear due to the watermark overlay. The table has headers, but the full context of what these headers represent is obscured by the pattern.\\n\\nAt the top of the document, there\\'s a title or heading that reads \"85%\" in bold text, which could suggest some form of percentage related to a study, report, or survey results, but without additional context, it\\'s difficult to determine its significance.\\n\\nThe paperwork has visible creases and folds, indicating that it has been handled or transported, possibly during a meeting or conference where such documents are commonly shared and discussed.\\n\\nGiven the watermark pattern across the document and the presence of numerical data in tables, this image might be relevant to someone who is involved in data analysis, research, or academic work requiring statistical summaries or performance metrics. However, without access to a higher-resolution version of the document, it\\'s impossible to provide further details on the content. ', \" The image you've provided is a grayscale, low-resolution photograph. It appears to show an object with various geometric shapes and textures. On the left side of the object, there is what seems to be a smooth, curved surface. In contrast, on the right side, there are more angular and jagged elements, suggesting a rougher texture.\\n\\nThe photograph itself has a pixelated quality, which could indicate that it was taken with a low-resolution camera or is a digital representation rather than an actual photograph. The image is also rotated about 90 degrees counterclockwise, as indicated by the orientation of what appears to be the bottom edge of the object.\\n\\nThere are no texts visible in the image, and the background is indistinct due to the low resolution and grayscale color scheme. The focus is entirely on the object itself, with no additional context provided within the frame of the photograph. \", ' This image features a photograph of an electronic device with a screen displaying a line graph. The graph appears to be a time-series plot, with horizontal and vertical axes that represent different parameters or variables.\\n\\nThe horizontal axis is labeled \"Time (s)\" which suggests the data points are measured in seconds, indicating a temporal component to the data being represented. However, the specific unit of measurement for each point along this axis is not provided.\\n\\nThe vertical axis is marked with numerical values ranging from 0 to 1.5, but without context or units, it\\'s unclear what these values represent; they could be a form of normalization or scaling commonly used in signal processing or data analysis.\\n\\nOn the graph, there are two lines, one in red and one in black. These lines appear to be different signals or measurements that are being compared or analyzed over time. The red line starts from 0 seconds and continues through what appears to be approximately 5.2 seconds of time. The black line starts at a slightly higher value than the red line but quickly drops below it, then remains relatively stable for a period before exhibiting some variability that resembles a square wave pattern.\\n\\nThe image also contains a watermark or overlay text on the bottom left corner. However, due to the resolution of the image and the size of the text, it is not legible enough to provide any specific details.\\n\\nOverall, the image provides a snapshot of a technical or scientific analysis being performed using this piece of equipment, which could be part of an experiment or monitoring system for some sort of process or data collection. ', ' The image you\\'ve shared is a grayscale photograph of what appears to be a computer screen displaying a software application or user interface. This interface includes various elements commonly found in software applications such as menus, toolbars, and windows.\\n\\nAt the top, there are menu options like \"File,\" \"Edit,\" \"View,\" \"Tools,\" \"Add-ons,\" \"Window,\" and \"Help.\" These suggest that the software is designed for a variety of functions and includes features for managing files, editing documents or images, viewing and organizing data, using tools for specific tasks, adding extensions or plugins to enhance functionality, opening multiple windows of different views or tools, and accessing help resources.\\n\\nBelow the menus, there is a toolbar with icons that represent different functions or tools within the application. The icons are too small to discern their exact purpose from this distance, but they seem to be related to common tasks like creating new documents, opening existing files, saving work, and other similar actions.\\n\\nIn the center of the screen, there is a large window with a grid-like structure that looks somewhat complex. The structure could represent various elements within the software such as data fields, columns of data, or a matrix for calculations or comparisons.\\n\\nThe bottom of the interface shows a status bar or docking area where smaller windows or icons can be docked for quick access. This suggests that the software supports multitasking or multi-window functionality.\\n\\nOn the right side of the screen, there is a vertical window that seems to contain text. The text is too small and blurry to read clearly, but it could be part of a settings panel, documentation, or another informational section.\\n\\nThe overall style of the image is utilitarian and suggests functionality over aesthetics. It does not include any visible graphical elements like charts or graphs, which might have been mistaken for financial data due to their similarity in appearance. ', ' The image is a grayscale, high-resolution photograph of a printed document or table. It appears to be a financial or accounting statement, as indicated by the columns and rows labeled with various numerical values. The columns are titled \"TOTALS,\" \"YTD,\" \"LAST 12 MONTHS,\" and \"CHANGE.\" Each row corresponds to different items or categories, such as \"INCOME STATEMENT OF CONTROLLED ENTITIES,\" \"TOTAL INCOME,\" and \"TOTAL EXPENSES.\"\\n\\nThe specific values are not clearly legible due to the small font size, but it\\'s evident that the document is structured with precision. The layout suggests a professional or corporate context for financial reporting. There are also numerical figures present, which provide quantitative data relevant to the document\\'s content. ', ' The image appears to be a screenshot of a computer screen displaying a table with columns and rows. The content of the table seems to relate to financial or accounting data, as suggested by the column headers \"Date,\" \"Invoice Number,\" \"Amount,\" and \"Description.\"\\n\\nThe \"Amount\" column shows figures in a currency not specified. The table itself is partially obscured by a watermark that reads \"Blink.\" This watermark indicates that the image may be subject to copyright or licensing restrictions, as it prevents copying of the underlying content.\\n\\nThe \"Description\" column contains text that is too small and blurred to read clearly, making it difficult to provide specific details about the transactions listed in this table. The watermark also covers the bottom part of the image, which may contain additional information or footers that are not visible due to the watermark\\'s presence.\\n\\nThe style of the image is typical for a screenshot of a spreadsheet or database application, with the grid structure and column headers commonly used in such software. The layout suggests an organized display of data for record-keeping or analysis purposes. ', ' The image is a graphical representation, likely from a scientific study or report, showcasing data on the effectiveness of a medication named \"Dexamethasone\" in treating patients with \"Cushing Syndrome\" and \"Hyperglycemia\". The plot style is a line graph with individual plotted points, which indicates that this is a bar chart representation.\\n\\nThe x-axis represents the dose of Dexamethasone administered to the patients, ranging from 0 mg (likely indicating zero dosage) to 24 mg in increments of 6 mg. The y-axis indicates the percentage of patients with Cushing Syndrome and Hyperglycemia who experienced an adverse event after treatment with Dexamethasone.\\n\\nThere are two distinct lines on the graph, each representing a different group: \"Cushing Syndrome\" and \"Hyperglycemia\". The line for Cushing Syndrome starts at the left of the scale, with an initial value of 0%, rises steadily with increasing dosage, peaking towards the right end of the scale at around 21 mg. It then declines slightly but remains relatively stable until it reaches a plateau just above the 50% mark near the 24 mg mark on the x-axis.\\n\\nThe line for Hyperglycemia starts at a similar position to that of Cushing Syndrome and also rises steeply as the dosage increases, peaking around 12 mg on the x-axis. Similar to the Cushing Syndrome line, it then declines slightly but remains relatively stable until it reaches a plateau near the 50% mark at approximately 23 mg on the x-axis.\\n\\nBoth lines show a sharp increase in the percentage of patients with an adverse event as the dosage of Dexamethasone increases, followed by a decline or stabilization as the dosage reaches a certain point. The chart suggests that for both conditions, there is a critical threshold of medication dose at which the risk of adverse events increases significantly.\\n\\nIn the lower left corner of the image, there\\'s a legend with two items: \"Dexamethasone 0 mg\" and \"Dexamethasone 24 mg\". This indicates that these are the two data series represented by the lines on the graph.\\n\\nThe title at the top reads \"Percentage of patients with Cushing Syndrome or Hyperglycemia who experienced an adverse event after treatment with Dexamethasone\", which explains the nature of the data displayed in the chart. The overall trend depicted in this image suggests that while a certain level of medication is beneficial for managing Cushing Syndrome and Hyperglycemia, there is a risk associated with higher dosages, and this risk increases sharply at a specific dose before decreasing or stabilizing. ', ' The image you\\'ve shared appears to be a screenshot of a computer application or software interface. It shows a window with a graphical user interface (GUI) that includes several elements such as buttons, input fields, and a chart.\\n\\nThe top part of the window has a title bar labeled \"Simulation\" which suggests that this interface is used for running simulations. Below the title bar, there are two rows of buttons, each containing multiple icons or text labels, but their exact functions or meanings are not clear from the image provided. The buttons could represent various options or tools within the software application.\\n\\nIn the center of the window, there\\'s a large chart that is divided into two sections. On the left side, there is a vertical axis labeled \"x\" with numerical values ranging from 0 to 1.25. This axis represents time or another continuous variable. Adjacent to it on the right side, there are two plots: one appears to be a line graph, and the other looks like a bar chart. The bars in the bar chart are tall and thin, and they are colored white.\\n\\nThe bottom part of the window features a text field labeled \"Enter text here...\" which is likely intended for user input. Next to the text field, there\\'s a button with an icon that resembles a floppy disk or a \\'save\\' symbol, suggesting this button is used for saving data or settings within the application.\\n\\nThe overall style of the image is digital and functional, indicative of the software interface which is probably used for data visualization, analysis, or simulation purposes in a professional or technical context. ', ' This is a grayscale image that appears to be a graphical representation of some data, likely from a scientific study or experiment. The image features two plots:\\n\\n1. On the left side of the image, there\\'s a plot with a vertical axis labeled \"N\" (which might stand for \\'normal,\\' \\'negative,\\' \\'noise,\\' or some other variable depending on the context) and a horizontal axis labeled \"RPM,\" which stands for \\'Revolutions Per Minute.\\' This suggests that the data points represent some quantity measured as a function of RPM. The plot includes a series of horizontal lines, each connecting to a set of data points, indicating different levels or categories of the variable N. These horizontal lines are annotated with numbers, which could be experimental conditions or group labels.\\n\\n2. On the right side of the image, there\\'s another plot with a vertical axis labeled \"A,\" which likely stands for \\'Another variable\\' or \\'Another quantity,\\' and a horizontal axis that seems to represent time, as indicated by the labels such as \"t = 0,\" \"t = 12,\" \"t = 24,\" etc., suggesting a time-series data representation. This plot also includes several horizontal lines similar to those in the left plot.\\n\\nThe color and style of the image suggest it\\'s from a scientific paper or presentation, where such graphs are used to visually present experimental results or to compare different treatments or conditions across multiple time points. The specific nature of the data is not clear without additional context, but it might relate to physics, engineering, or some other technical field where RPM is commonly used in machinery analysis or design. ', ' The image shows a table with a title that reads \"PATIENTS\\' MEDICAL RECORD,\" but the content of the table is partially obscured, as the first column is covered by an overlaid image. There are visible numbers in the first column, indicating some form of identification or tracking number for each patient record. The rest of the text and details in the subsequent columns are not visible due to the overlay. The style of the image suggests it might be a screenshot from a computer application or software used for medical records management. The background is nondescript, with no additional context provided. ', ' The image shows a logo with the word \"Socrecvs\" prominently displayed in uppercase letters. To the left of the text is an emblem that appears to be a stylized representation of a sun or moon, featuring a white circular pattern with rays or lines emanating from it, suggesting radiance or luminosity. The background of the logo is light gray, and there is a watermark or image overlay in the bottom right corner that includes a textured background and what appears to be a small graphic or icon.\\n\\nThe font used for \"Socrecvs\" has a modern and slightly sans-serif style, which gives it a contemporary look. The logo\\'s overall design is simple yet striking, with the use of white for both the text and the emblem providing a clear contrast against the light gray background. The graphic element on the right side suggests that the logo may be associated with something related to health or wellness, as the sun-like emblem often symbolizes enlightenment or well-being in various contexts.\\n\\nThere is no additional information provided about the nature of \"Socrecvs\" beyond what is visible in the image. The style of the image is graphic and promotional, designed to be visually appealing while conveying a sense of professionalism. ', ' The image appears to be a graphical representation of a longitudinal study or trend analysis, likely from a scientific paper or presentation. At the top left, there is a label \"Vvsd,\" which might refer to an acronym or initials for the research or institution involved in the study.\\n\\nThe main figure in the image is a line graph with two sets of data: one set represented by dots and labeled \"months,\" suggesting that the data points represent observations made over a period of time, possibly months, as indicated by the label on the x-axis. The second set of data is shown by a solid line with shaded areas on both sides, labeled \"total number.\" This suggests that there are two categories being tracked: one represented by the dots and another represented by the line.\\n\\nThe y-axis is titled \"Total number,\" which implies that the vertical axis measures some form of numerical output or result from the study. The x-axis is labeled \"months,\" indicating that the data points are plotted against time intervals, most likely in a monthly context, as suggested by the title at the top.\\n\\nAt the top right, there\\'s a note that says \"3190:26\" with an arrow pointing to the month of 2 on the x-axis, indicating a specific moment or point in time corresponding to the second month shown in the graph. This could be significant for the context of the study but without additional information, it\\'s unclear what it signifies.\\n\\nThe graph shows a general downward trend with some fluctuations over the depicted period. The line and dots intersect at various points on the graph, indicating periods where both sets of data align closely together or where one set is ahead of the other.\\n\\nBelow the main graph, there\\'s a subtitle that says \"Evrsd - Pillar,\" which could be referring to two different groups, treatments, or variables being compared in the study. Without more context, it\\'s difficult to provide further details about this aspect.\\n\\nThe overall style of the image suggests an academic or professional presentation related to medical research or clinical trial data tracking. The data points are shown with a certain level of precision, and there is no additional text or annotations on the graph other than the ones already described. ', ' The image shows a sign with text, which appears to be in Spanish. The text on the sign reads \"SOCRECVUS.\" Below the main text, there is smaller text that says \"SOCIEDAD DE PRODUCTIONES Y ALCANZAR.\" The logo of the company, which seems to be a stylized representation of a hand and a flame or torch, is visible at the top right corner. The background of the sign is a plain grey color.\\n\\nThe style of the image is a straightforward photograph of an advertisement or informational sign. There are no additional elements or distinguishing features within the frame. The focus is solely on the text and logo of the company, suggesting that this might be an outdoor signage for a business establishment named Socrecvus, which is presumably involved in production activities. ', ' The image is a screenshot of a digital interface, likely from a presentation or informational website. It features a pair of bar graphs, each representing different data sets with percentages. The left graph is labeled \"OCEVUS,\" and the right one is labeled \"OCEREUS.\" Each graph has two bars, indicating two data points being compared.\\n\\nOn the left side, under the heading \"OCEVUS,\" there is a bar marked with a percentage of 83. In contrast, on the right side, under \"OCEREUS,\" the percentage is lower at 46.\\n\\nAbove each graph, there are two statements: \"More people taking OCEVUS had no adverse effects\" and \"More people taking OCEREUS had adverse effects.\" These statements suggest a comparison between the safety profiles of the two medications.\\n\\nBelow each bar graph, there is text indicating the results of a statistical study. For OCEVUS, the result was that if individuals were not taking OCEVUS, 79% had no adverse effects compared to 83% with OCEVUS. The opposite is true for OCEREUS; if people were not taking it, 46% did not have adverse effects, but 83% had adverse effects when they started taking it.\\n\\nAt the bottom of the screenshot, there is a caption that reads \"Results were consistent in Study 2,\" implying that the results shown are consistent across different studies or data sets. The image itself has a plain background and is straightforwardly informational, designed to present statistical data in an easy-to-understand visual format. ', ' The image appears to be a screenshot of a mobile phone displaying a graphic design or possibly an online advertisement. It features text and a background with two distinct sections.\\n\\nThe top portion is a solid mustard yellow color, upon which there\\'s a large text that reads \"40% of people taking COVID-19 vaccine were 65 years old or older.\" This statement is emphasized by the font size and boldness. Below this main text, there\\'s smaller text in a contrasting white color stating \"People with disabilities progressed slower than those without,\" suggesting a comparison between different demographic groups regarding the COVID-19 vaccine.\\n\\nThe bottom section of the image has a gradient background that transitions from dark blue at the top to purple at the bottom, resembling a watercolor effect. On this area, there is another line of text in white that reads \"40% of people taking COVID-19 vaccine were 65 years old or older.\" The repetition of this statistic could be a typographical error or a design choice for emphasis.\\n\\nThe style of the image is informational and seems to be conveying some data related to the demographic distribution of individuals receiving the COVID-19 vaccine, although there\\'s an inconsistency in the text, which repeats the same statistic twice. ', ' The image features a logo with the text \"Evrysdí\" prominently displayed. The design is simple yet striking, with the brand name at its core. To the left of the text, there\\'s a circular graphic composed of vibrant dots in hues of blue, pink, green, and yellow, creating an abstract pattern that adds a dynamic element to the logo.\\n\\nThe background of the image is white, which serves to highlight the elements of the logo. Above the brand name, there are two small lines of text in blue. The first line reads \"RIDSDIPLÁM,\" and the second line says \"RIDSDÍKOVÉS.\" These phrases suggest that the brand may be related to dental implants or similar dental services.\\n\\nThe overall design is clean and modern, with a clear focus on the brand name and its associated products or services. The use of bright colors in the dots provides a visual contrast against the white background, making the logo easily recognizable and memorable. ', ' The image is a graphical representation, possibly from a scientific paper or presentation, illustrating the process of molecular docking. It shows a two-step sequence that seems to represent an interaction between molecules.\\n\\nOn the left side, there\\'s a diagram with three circles of varying sizes, representing different stages of the docking process. The largest circle at the top represents the initial stage where one or more molecules are brought together in a binding pocket or a similar environment within a cell. This is labeled as \"HE(95)\".\\n\\nThe second step is represented by two circles, with the larger one positioned on top of the smaller one, suggesting that this could be the interaction between two molecules during docking. The label for this step reads \"HE(95) + Molecule\", indicating that the HE(95) molecule interacts with another unspecified molecule.\\n\\nThe right side of the image shows a close-up view of two molecular structures, which appear to be in close proximity or possibly overlapping each other. The larger structure is labeled \"HE(95)\", suggesting that it is the same HE(95) molecule from the initial stage of the docking process.\\n\\nBelow the diagram, there are some text elements and mathematical equations. The text on the left says \"Normal amount of HE(95)\" with a numerical value \"20\" following it, indicating a concentration or quantity of the HE(95) molecule. On the right side, next to the molecular structures, there\\'s a caption that reads \"HE(95) + Molecule = 17\", which might be representing some form of score, energy difference, or another quantitative measure related to molecular docking, where the number \"17\" could be an indicator of how well the HE(95) molecule is interacting with the other unspecified molecule.\\n\\nThe background color of the image is light grey, and the text and graphical elements are in black, providing a clear contrast for easy readability. The style of the image suggests it\\'s intended for educational or informational purposes to explain scientific concepts related to molecular interactions. ', ' The image is a composite of two separate pieces, each representing different aspects of scientific or medical research.\\n\\nIn the upper half of the image, there is an illustration of a human cell. The cell is depicted in shades of green and blue, suggesting a focus on genetic or molecular biology. Inside the cell, there are various organelles that can be identified, such as mitochondria (the powerhouses of the cell), endoplasmic reticulum (involved in protein synthesis), and possibly vesicles or other membrane-bound structures.\\n\\nThe lower half of the image shows a graphic that appears to be explaining the process of gene editing using a method known as CRISPR-Cas9, which is highlighted by the arrow pointing at the cell in the upper part of the image. The text above the arrow reads \"Too much HER2 protein can cause cancer,\" indicating that the CRISPR technology is being used to modify or inhibit the expression of a gene associated with the HER2 protein.\\n\\nThe text below the arrow explains, \"CRISPR-CAS9 system can be programmed to cut and divide cancer cells.\" This suggests that the method being illustrated has the potential to specifically target and disrupt the DNA of cancer cells that are overexpressing HER2, which is a common feature in many types of cancer.\\n\\nThe overall image seems to be a visual representation of how gene editing technology can be applied to address issues related to cancer at the molecular level. ', ' The image presents a detailed diagram of the human heart and circulatory system. At the center of the image, there is a depiction of a human figure from a side view, with the back facing forward. The heart, marked by a red circle, is located in the chest area between the lungs. \\n\\nThe circulatory system is represented by various lines and arrows that flow from the heart, illustrating the complex network of blood vessels. There are labels on the diagram, indicating different parts of the circulatory system. For instance, the \"aorta\" is labeled as a large artery that carries oxygenated blood away from the heart to supply oxygen to the body\\'s tissues. \\n\\nAdditionally, the \"vena cava\" is labeled as a large vein that returns deoxygenated blood back to the heart. The \"brain\" and \"lungs\" are also labeled on the diagram, providing further context for the circulatory system\\'s function in delivering oxygen and nutrients to these vital organs. \\n\\nThe background of the image is a light beige color, which contrasts with the detailed illustration of the human heart and circulatory system, making it easier to understand the intricate workings of the system. Overall, the image provides a comprehensive overview of the human heart and circulatory system, providing an educational resource for those interested in understanding how the body functions. ', ' The image appears to be a screenshot of a computer screen with a web page open. The URL \"generated\" is visible in the address bar, suggesting that the user might be viewing a webpage generated by some process or software. The content of the webpage itself is not fully visible due to the resolution and angle of the image; however, we can see the top of what looks like a page with a title \"Generated,\" which is consistent with the URL\\'s suggestion that it is displaying the output of some sort of generation process.\\n\\nThe overall style of the image suggests that this might be an educational or technical screenshot, possibly showing the outcome of running some kind of code, software, or algorithm that generates content such as text, images, or data. The gray background and the plain white box in the lower-right corner are indicative of a typical web page layout.\\n\\nWithout more context or information about the image, it\\'s difficult to provide any additional details. The focus is on the webpage being displayed rather than any particular feature or detail within the screenshot itself. ', \" The image appears to be a close-up of a computer monitor displaying a blurry image. The focus is on the monitor, showing what seems to be a screenshot of another application or window, possibly an email or a document with text and graphics. Due to the low resolution and blurriness, it's not possible to provide specific details about the content displayed on the monitor.\\n\\nThe background behind the monitor shows a person with dark hair wearing glasses, and they seem to be engaged in some activity that requires concentration or focus. The lighting in the background is dim, with the light source coming from the front and shining downwards, creating a contrast between the illuminated area near the monitor and the darker areas around it.\\n\\nThe perspective of the photograph suggests that the person holding the camera was standing at an angle slightly above and to the side of the monitor, capturing this moment candidly. The photo is taken from a low angle looking upwards towards the person's head, which gives prominence to the monitor over the individual. \", ' The image displays a computer screen showing a text document with German language text. The text appears to be related to a technical or engineering subject, given the mention of \"Steinbrucher,\" which translates to \"steel construction\" in English. However, without additional context, it\\'s difficult to provide more specific information about the content of the text.\\n\\nAt the bottom of the screen, there\\'s a horizontal toolbar with various icons that suggest functions such as undo, redo, cut, copy, paste, select all, and more. The image is cropped, focusing on the document content without showing any surrounding interface elements that might indicate a specific software application or operating system.\\n\\nThe style of the image is a straightforward capture of a digital screen displaying text, intended to convey information about the displayed content rather than aesthetic elements. ', ' The image is a screenshot of a web page with a focus on the content rather than the design. It features a logo at the top left corner that reads \"SPES,\" suggesting it may be the name of the company or product line. Below the logo, there\\'s a text that appears to be in Greek and mentions \"SPES,\" which could indicate a brand or product name.\\n\\nIn the center of the image, there is a placeholder graphic for an image or video, commonly known as a \"Lorem ipsum\" placeholder text. This text typically consists of nonsensical words like \"Lorem ipsum dolor sit amet, consectetur adipiscing elit.\" It is used to demonstrate how text will appear in a design without relying on meaningful content.\\n\\nThe web page has a navigation bar at the top with links that may include options such as \"Home,\" \"About,\" \"Services,\" \"Contact,\" and \"Blog.\" The style of the image suggests it could be from a technology, healthcare, or lifestyle-oriented website given the mention of \"SPES\" which might suggest a health or wellness context.\\n\\nThe bottom part of the screenshot shows a footer with additional links that are likely to include \"Privacy,\" \"Terms,\" and other legal disclaimers or site information. The overall appearance is quite simple, with a white background and the content centered in the image. ', ' This image is a humorous illustration that depicts the concept of \"Phesgo,\" which seems to be an invention or technology. The central focus of the image is a syringe labeled with a plus sign, symbolizing its positive impact on health. On the right side, there\\'s a small figure with a heart on it, indicating that the technology has been well-received and appreciated.\\n\\nTo the left of the syringe, there are two additional elements: a pill bottle and a medical device, both of which appear to be part of the Phesgo system. These items suggest that Phesgo is not just a single tool or medication but rather an integrated approach to healthcare.\\n\\nThe background features a gray gradient, providing a neutral backdrop that allows the viewer\\'s attention to remain on the Phesgo technology. The overall style of the image is simple and cartoonish, using basic shapes and colors to convey its message.\\n\\nDespite the absence of text in the image, the visual elements strongly suggest that Phesgo is a comprehensive healthcare solution that combines medication with some form of medical device. It implies that this invention or technology has been well-received and appreciated, as indicated by the positive reactions from those it\\'s helping. The inclusion of the heart symbol next to the figure suggests that Phesgo has a significant emotional impact on its users, potentially improving not just their physical health but also their emotional well-being. ', \" The image displays a stylized icon of an individual wearing professional attire, which includes a white lab coat over a dark shirt. The person is depicted with a simplistic head silhouette and what appears to be a pair of glasses. To the right of the person's face, there's a green badge or tag, which suggests some form of identification or certification. Below this badge, there is a gray banner that contains white text; however, due to the image quality, it is not legible. The icon has a flat design style and uses a limited color palette, primarily consisting of shades of green and gray. There are no additional texts or elements within the image that provide context or information about the individual's profession or status. \", ' The image is a digital graphic with a white background. It features two sets of text and symbols overlaid on each other, creating a visual comparison or contrast between the concepts depicted.\\n\\nOn the left side, there is a timer icon showing that it has been running for 60 minutes, indicated by the numbers \"5\" and \"120\". Below the timer, the word \"PERJITA\" is written in bold letters.\\n\\nOn the right side, there is a similar timer icon with the numbers \"60\" and \"180\" visible, suggesting it has been running for 60 minutes and 180 seconds, which is equal to 3 hours. The word \"PERJITA\" is also present here, but it appears twice, one above the other.\\n\\nThe text \"PENALIDAD\" is prominently displayed at the top of the right side of the image, and \"HERBAL\" is written below it. Both words are in a bold font, but \"PENALIDAD\" is larger and more prominent than \"HERBAL\".\\n\\nThe overall style of the image is clean and straightforward, with a focus on conveying information about the duration of an activity or process related to penalties and herbal substances. The use of contrasting colors for the text might be intended to draw attention to specific elements within the graphic. ', ' The image presents a striking contrast between two different types of vaccines, each represented by an animal. On the left, we see a cartoon depiction of a peregrine falcon with a syringe in its beak and a vaccine vial in its claws. This illustrates the Pfizer-BioNTech COVID-19 vaccine, which was one of the first mRNA vaccines to receive emergency use authorization (EUA).\\n\\nOn the right, there is another cartoon depicting a honey badger with a syringe in its nose and another vial in its claws. This represents the Johnson & Johnson COVID-19 vaccine, which was another type of mRNA vaccine that was also granted EUA status.\\n\\nThe image uses these two contrasting images to explain how antibodies are produced by the immune system in response to a vaccination. The text at the top explains that \"periceta\" (a type of cell) produces antibodies to fight the infection or disease. The bottom part of the text indicates that \"herceptin\" and \"trastuzumab\" are drugs used for cancer treatment, implying that they are examples of how vaccines work in general by stimulating an immune response.\\n\\nThe image uses a visual metaphor to explain the concept of immunity, using animals as a creative way to illustrate the different types of vaccines and their mechanisms of action. It\\'s a simplified and stylized representation, likely intended for educational purposes to make complex scientific concepts accessible and understandable to a general audience. ', \" The image you've provided appears to be a digital graphic or an illustration of a concept rather than a photograph of a real object. It shows a circular diagram with a series of concentric circles, each containing what looks like a small circular design at the center. The design within each circle varies slightly in size and shape but shares a common geometric pattern.\\n\\nStarting from the innermost circle, there are four visible rings before the background fades into a lighter shade. The central design is simplistic with simple lines connecting points, suggesting an abstract or conceptual model. There are no texts or additional elements that provide context or information about the diagram. The style of the image is minimalist and schematic, with no attempt to represent realistic colors or shading, which is typical for technical illustrations or diagrams meant to convey ideas rather than a realistic representation. \", ' The image presents a pie chart and accompanying text, which appears to be in French. The pie chart is the central focus of the image, with a series of concentric circles emanating from its center. The first circle represents 85% and is colored green; the second circle represents 14% and is colored blue; the third circle represents 1% and is colored red. Within these circles, there is a darker green area that accounts for 14% of the whole pie chart, which corresponds to the second circle.\\n\\nTo the right of the pie chart, there is a text in French that reads \"85%\". This likely indicates the percentage value represented by the largest circle on the left, which is colored green and accounts for 85% of the entire pie chart.\\n\\nBelow this main section, there is another line of text in French, which is not fully legible due to its small size and resolution. However, it seems to contain additional information related to the data presented by the pie chart. The overall style of the image suggests a presentation or graphic design used for reporting statistics or results. ', ' The image displays a simple, stylized graphic with a white background. On the left side of the image, there is a circular clock displaying \"5 mins\" and \"1st injection\". The clock\\'s hands are in the position representing 5 minutes past one o\\'clock. To the right of this clock, another circular clock shows \"8 mins\" and \"Future Injections\". This clock\\'s hands are positioned between the six o\\'clock and eight o\\'clock marks, indicating a time period that is less than an hour but more than 5 minutes.\\n\\nBetween the two clocks, there is a horizontal line with the word \"INJECTIONS\" in bold, capital letters, emphasizing the comparison or relationship between the durations of time shown by the clocks. The style of the image appears to be educational or informative, possibly related to medical treatment or a schedule for some kind of process. ', ' The image is a screenshot of a website or online document, featuring text and images in various stages of loading. It appears to be a page from a medical or healthcare site, indicated by the presence of medical equipment icons and what looks like patient information fields.\\n\\nOn the left side of the screenshot, there\\'s a vertical navigation menu with a list of links that seem to point to different sections of the website: \"Patient Information,\" \"Insurance and Finances,\" \"Preparing for Your Visit,\" and \"Your Health and Wellness.\" The text is too small to read clearly, but it appears to be in English.\\n\\nThe main content area on the right side shows a placeholder graphic commonly used in web development to indicate where images will go once they are ready to load. It consists of a rectangular box with a plus sign inside, symbolizing that the space is intended for an image. Below this placeholder graphic, there\\'s a series of bullet points, but the text is too small to decipher.\\n\\nThe overall style of the website suggests it is still in development or undergoing updates, as suggested by the placeholder graphics and text that are not yet fully loaded. The color scheme is muted, with the predominant colors being shades of gray and blue, which may be intentional for a medical site to convey a sense of professionalism and trustworthiness. ', ' The image features a background that appears to be a muted, light-colored surface with a texture that could be fabric or a similar material. Overlaying the background is an icon that resembles a magnifying glass, which suggests the function of search or zoom in certain software applications or websites.\\n\\nThe icon itself consists of two main components: a circle and a question mark. The circular part has a dashed border and seems to be filled with a lighter shade of gray compared to the rest of the icon. Inside this circle is another shape, which could be interpreted as an eye, given its teardrop shape and the positioning it resembles a pupil and iris.\\n\\nThe question mark is superimposed on top of the eye-like shape within the circular border. It is stylized with a bold outline and filled with the same lighter gray color as the rest of the icon, ensuring contrast against both the circle and the background.\\n\\nThis image is designed in such a way that it communicates a concept of searching or examining something closely. The use of a question mark suggests curiosity or inquiry, while the magnifying glass typically signifies looking for something more intently. ', ' The image presents a humorous take on the current healthcare situation by comparing the processes of receiving medical treatment in two different countries. On the left side of the image, labeled \"PHESGO,\" there\\'s a diagram showing a syringe with a needle and a plunger. The process is represented by an arrow pointing from the syringe to a text box that reads \"12 days.\"\\n\\nOn the right side of the image, labeled \"THE SURGERY IN THE US,\" there\\'s another diagram that mimics the first but with a crucial difference. Instead of a single syringe, there are two syringes, each connected by a small hose to an IV drip bag labeled \"SURGERY.\" The arrow pointing from these syringes to the text box reads \"12 weeks.\"\\n\\nThe image seems to be commenting on the long wait times for medical procedures in some countries. It\\'s a playful comparison using simple medical equipment and time intervals, likely meant to spark discussion or laughter. ', ' The image presents a vivid scene of a surgical procedure that has just been completed. At the center, there\\'s a white board with a blue and red striped bandage on it, symbolizing the completion of the surgery. The bandage is secured with a small blue clip, suggesting recent application or removal.\\n\\nTo the right, there\\'s a blue surgical instrument that has been used in the procedure. Its presence indicates that it was likely one of the tools employed during the surgery.\\n\\nOn the left side of the image, there\\'s a text that reads \"SURGERY PHASE\". This could imply that the surgery phase is now over and we are transitioning to another phase of care or recovery.\\n\\nA key element in the image is the word \"PHESGO\", which appears twice. It might be referring to a medical condition or treatment related to the surgical procedure, possibly indicating that the patient had Phescgo before the surgery and now they don\\'t have it anymore due to the surgery.\\n\\nThe overall image suggests a successful surgical procedure with careful attention given to the healing process. The blue and red striped bandage and the blue surgical instrument are indicative of common tools used in such procedures. ', ' The image is a digital graphic that features text and illustrations. At the top, there\\'s a large illustration of an insulin syringe next to the word \"DOCETAXEL,\" which is likely referring to a medication or treatment called Docetaxel, typically associated with chemotherapy for cancer patients.\\n\\nBelow this, two pieces of text are present. The first piece says \"FESGO,\" which could refer to a condition, a location, or an acronym that has context-specific meaning. The second piece of text reads \"DOCETAXEL,\" again likely referring to the chemotherapy drug mentioned above.\\n\\nIn the center of the image is a small illustration depicting a syringe, with a needle and a plunger, suggesting a medical or health theme that continues with the text below.\\n\\nThe bottom part of the image shows two pieces of text side by side: \"DOCETAXEL\" on the left and \"FESGO\" on the right. The number \"6\" is written above each piece of text, which might indicate a dosage or frequency of use for the mentioned medication.\\n\\nThe style of the image is informational and educational, possibly intended to explain or advertise Docetaxel as part of FESGO treatment. The overall design is simple with a focus on conveying information through text and symbols that are easily understood within the context of healthcare or medical treatments. ', ' The image displays a webpage with a focus on a product or service called \"CyphGO\". This is indicated by the word \"CyphGO\" prominently displayed in bold letters at the top of the page. Below this title, there\\'s a URL that reads \"www.cyphgo.com\", suggesting that this is the official website for CyphGO.\\n\\nThe webpage design appears modern and clean with a light color scheme, primarily using shades of beige and white. On the right side of the page, there is a text box containing more information about CyphGO. The text is partially obscured, but it mentions \"substantiated in action\" and \"CyphGO - 100% NATURAL SUPPLEMENT\". This suggests that CyphGO is advertised as a natural supplement backed by evidence of its effectiveness.\\n\\nThe style of the image is a standard screenshot of a webpage, capturing the layout and design elements such as the logo, color scheme, and textual information provided by the website. The overall impression is that of an online marketing or sales platform for CyphGO. ', ' The image appears to be a graph with multiple elements. It\\'s a digital screenshot of what seems to be a medical or scientific paper, given the style of the graph and the context.\\n\\nThe graph itself is a line graph with various annotations. There are three lines representing different measures or datasets: one in blue, another in black, and the third in red. Each line represents some form of statistical data, possibly related to medical trials or clinical outcomes. The axes of the graph are labeled as \"Value\" on the y-axis and \"Time (Days)\" on the x-axis.\\n\\nThe lines fluctuate over time, with the blue line appearing to show a more gradual increase in value compared to the black line, which has more pronounced peaks and troughs. The red line is less visible due to the image\\'s resolution, but it seems to track closely with the black line.\\n\\nOn the right side of the graph, there are several annotations with labels like \"Value,\" \"0.01,\" \"0.5,\" and \"1.0.\" These could be specific values or milestones that correspond to the data represented by the lines. There is also a shaded area marked as \"Supportive care\" on the right side of the graph, which suggests a comparison between different treatment approaches or intervention thresholds.\\n\\nBelow the graph, there are additional annotations and numbers that provide further context:\\n\\n- \"Treatment_Care\" indicates that this is a comparison between two different treatments or care models.\\n- \"Treatment_Care\" and \"Supportive care\" suggest a comparison between standard treatment or care and supportive care only.\\n- \"0.01\" could be a baseline value or threshold for some measure of clinical outcome or efficacy.\\n- \"0.5\" might represent a specific point in time where there is a significant difference or event in the data.\\n- \"1.0\" could mark the end of the observation period or the time at which the data was last recorded or measured.\\n- \"Best Supportive Care\" implies that the red line represents the optimal or most effective supportive care scenario.\\n- The shaded area under the blue and black lines labeled as \"Supportive care\" indicates that this is an area where the outcome of treatment plus supportive care is better than standard treatment alone.\\n\\nThe image also includes a watermark or text overlay at the bottom left corner, which reads \"Best Supportive Care,\" suggesting that this is a key aspect of the data being presented.\\n\\nOverall, the image seems to be from a scientific study or analysis where the authors are comparing different treatment models and assessing the efficacy of supportive care in conjunction with standard treatments. ', ' This image is a screenshot of a chart from an Excel spreadsheet. The chart displays a line graph with the title \"Tracking Mortality by Age\" at the top. Below the title, there are two axes: the x-axis represents age in years and the y-axis represents mortality rates, which seem to be calculated using a methodology described as \"Mortality Rate per 100 Person-Years.\"\\n\\nThe chart is overlaid on a table that contains numerical data. The table has columns titled \"Age,\" \"Number of Deaths,\" and \"Population.\" The first column shows the age range, the second column lists the number of deaths in each age group, and the third column indicates the population size corresponding to each age group.\\n\\nThe line graph itself is populated with black dots that represent data points, a trendline in red, and shaded areas under the line that likely represent the confidence intervals or error bars. The data shows fluctuating mortality rates across different age groups over time, with the most recent data point showing a higher rate than previous ones.\\n\\nAt the top of the image, there is a text box that reads \"1,00\" indicating a value on the y-axis scale. This label corresponds to a specific point on the line graph, suggesting it is the maximum mortality rate per 100 person-years observed at the oldest age group shown.\\n\\nThe background of the image is a gradient of light colors transitioning from white to grey towards the bottom right corner. The style of the image suggests it is a snapshot from a presentation or analysis related to public health data and trends over time. ', ' The image appears to be a screenshot from a computer interface, specifically showing a graph or plot with statistical data. The central focus is on a line graph, which seems to represent some form of data trend over time. The horizontal axis of the graph is labeled \"Tecnología,\" indicating that this variable represents technological advancement or development over a period of time.\\n\\nThe vertical axis is labeled \"Proporción,\" suggesting that it represents the proportion of something within a specific context, such as the number of patients with a certain condition out of a total population or sample size. The line graph itself shows an increasing trend in this proportion as technological advancement increases, which could imply improved outcomes or prevalence rates for the phenomenon being measured by the graph.\\n\\nThe data points are plotted on a scatter plot, showing the relationship between the two variables: time (Tecnología) and proportion of something (Proporción). There is a clear upward trend visible in the graph.\\n\\nBelow the graph, there is a line segment with a label that reads \"By surgery.\" This suggests that the graph specifically compares data related to outcomes or conditions measured by technology versus those measured by surgical intervention. The segmented area seems to show two separate lines representing different categories of measurement or analysis: one labeled \"Tecnología\" and another labeled \"Surgical intervention.\"\\n\\nThe title at the top left corner reads \"Survival by surgery,\" which aligns with the context provided by the graph and the labels. This implies that the data being presented are related to survival rates, and the comparison between technology and surgery is meant to highlight how each method impacts or influences these rates.\\n\\nThe overall style of the image suggests it\\'s from a medical or healthcare context, where technological advancements in treatments might be compared to traditional surgical methods for analyzing their respective impacts on patient outcomes or survival rates. The presence of Spanish text within the graph implies that the data may be specific to Spanish-speaking regions or related to research or studies conducted in Spain. ', ' The image presents a line graph, which serves as the main focus. This graph appears to represent some form of data over time, with the x-axis labeled \"Time (months)\" and the y-axis labeled \"Number of Cases\". The graph shows three lines representing different categories or groups: \"Presence\", \"Potential\", and \"New\". Each line is color-coded differently, making it easy to distinguish between them.\\n\\nThe \"Presence\" line seems to start at the beginning of the timeframe and continues to rise steadily, indicating an increasing number of cases over the period shown. The \"Potential\" line also begins near the beginning of the graph but rises less steeply compared to the \"Presence\" line. The \"New\" line starts much later than the other two lines and increases at a relatively fast rate, suggesting that it might represent data from a different source or category.\\n\\nThe title of the graph is \"Survival of COVID-19 by age\", which implies that the data represents the survival rates of COVID-19 across different age groups. The graph appears to be sourced from an entity named \"Yale School of Medicine\", as indicated by the text at the top right corner.\\n\\nThe image also contains a legend, explaining the meaning of each line in the graph. This helps viewers understand what each line represents. The overall layout and style of the image suggest it is designed to present scientific or medical data clearly and effectively for interpretation. ', ' The image appears to be a screenshot of a computer monitor displaying a graphical plot, which seems to represent some sort of data over time. The plot features two lines: one is in black, and the other is in red. Both lines show a similar trend with small fluctuations around a central value, suggesting that they are tracking the same variable.\\n\\nThe horizontal axis of the plot is labeled \"Time,\" indicating that the measurements or values on this axis represent moments in time. The vertical axis is labeled \"Value,\" which implies that the numbers along this axis correspond to some measure of magnitude or importance related to whatever is being measured.\\n\\nThere are also several text annotations in the image, although their content and context are not clear due to the low resolution of the image. Additionally, there is a watermark on the bottom right corner that reads \"1/2,\" which might be indicating some sort of fraction or ratio related to the data presented.\\n\\nThe overall style of the image suggests it could be from an academic paper, presentation slide, or other document where scientific data is being visualized for analysis and interpretation. However, without a clearer view or additional context, it\\'s difficult to provide more detailed information about the content or purpose of this plot. ', ' The image is a composite of two separate visuals, each conveying different data.\\n\\nThe upper visual appears to be a line graph with a scatter plot overlaid on it. This graph has a horizontal axis labeled \"months\" and a vertical axis labeled \"Survival probability.\" A line representing the survival probability starts at 100% on the left side of the graph and declines as we move towards the right, suggesting a decrease in survival probability with time. The scatter plot shows various points above the line, which might represent individual data points that deviate from the overall trend of the line graph.\\n\\nThe lower visual is a line chart showing \"Sentiments\" over time. This chart also has a horizontal axis labeled \"months\" and a vertical axis labeled \"Sentiment.\" The line representing sentiment starts at 0 on the left side of the graph and rises to around 50 near the right end, indicating that sentiment increased over time.\\n\\nThe data points are represented by small black squares against a white background for both graphs. The upper graph shows a single line with multiple black dots, while the lower graph has a continuous line without any additional symbols.\\n\\nThere is a legend at the bottom right of the image that explains that the gray dots represent \"Sentiments.\" Additionally, there\\'s text indicating that the survival probability starts at 100% on the left side and ends near 25% on the right side.\\n\\nThe style of the image suggests it is a screenshot from a presentation or report, possibly used in a medical or health context to illustrate longitudinal data related to patient outcomes (survival probability) and perceptions (sentiments). The specific context or data interpretation is not provided within the image itself. ', ' The image is a graph with two different plots, each representing a different data set. \\n\\nOn the left side of the image, there\\'s a plot labeled \"Test Set\" in black text. This plot shows a line that increases over time, starting from an initial value near zero and reaching a peak value after a certain period before dropping off again towards the end of the graph. The x-axis represents time in months, ranging from 0 to about 32 months. The y-axis is labeled \"Count\" in black text, indicating that the values on the y-axis represent some sort of count or measurement.\\n\\nOn the right side of the image, there\\'s another plot with a similar label \"Test Set\" but colored in red. This plot also shows a line that increases over time, following a similar trend as the first plot. The same axes labels are used for this plot as well.\\n\\nBoth plots have vertical dashed lines labeled \"0.5\", which likely mark a significant threshold or point of interest in the data. There is also a horizontal dashed line at the top of the y-axis, labeled with an unreadable value that could be a specific count or threshold.\\n\\nAt the bottom of the image, there\\'s another set of values shown without any plotting. The values are listed as \"Prediction\" and are associated with the x-axis from left to right. The text \"Prediction\" is repeated for each value on this line. ', ' The image is a composite of two different sections, each with its own set of data represented visually.\\n\\nOn the left side of the image, there\\'s a line graph with a title that reads \"Tecnitro / Carboplatin / Neuromuscular blocker / Tocilizumab.\" This section seems to be comparing the outcomes of different treatments or drugs in relation to a certain metric, likely a clinical endpoint. The x-axis is labeled \"Centro / cardiopulmonaire / telitropin,\" which suggests that the data points represent cases from a center with a focus on the heart and lungs, possibly related to cardiopulmonary diseases, and another group or cohort of patients receiving telitropin, a medication known for its potential immunomodulatory effects. The y-axis is labeled \"Ave / %\" with increments of 10%, indicating that the data points represent some form of average or percentage change across different timepoints represented by the horizontal axis, although the specific time intervals are not visible in this image.\\n\\nThe line graph has a series of connected points that show fluctuations and trends over time, with each line corresponding to one of the treatments or medications mentioned in the title. It appears that the data for Tecnitro (the blue line) is relatively stable over time with minimal variation, while the data for Carboplatin (the red line) shows a more pronounced variability. The lines for Neuromuscular blocker and Tocilizumab are not clearly visible in this image, but their presence suggests that they may also show trends similar to those seen in the other lines.\\n\\nThe right side of the image contains another graph with two line charts. This section is titled \"Tecnitro / Carboplatin / Tocilizumab,\" which mirrors the title on the left side, suggesting that it\\'s a continuation or comparison between the same treatments as seen in the left graph. The y-axis of this section is labeled with increments of 10%, indicating that the data points represent some form of change or percentage variation over time.\\n\\nThe x-axis on this right side graph is also labeled \"Centro / cardiopulmonaire / telitropin,\" which implies that the data is organized in a similar manner as it was in the left section. The line charts for Tecnitro and Carboplatin are visible, showing a more gradual increase in percentage change compared to the left graph.\\n\\nOverall, the image appears to be comparing different treatments or medications over time in relation to some clinical outcome, with the data represented in two separate sections of the image. ', \" The image you've shared appears to be a screenshot of a webpage or an application displaying a line chart. The chart is simple and straightforward, with one line that seems to be tracking some kind of data over time. However, without more context, it's difficult to determine the exact nature of the data represented by the line on the chart.\\n\\nThe x-axis (horizontal) represents time, but the specific intervals or units are not provided. The y-axis (vertical) likely corresponds to a value or quantity that is being measured or tracked, though the exact scale and units are also unknown from this image.\\n\\nThere are two main areas in the chart: one with a darker shade of color where the line intersects, suggesting that there might be a significant event or change at that point, and another area on the right side where the line is lighter and seems to be decreasing, indicating a downward trend.\\n\\nThe background of the image has been edited to remove the context of the webpage or application, leaving only the chart visible. This obscures any additional information that might have provided more details about the data being plotted. \", ' The image presents a striking visual of data represented as a line graph on a white background. The x-axis of the graph is marked from 1 to 20 in increments of 5, while the y-axis ranges from 0 to 9, also with intervals of 5. \\n\\nThe main line graph shows a downward trend, starting at 7 and ending at 0 on the x-axis. This line is filled with small black dots, creating a jagged pattern that suggests fluctuations in the data being represented. A smaller inset graph, located in the lower right corner of the image, displays a more detailed view of the same data. The title \"TEMPESTR\" is visible in the top right corner of this inset graph, indicating the name of the dataset or study.\\n\\nTo the left of the main graph, a text box contains a list of values, each marked with an asterisk symbol. These values are: 1, 2, 5, 6, 8, 9, and 10. The values are displayed in ascending order and seem to correspond to different points on the graph.\\n\\nThe image also contains a legend that helps interpret the graph. The legend mentions two groups of data: \"TEMPESTR\" and \"BREVITATE\". These two groups are represented by different symbols on the line graph: filled circles for TEMPESTR and open squares for BREVITATE.\\n\\nIn addition to these, there is a vertical bar with two horizontal bars inside it. This vertical bar contains numbers that correspond to the height of each horizontal bar. The top horizontal bar has the number \"7\" next to it, while the bottom horizontal bar has the number \"0\".\\n\\nOverall, the image provides a visual representation of data related to TEMPERSTR and BREVITATE, with a focus on the fluctuations in the values over time. ', ' This image is a photograph of a computer screen displaying a graph with statistical data. The graph appears to be a scatter plot, where each point represents an observation or measurement. It has multiple layers of data, with different types of markers indicating the nature of the observations.\\n\\nOn the x-axis, there is a label that reads \"Time (months),\" suggesting that the data is presented over time in months. The y-axis is labeled \"Treatment (mg/kg),\" indicating the treatment received by an entity or group of entities. There are two vertical axes, one for each axis, which represent the scale of measurement for the x and y variables respectively.\\n\\nThe data points are color-coded and overlaid on a background that seems to be a grayscale image, possibly another type of graph or dataset, but it is not fully visible due to the partial nature of the image.\\n\\nIn addition to the scatter plot, there is a bar graph below it with a label \"Cumulative incidence.\" This suggests that the bars represent the cumulative occurrence of an event (perhaps related to the treatment and time axis) over time. Each bar has a corresponding value labeled above it, which likely represents the number of events in the data set up to that point in time.\\n\\nThe image also contains text that is partially obscured and not fully legible due to the resolution and angle of the photograph. However, one can see parts of the text that mention \"Treatment (mg/kg),\" \"Time (months),\" \"Cumulative incidence,\" and \"100.\"\\n\\nThe image has a grainy texture and is taken at an angle, which makes the edges of the screen visible. The lighting in the photograph is not even, with some areas more brightly lit than others. ', ' The image appears to be a graphical representation of data, possibly from a scientific or statistical study. It features a line graph with two lines, one solid and the other dashed, both plotted against an X-axis labeled \"Weeks since admission.\" Both lines are trending downwards, suggesting a decrease in some measure over time.\\n\\nThe vertical axis, on the left side of the image, is labeled with numbers ranging from 0 to 100. The horizontal axis, at the bottom, is marked with dates, indicating that the data spans a period of time, although the exact duration is not visible due to the resolution.\\n\\nAbove each line, there are two sets of numbers and symbols: one set represents values in a unit not specified (possibly percentages or other ratios), while the other set is labeled as \"Treatment group\" with a series of dots representing individual data points, and a line connecting these dots.\\n\\nThe top right corner contains text that reads \"TREATMENT GROUP,\" which likely refers to the group of individuals or subjects included in the treatment intervention represented by the solid line graph.\\n\\nIn the upper left corner, there\\'s a legend with symbols indicating different groups or categories. The specific labels for these symbols are not clearly visible due to the resolution.\\n\\nThe image also has a text watermark at the bottom that reads \"2017,\" which may indicate the year when the data was collected or analyzed.\\n\\nOverall, the image is likely intended to convey the results of an experiment or observational study involving two groups, with the line graph serving as a visual means of comparing their values over time. ', ' The image presents a clear and concise visual comparison of the lungs in two different states. On the left, we see a healthy set of lungs with labels indicating their condition. The lung labeled \"Normal\" is a pristine white, suggesting it\\'s in optimal health. On the right side, there\\'s another pair of lungs with a label that reads \"Asthma.\" These lungs are depicted in shades of blue and gray, with additional coloring to highlight specific areas affected by asthma.\\n\\nThe image serves as an educational tool, visually representing how the structure of healthy lungs differs from those affected by asthma. The labels on the \"Asthma\" lungs suggest that certain parts are either inflamed or damaged due to this respiratory condition. This could be a helpful tool for medical professionals to educate patients about asthma and its impact on lung function, or it may be used in an educational context to illustrate the complexity of human anatomy and the potential effects of various health conditions. ', ' The image displays a detailed diagram of an organ system, specifically focusing on the lungs and the respiratory system. The central feature is a pair of lungs depicted in blue against a white background, with the left side larger than the right. Each lung has multiple lobes, which are further divided into smaller segments.\\n\\nThe lungs contain air spaces, as indicated by the black areas within them. These air spaces provide room for gas exchange and allow for the expansion of the lungs during breathing.\\n\\nOn the upper left side of the image, there is a labeled illustration of a non-small cell lung cancer. The cancer cells are depicted in red, with one cell showing a mutation as indicated by the purple circle with a dot inside it, suggesting genetic alterations that can occur in such tumors.\\n\\nTo the right of the cancer, there\\'s an explanation in white text that reads: \"Primary tumor lymph node\". This suggests that the cancer has spread to nearby lymph nodes, which are part of the immune system and help filter out foreign substances or pathogens.\\n\\nBelow the lungs, there is a section labeled \"Pulmonary veins\", indicating the major vein that carries blood from the lungs back to the heart. This is crucial for the circulation of oxygenated blood throughout the body.\\n\\nThe diagram also labels a part of the lung as \"Bronchial tree\", which is responsible for branching into smaller airways and leading to alveoli, where gas exchange takes place.\\n\\nIn summary, this image provides a comprehensive view of the respiratory system, emphasizing the normal structure of the lungs and illustrating how cancer can affect the organ. It also highlights the role of lymph nodes in filtering the blood. ', ' The image is a digital composition with text overlaying on the bottom. It features two main elements: an illustration and a photograph.\\n\\nThe illustration is situated at the top of the image, showcasing a small figure carrying out a preparation in a lab setting. This character is depicted using various pieces of equipment such as test tubes, beakers, and what appears to be a microscope or similar device. The figure is focused on the task at hand, with the eyes looking downward towards the glassware and instruments.\\n\\nBelow this illustration, there\\'s a photograph. It displays a pair of human eyes looking upwards, as if focusing on something above or outside the frame. The background is indistinct, but it suggests an outdoor setting due to the natural light illuminating the scene.\\n\\nOverlaying both the illustration and the photograph is text that reads: \"Answer to carry out the preparation of the INTRAMEDECATORE.\" The word \"INTRAMEDECATORE\" stands out in bold, black font.\\n\\nThe image seems to be educational or instructional, potentially related to chemistry or biology, given the lab equipment and the focus on a preparation process. ', ' The image is a graphical representation of an eye dropper being filled with medication. It is a photograph or an illustration rather than a digitally created image. On the left side of the image, there\\'s an eye dropper in action, with liquid being dispensed into it. To the right, we see a close-up view of the eye dropper. The liquid being dispensed appears to be medication, as indicated by the small bottle attached to the dropper, which has the word \"EXP\" on it, suggesting that this is expired medication. ', ' The image is a composite of three separate photographs, each depicting a different scene with the same subject matter. In each photo, there\\'s an object that looks like a white, cylindrical container with a black lid and a small amount of yellow liquid inside.\\n\\n1. In the top left photo, we see a close-up view of this container from above. The lid is attached, and the container appears to be placed on a surface with a dark background.\\n\\n2. In the top right photo, there\\'s a clear, rectangular container in the foreground, with a white label that has some text written on it; however, the text is not clearly legible. Behind this container, there\\'s another similar container placed upside down on a surface with a dark background.\\n\\n3. In the bottom photo, there are two identical containers. One container is in the foreground and placed right-side up on a surface with a dark background. The other container is in the background, also upside down but rotated differently than the one in the foreground.\\n\\nAcross all three photos, there\\'s an overlaid text that reads \"Figure B\", indicating that these are part of a figure or a series labeled as \\'B\\'. ', ' The image presents a step-by-step demonstration of the process of taking a medication from a blister pack. The sequence is depicted in three distinct stages, each highlighting a different action that one would take to access the medication inside the pack.\\n\\nIn the first stage, labeled as Figure D, we see a hand holding a blister pack. The hand appears ready to peel back the protective cover of the blister pack to reveal the medication inside.\\n\\nMoving to the second stage, labeled as Figure E, the same hand is seen gently lifting the corner of the cover to separate it from the blister pack. This action typically requires a certain amount of force to ensure that no other tablets are dislodged or damaged in the process.\\n\\nFinally, in the third and final stage, labeled as Figure D, we see the blister pack fully opened, revealing the medication inside. The hand is now holding the cover open, ready to dispense the medication onto a surface. The entire sequence seems to be carefully choreographed to show the correct method of opening a blister pack without causing any damage or disruption to the remaining tablets within the pack.\\n\\nThe image serves as a clear and concise guide for those unfamiliar with how to open a blister pack, ensuring that the medication is accessed safely and correctly. ', ' The image is a grayscale photograph depicting two hands interacting with a device. On the left side of the image, one hand appears to be holding something small and cylindrical, which could possibly be a tube or a roll. This object has an opening at one end, suggesting it might contain some material that can be dispensed or applied in a precise manner.\\n\\nOn the right side, another hand is seen using what looks like a screwdriver to tighten or adjust a small knob or wheel, which is likely part of the same device as the item in the left hand. This action implies that the person is assembling, calibrating, or maintaining the device.\\n\\nThe background of the image is not detailed, but it seems to be an indistinct neutral surface that does not provide any context for the location or setting where this activity is taking place. The focus of the image is on the hands and the object they are working with, emphasizing the task being performed. There are no visible texts within the image. ', ' The image displays a humorous illustration of an unconventional method for filtering a liquid using a syringe. A hand is seen holding the plunger end of a syringe, which is in contact with another syringe containing the liquid to be filtered. The syringes are connected by a thin tube, indicating the flow of liquid from one to the other.\\n\\nThe text above the image reads \"Figure F,\" suggesting that this method might be part of a series or an educational context. It describes the process as follows: \"push the transfer filter needle into the syringe, then push it all the way in; then tilt the syringe from edge of the vial [see Figure H].\"\\n\\nBelow the illustration, there is a note that says \"see Figure H,\" indicating that there is further instruction or information in another part of the document. The figure number \"H\" is not visible in this image. The humorous aspect of the image likely lies in the absurdity of using a syringe as a filter, which is typically used for injecting liquids, and the suggestion to use it for filtering liquids by physically pushing the needle into the syringe. ', ' The image appears to be a composite of two separate photographs placed one above the other. In the top photograph, there is a pair of scissors with their blades open and pointing towards the center of the image. These scissors have black handles and are made of a metal that looks like it could be stainless steel or aluminum. The scissors are resting on what appears to be a piece of paper or cardstock, which has text written in a foreign language.\\n\\nThe bottom photograph shows a different object; it is a small white bottle with a pointed cap, suggesting it may contain some sort of liquid or powder. The bottle is positioned upside down and appears to be empty, as no contents are visible through the cap opening. It is placed on top of what seems to be another piece of paper or cardstock, which also has text written in the same foreign language as the paper in the upper photo.\\n\\nThe style of the image is simple and clear, with a focus on these two objects. The background is neutral and does not distract from the items being showcased. There are no additional contextual elements that would provide information about the location or purpose of these objects. The text within the images, while present, is too small to read clearly, which makes it difficult to provide any insights based on its content. ', ' The image displays a diagrammatic illustration of an intravenous (IV) drip setup. The central figure in the image is a clear plastic bag, which contains a yellow liquid, presumably the substance that will be administered via the IV drip. This bag is connected to a needle by a transparent flexible tube, typically made of silicone or other flexible materials. \\n\\nTo the right of this setup, there\\'s a diagrammatic representation of the needles and tubing involved in an IV drip system. There are two types of needles depicted: one for drawing up the liquid from the bag into the needle, and another for transferring the liquid from the needle to the patient\\'s bloodstream through a process known as filtering. The tube connecting these needles is labeled \"Filtering,\" indicating that it contains a filter designed to remove any particles or contaminants from the liquid before it reaches the patient\\'s bloodstream. \\n\\nThe background of the image is white, providing a clean and uncluttered backdrop for the illustration. There are no texts or additional graphics within the image. The focus is solely on the IV drip setup, its components, and their functions in the medical setting. The image serves as an educational tool to explain the process of administering IV fluids. ', ' The image shows a hand holding a syringe with a needle inserted into the barrel, which is connected to a cartridge. The cartridge appears to be made of clear plastic and contains what looks like a black substance within it. The hand holds the needle steady, suggesting an injection or dosing process. The background is neutral and does not distract from the subject at hand.\\n\\nAt the bottom of the image, there is text that reads \"Figure 1\". This could indicate that this image is part of a series or is meant to illustrate a concept or step in a process related to the substance inside the cartridge. The text suggests that this might be related to a technical or medical context, possibly discussing the administration of medication or treatment.\\n\\nThe image itself seems to serve an educational or instructional purpose, showing the proper way to use a syringe with a cartridge for dispensing or injecting the contents, which could be medication or another type of liquid or gel substance. The style of the image is simple and utilitarian, focusing on clarity of the object being demonstrated. ', ' The image shows a hand holding a syringe with its needle pointing upwards, ready for use. The syringe is being prepared to be injected into a human figure depicted on the right side of the image. The figure appears to have a visible vein or blood vessel in the arm, which is a common site for intravenous (IV) injections.\\n\\nThere are two main points of interest in this illustration:\\n\\n1. Syringe and Needle: A syringe with a needle is being held up, suggesting that it\\'s about to be injected into the vein of the human figure. The syringe has a visible plunger at its base, which is used to draw liquid from a container or to inject liquid into the body.\\n\\n2. Human Figure: On the right side of the image, there is a simplified representation of a human figure with an arm extended. The figure\\'s head is not visible in this illustration. The visible vein on the arm indicates where the injection will be administered.\\n\\nThere are three additional elements in the image:\\n\\n1. A small circle with a checkmark inside it, which could indicate some form of approval or verification process related to the medical procedure being depicted.\\n\\n2. An instructional text \"Figure K,\" suggesting that this image might be part of an educational resource or manual, possibly teaching how to perform a specific medical procedure.\\n\\n3. A red circle with a diagonal line through it, which is often used in diagrams to indicate that the item shown should not be done (in this case, indicating that the injection is not yet completed).\\n\\nThe overall context of the image suggests that it might be illustrating an educational step-by-step guide or a pictorial representation of an intravenous procedure. The image does not contain any text other than the text mentioned above and the \"Figure K\" label. ', ' The image appears to be a photograph of a printed document, possibly an academic paper or a technical report, which includes text and images. At the top of the image, there\\'s a title \"Vascular Interference in Infertility: A Comparative Analysis Between Diabetic Vascular Diseases and Non-Diabetic Vascular Diseases\".\\n\\nBelow the title is a list of keywords or topics related to the paper: \"Diabetic vascular diseases, Vascular interference, Infertility, Diagnosis, Treatment, Vascular screening, Reproductive health, Endothelial function\".\\n\\nThe document contains several paragraphs of text, which are likely to be the introduction and methodology sections of a research paper. These sections discuss the importance of vascular interference in infertility and provide an overview of the study\\'s goals and methods used.\\n\\nThere is a table included within the text, labeled as \"Table 1\". The content of this table isn\\'t fully visible, but it seems to compare different parameters between diabetic vascular diseases and non-diabetic vascular diseases in relation to infertility.\\n\\nFurthermore, there are two figures presented in the document, both labeled as \"Figure 2\". These figures appear to be scatterplots with a legend, but the specific details of the plots are not entirely clear due to the resolution and size of the images within the document.\\n\\nAt the bottom of the image, there is a footnote that states: \"The authors acknowledge that the study was conducted without ethical approval.\" This statement indicates that the research methodology may have been criticized or questioned for lack of ethical oversight.\\n\\nOverall, the image conveys the essence of an academic paper discussing a specific topic in medical research and its implications in reproductive health. The quality and legibility of the text suggest that this is a professional or scholarly publication intended for an audience familiar with the subject matter. ', ' The image displays a table titled \"Table 2: Primary Impact Results in the Huna Valley and Lusaka.\" The table is structured with four columns, each headed by a capital letter. The first column lists different sites, including Kafue, Huttoo, Kapiri, and Chilenje. The second column indicates the results of an impact assessment for each site. The third column shows the impact assessment scores, which appear to be numerical values ranging from 6 to 9. The fourth column provides a brief description or comment about the impact assessment results at each site.\\n\\nEach row in the table corresponds to a different site, and there is a fifth row that seems to summarize the results for all sites combined. The last row appears to be the total for the impact assessment across all sites.\\n\\nIn the fourth column, there are comments such as \"Mean change is 5\", \"Mean change is 7\", \"Mean change is 8.1\", and so on, which provide a sense of how much the impact assessment score has changed from the baseline at each site. The comments also indicate that some sites have seen an increase in their scores, while others have experienced a decrease.\\n\\nThe image quality is low, with text that\\'s somewhat blurry and difficult to read accurately. This suggests that the image might be of a lower resolution or that it was taken from a distance where the details are not clear. The context of the image—whether it\\'s an academic paper, a report from a consulting firm, or something else—is not immediately apparent. ', ' The image appears to be a screenshot of an electronic document or application, which seems to be related to health, medical records, or clinical data. At the top of the document, there is text that reads \"Best connected visualization study.\" This suggests that the content may discuss a research project or analysis concerning visualizations and their connection within a study or context.\\n\\nThe main body of the image shows a table with several columns, each heading with an abbreviation:\\n\\n- DVA (which could stand for \"Diabetic Value Assessment\")\\n- ETS (which could be an acronym for something specific to the context of the document)\\n- Early Diabet Retinopathy (EDRT)\\n- Least Space (LS)\\n\\nBelow these headers, there is a numerical value in the DVA column and two columns titled \"ETDRS.\" The values in the ETS column seem to be percentages or scores associated with each row. There are also two rows of data in the ETS columns, one under \"EDRT\" with a score of 1 and another under \"LS,\" which has a value of 0.\\n\\nThe document is set against a grey background with a faint shadow on the left side, suggesting that the image might have been taken from a computer screen or a digital display device. The style of the image is informational, similar to what one would expect from a research paper, academic presentation, or clinical report. ', ' The image is a black and white graphical representation of some data, likely from a scientific study or experiment. It features two main plots:\\n\\n1. A bar plot located at the top left quadrant of the image shows the frequency distribution of a certain variable. There are three bars visible, each corresponding to different categories of a numerical variable (with values ranging from -15 to 90). The x-axis represents the range of values, and the y-axis indicates the number of occurrences or count for each value category.\\n\\n2. Below the bar plot, there is a line graph with two lines. These lines represent different categories of another variable that are not specified in the image. The horizontal axis labels the time points at which the data was collected or measured, ranging from 0 to approximately 55 units. The vertical axis on the right side indicates some quantitative metric, which could be related to a performance measure or an error rate for both line graphs.\\n\\n3. At the bottom of the image, there is a pie chart with four slices. Each slice represents a different category of another variable that is not specified in the image. The labels \"weekly average,\" \"weekend average,\" \"weekly total,\" and \"weekend total\" suggest that these categories relate to some form of aggregated data across the week versus the weekend.\\n\\nThe overall style of the image is functional, with a focus on presenting numerical data visually. There are no visible texts providing additional context or explanations about what the data represents, how it was collected, or what it suggests. The choice of black and white may be for aesthetic reasons or to highlight certain aspects of the data more clearly. ', ' The image displays a line graph with two sets of data points, one in black and the other in red. Both datasets represent a numerical value on the y-axis, which ranges from 0 to 18, and is labeled \"Percentage of EV\" at the top left corner. There is also a legend on the left side of the graph indicating that the black line represents \"Voter,\" while the red line represents \"Nonvoter.\" The x-axis shows age groups ranging from \"Age < 18\" to \"Age > 65,\" with increments of 5 years, except for the last group which includes ages over 65.\\n\\nThe graph is superimposed on a gray background and is set against a light beige or cream-colored backdrop. In the upper right corner of the image, there\\'s a small text that reads \"Voter\" and \"Nonvoter.\" The title of the graph, which is at the top center, is not fully visible due to the angle of the image; however, it starts with \"Comparison of\" and seems to be discussing electoral data.\\n\\nThe style of the image is a standard line chart typically used in academic or statistical analysis to represent data over time or across categories. The graph is simple and informative, designed to compare two groups (voters and non-voters) across age ranges. The presence of a legend indicates that the viewer is meant to distinguish between the two sets of data points. ', ' The image displays a table titled \"Efficiency results at year 1 and year 2 of the Yosemite and Rhine Studies\". The table is organized into three columns: \"Year\", \"Site\", and \"Efficiency\". There are two rows in the table, corresponding to years 1 and 2. Each row has four entries under each column.\\n\\nUnder the \"Year\" column, there are entries for \"Year 1\" and \"Year 2\". Similarly, under the \"Site\" column, there are entries for \"Yosemite\" and \"Rhine\". Finally, the \"Efficiency\" column lists values that represent some measure of efficiency or performance in each site at each year.\\n\\nThe numbers in the \"Efficiency\" column are presented with a plus sign, indicating that they might be positive values or percentages. The specific nature of these numbers is not clear from the image alone.\\n\\nOverall, the table appears to be a summary or comparison of efficiency measurements at two different sites (Yosemite and Rhine) across two years (Year 1 and Year 2). However, without additional context, it\\'s difficult to determine what specific metrics these efficiency numbers represent or how they are being used for decision-making or reporting purposes. The image itself does not contain any other discernible details or elements that would provide further context about the nature of the data or its significance within the broader context of the Yosemite and Rhine Studies. ', ' The image presents a graph, which appears to be a scatter plot with a regression line. The x-axis is labeled \"VASI,\" which might stand for a variable or indicator of some sort, possibly related to healthcare or medical care, such as a score for vascular health or the number of vasculitis cases in a study. The y-axis is labeled \"Change in ESV/M2,\" suggesting that this graph is tracking changes in the endothelium shear velocity (ESV) per square meter (M2).\\n\\nThe scatter plot consists of multiple data points connected by lines, indicating the relationship between VASI and ESV/M2. The regression line is a smooth curve that represents the best fit for the data points, showing how ESV/M2 tends to change as VASI increases or decreases.\\n\\nThere are three bars on the right side of the graph, each representing different groups or categories based on the color codes. These bars likely represent some form of comparison between different groups in a study or population:\\n- The first bar is black and labeled \"ALL,\" suggesting it represents all participants or cases in the study.\\n- The second bar is white and labeled \"VASI>1500,\" indicating that this bar only includes data points from participants with VASI values greater than 15,000.\\n- The third bar is gray and labeled \"VASI<1500,\" showing the change in ESV/M2 for those with VASI values less than 15,000.\\n\\nAt the bottom of the graph, there\\'s a note that says \"Change in ESV/M2 is not adjusted for age or sex,\" which implies that the data points are not normalized for these factors. The top left corner of the image contains a watermark or logo, but it is partially obscured and unreadable. ', \" The image you've provided appears to be a graphical representation of some data, possibly from a scientific or technical field. Here are the details I can observe:\\n\\n- **Title and Axes**: There is no visible title at the top of the image, but we can see that the x-axis represents days and the y-axis represents some numerical value, which could be related to a parameter such as temperature, pressure, or another quantitative measure. However, without specific labels, it's not possible to provide precise details about what these axes represent.\\n\\n- **Graph Type**: The graph is line-based, with multiple lines representing different sets of data over time. Each line is labeled with a legend at the bottom right corner, indicating that each color represents a different variable or category being measured.\\n\\n- **Data Points and Trends**: There are several lines that show fluctuating values over the course of the day. Some lines show a clear trend, while others appear more irregular. The lines are color-coded and seem to converge towards certain points in time.\\n\\n- **Additional Information at the Bottom Right**: Below the graph, there is a table or summary that includes various numbers, possibly representing statistical measures related to the data presented. These might include means (AVG), standard deviations (STD), and other statistical parameters. However, without specific labels on the lines or in the table, it's not possible to provide a detailed explanation of each number.\\n\\n- **Context and Interpretation**: Without any accompanying text, it's challenging to provide a full interpretation of this image. The context in which this graph was created is likely specialized, requiring knowledge about the specific field or data being represented. It could be related to meteorology, physics, engineering, or another technical discipline where time-series data is commonplace.\\n\\nGiven the limitations of visual analysis without additional context and information, it's difficult to provide a comprehensive analysis of this image. The image serves as a visualization tool for someone familiar with the subject matter to analyze and interpret the trends and patterns within the data. \", ' The image displays a printed document with text. The text at the top of the document reads \"14. MACULAR EDENA FOLLOWING VENOUS OCCLUSION (YVO).\" Below this title is a paragraph of text that discusses the prevalence and incidence of macular edema following venous occlusion, mentioning specific patient demographics.\\n\\nThe text emphasizes the safety and efficacy of a particular intervention or treatment, noting that it was tested on 127 patients with a 95% confidence interval. It also mentions \"YVO,\" which might refer to an acronym or abbreviation related to the context of the document.\\n\\nFurther down, the text highlights some statistics: \"498 patients treated from 3688-2017, 86% were white; 2017-2018, 85% were white.\" It also mentions that there were 13,273 treatments in total and a specific dose was administered to patients.\\n\\nAt the bottom of the document, there is additional text providing further details about the study or treatment. The text reads: \"In both cases, retinoids were randomized with placebo for a period of one year.\" It also states that 497 patients received 20mg of YVO every four weeks, and mentions the number of treatments received by different age groups.\\n\\nThe document is part of an academic or clinical publication, as indicated by the layout, font, and the presence of tables with data. The style of the image is a straightforward printout, and no images or graphics accompany the text. ', ' The image is a photograph of a printed document that appears to be a research paper or academic report. At the top, there\\'s a title in bold letters, but the text is cut off and not fully visible. Below the title, there are three sections with different headings.\\n\\n1. The first section has two sub-headings: \"Introduction\" and \"Objectives of the study.\" These sections contain text that is partially obscured by the angle of the photograph and the focus on another part of the document, making it challenging to read all the details. However, it seems to be a standard introduction or methodology section, which often includes information about the background and significance of the research, as well as the objectives of the study.\\n\\n2. The second section is titled \"Primary Empirical Results at Balaton.\" This section also has several sub-headings, such as \"Balaton Week 34 in the Coming Studies,\" which seems to relate to data collected from a specific week at Balaton in relation to the studies being referenced. The results are presented in a table with three columns: \"VARYING,\" \"BALATON WEEK 34,\" and \"COMING.\" Each row of the table contains two numbers, which appear to be statistical values or measurements of some sort.\\n\\n3. The third section has a headline that is also cut off, but it seems to say \"WEEK IN THE COMING STUDIES\" with sub-headings that include \"BALATON WEEK 34,\" similar to the second section. This section includes additional tables and statistical data.\\n\\nThe document includes other typical elements of an academic paper, such as a reference or citation style for the sources cited in the text. The overall layout is structured with headings, sub-headings, and tabular data designed to present and analyze research findings related to Balaton Week 34. ', ' The image is a graphical representation of data related to a subject, which appears to be Balaton. It shows the weekly rate of positive change in visual acuity from baseline to week 21, with a significant drop at week 16. The line graph is overlaid on top of a bar graph that represents the number of patients experiencing an energy drop from baseline to week 16.\\n\\nOn the left side of the image, there\\'s a text box containing the title \"Mean change in visual acuity from baseline to week 21 Balaton\" and below it is a footnote stating \"From week 1 to week 7: 38%\". This implies that the initial mean change in visual acuity was 38%, but after week 1, there was a decrease.\\n\\nThe right side of the image shows a bar graph with a single bar representing the number of patients experiencing an energy drop from baseline to week 16. The bar is labeled as \"Week 16,\" suggesting that this is the point in time when the drop occurred.\\n\\nBelow these two graphs, there\\'s another line graph showing the weekly rate of positive change in visual acuity from baseline to week 21 Balaton overlaid on top of a second bar graph representing the number of patients experiencing an energy drop from baseline to week 16. This suggests that the data is being visualized in two different ways, possibly to highlight different aspects of the data or to compare them more effectively.\\n\\nThe image seems to be from a scientific publication or a presentation related to medical research, specifically focusing on Balaton, which may refer to a location, a condition, or some other specific context within the field of medicine or health care. The exact nature of Balaton is not clear from the image alone. ', ' The image you\\'ve provided appears to be a screenshot from a statistical analysis software. It shows a line graph with two lines, each representing different data points.\\n\\nThe x-axis of the graph is labeled \"weeks,\" indicating that the graph is plotting some kind of metric over time in weeks. There are 10 intervals on the x-axis, ranging from week 0 to week 9.\\n\\nOn the y-axis, there are numerical values ranging from 0 to approximately 8, which likely represent the magnitude of the variable being measured. The numbers \"0\" through \"6\" are marked along the y-axis.\\n\\nThe graph itself contains two lines: a solid line and a dashed line with filled circles. These lines represent different data sets or variables being compared over time.\\n\\nIn addition to the graph, there is a table on the right side of the image, which seems to provide additional context or results from the analysis. The table includes rows with numerical values and labels such as \"Mean,\" \"Std. Error,\" \"Minimum,\" \"Maximum,\" \"Variance,\" and \"Sample Size.\"\\n\\nThere are also several annotations on the graph:\\n\\n- At the top left of the graph, there is a vertical line labeled \"0,\" which likely indicates the baseline or starting point for the data being plotted.\\n- To the right of the solid line, there is a shaded area that appears to represent an upper and lower bound within which the data points are expected to fall with a certain level of confidence. This is typically represented as a \"confidence interval\" or \"error bar.\"\\n- There are two data points on the graph: one on week 1 and one on week 9, both located slightly above the solid line, indicating that these values are higher than the overall trend suggested by the solid line.\\n\\nThe image does not contain any text or legends explaining what the data represents specifically, so it is open to interpretation without additional context. The software interface elements suggest that this could be a screenshot from statistical analysis software used for plotting and analyzing data in fields such as finance, economics, social sciences, or engineering where time-series data is common. ', \" The image is a digital illustration that appears to represent a conceptual or symbolic model of an organism. At the center, there's a blue sphere with multiple smaller circles, suggesting it could be a representation of a cell or cells within an organism. The larger circle at the bottom of this central sphere seems to have a structure that could be interpreted as a nucleus.\\n\\nInside this large circle, there are various shapes and forms that might symbolize different organelles or parts of a cell. There's a flower-like shape in the top left corner, possibly indicating a chloroplast involved in photosynthesis, and a star-shaped structure in the top right, which could represent a mitochondrion, where energy is produced.\\n\\nOn the bottom left side of this sphere, there's a representation of a cell membrane with what looks like a vesicle or secretory granule nearby, indicating active transport and synthesis processes within the cell. The bottom right corner features a more abstract representation of a structure that could be interpreted as an endoplasmic reticulum (ER), which is involved in protein synthesis and folding.\\n\\nThe background of the image transitions from dark to light, with the outermost layer being white, providing a stark contrast to the colorful cellular structures. This kind of illustration might be used for educational purposes, such as teaching biological concepts or for artistic representation of a scientific concept. \", ' The image appears to be a screenshot of a website or an application. The visible portion of the webpage is dominated by a purple-grey color scheme with text elements in white and shades of yellow.\\n\\nOn the left side of the page, there\\'s a large image of a person who seems to be a woman with brown hair. She is wearing a plaid shirt and has a slight smile. To her right, there\\'s a section with text that seems to describe a medical process or procedure, possibly related to cardiology, as indicated by the word \"CARDIO\" in large white letters.\\n\\nIn the center of the page, there\\'s a prominent white circular box with an icon that resembles a heartbeat monitor, and some text inside it which appears to be related to health or medical services. The icon is likely used as part of the user interface for selecting options within the app or website.\\n\\nTo the right of this circular box, there\\'s another section with more text, although the resolution is not high enough to discern its content clearly.\\n\\nThe bottom of the image shows a footer with various links and icons, which are common on websites for navigational purposes. The overall style of the webpage suggests it could be related to healthcare services, possibly providing information or offering an online platform for such services. However, without higher resolution or more context, it\\'s challenging to provide specific details about the content or functionality of the website. ', \" The image appears to be a screenshot of a computer screen displaying a webpage. The content of the page is partially obscured due to the angle at which the photo was taken and by the presence of a watermark or overlay text on top, making it difficult to read the full details of the page.\\n\\nAt the center, there's a large image occupying most of the page, showing a person from behind, standing in front of what seems to be a window with curtains partially drawn. The person is wearing a light-colored top and dark pants or shorts. The window provides a glimpse of an urban setting outside, with buildings and trees visible.\\n\\nBelow this central image, there are sections with text and buttons that likely offer different functionalities on the website, such as navigation links or call-to-action buttons. However, due to the watermark and angle, it is challenging to provide a detailed description of the text or specific elements in these sections.\\n\\nOn the left side of the webpage, there's a vertical menu bar that might include additional navigation options or links to other parts of the website.\\n\\nThe bottom section of the webpage seems to have more text, which could be related to content marketing or blog posts, but again, the watermark obscures this information.\\n\\nThe overall style of the image is informational and possibly promotional, as suggested by the text overlay. However, due to the visual distractions and angle, it's challenging to provide a detailed analysis of the content or design of the webpage. \", ' The image is a screenshot of an online platform, possibly a travel website or an online booking service. At the top of the page, there\\'s a header with the text \"Patient Brochure\" in purple, suggesting that this might be a special section of the site for medical tourism or health-related travel offerings. The main heading of the brochure, located just below the header, reads \"Open Up Your World,\" indicating a welcoming and expansive viewpoint on travel opportunities.\\n\\nBeneath this headline, there\\'s an image of a beach scene with people lounging under umbrellas, which seems to represent relaxation or leisure activities. The bottom right corner has the logo for \"Vabysmo,\" which might be the name of the company or service offering travel services.\\n\\nThe overall design of the screenshot is clean and professional, with a color palette that includes shades of blue, purple, and white, creating a calming and inviting atmosphere for potential visitors. The use of imagery suggests that the platform offers experiences that include relaxation and outdoor activities. The design elements are arranged in a way that guides the user\\'s attention from the top, where the \"Patient Brochure\" header is located, down to the bottom right corner with the company logo, emphasizing both the category and the branding of the service. ', ' The image appears to be a screenshot of a digital device displaying a website page. The website has a colorful and engaging design, featuring a photo at the top right corner showing three individuals on a beach setting, with one person seated on a chair under an umbrella and two others standing in the background.\\n\\nThe main content of the webpage includes a headline that says \"The Patient Brochure contains important information about AMD and Various Treatment Options\" and a button below it labeled \"DOWNLOAD PATIENT BROCHURE.\" The text suggests that the website is informing visitors about brochures related to Age-Related Macular Degeneration (AMD) and various treatment options.\\n\\nThe webpage has a clean layout with a navigation bar at the top, which includes links to \"HOME,\" \"PRODUCTS,\" \"PATIENTS,\" \"RESEARCHERS,\" \"CAREGIVERS,\" \"PARTNERS,\" \"INVESTORS,\" \"MEDIA,\" and \"CONTACT US.\" These elements indicate that the website is likely an educational or informational portal related to medical topics, specifically AMD and its treatments.\\n\\nThe overall style of the image is consistent with a typical webpage design, which aims to present information in an organized and visually appealing manner. The use of a beach photo might be intended to create a connection between the content of the website (which could relate to vision or health) and relaxation, although it\\'s not clear from the image alone how this relates to the AMD information provided on the website. ', ' The image appears to be a screenshot of a webpage. The top part of the page displays the name \"Wet AMD and\" followed by a description that seems to be incomplete or cut off, making it difficult to read the full text. There is also an image of a purple and white cupcake with a bite taken out of it, located just below the text.\\n\\nTo the right of this central content area, there is an email address \"info@prevention.com.\" This suggests that there might be an option for users to contact the organization associated with the webpage.\\n\\nThe bottom part of the image contains a notice from a company named \"Prevention,\" which provides information about supporting these organizations. The text is small and partially obscured, but it seems to encourage visitors to get involved in some way, possibly by making a donation or signing up for newsletters.\\n\\nOverall, the style of the image suggests that it could be a screenshot from an older website design, as evidenced by the text formatting and the layout of the page elements. The image quality is not very high, which makes some details hard to discern. ', ' The image appears to be a screenshot from a computer screen displaying a webpage. At the top of the page, there is a logo with the text \"PREVENT BLINDNESS\" and a globe icon inside a stylized circle. Below the logo, the main body of the webpage shows a plain gray background. The layout suggests that this might be a homepage or landing page for an organization dedicated to preventing blindness. The overall impression is that of a simple and clean design commonly used in non-profit websites. ', ' The image appears to be a screenshot of a website from the organization \"Bright Focus.\" The main focus of the image is a banner at the top, which prominently displays a message: \"Fighting Blindness Together. We\\'re winning!\" This suggests that the organization is united in its efforts to combat blindness.\\n\\nBelow the banner, there are two sections visible in the screenshot. The upper section includes text and an image of a person with what seems to be a bright light around their eyes, which may symbolize the focus on vision or the idea that the organization is bringing light into people\\'s lives.\\n\\nThe lower section of the image features additional text and logos. It mentions \"Bright Focus\" again and includes a logo for \"MDS Support.\" The presence of these two elements suggests that the website may offer resources and support for those with multiple sclerosis (MSD), a condition that can cause vision problems among other symptoms.\\n\\nThe overall layout of the webpage is clean and straightforward, with a clear focus on the organization\\'s mission to fight blindness and possibly its association with MS support through MDS Support. The color scheme includes shades of blue and white, which may be part of the branding for Bright Focus. ', ' The image appears to be a composite of two different elements, one on the left and one on the right. On the left, there\\'s a graphic with a dark background featuring an abstract design that includes diagonal lines and shapes, predominantly in shades of purple and white, giving it a modern and possibly tech-oriented look.\\n\\nOn the right side of the image, there is a logo or emblem which seems to be associated with \"VAB\" as indicated by the text beneath it. The VAB logo consists of a stylized letter \\'V\\' in purple, followed by the acronym \\'AB\\', likely representing some form of organization or company. Below this, there\\'s additional text that is too small to read clearly, but it appears to be a website address: \"vab.com\".\\n\\nThe overall style of the image suggests that it might be related to technology, software, or a digital service due to the abstract design and modern typography used in the logo. The color scheme, with its purple accents, implies a corporate or branding context. ', ' The image appears to be a screenshot of a webpage related to vaccines, specifically focusing on the topic of COVID-19. The page is designed with a clean, professional layout and includes both textual and visual elements.\\n\\nAt the top, there\\'s a header that reads \"LEARN ABOUT RV\" in white font against a dark background. Directly below the header, on the left side of the screenshot, is a photograph of an older woman with gray hair, wearing a light-colored shirt. She seems to be interacting with or showing something on the screen of what appears to be a tablet or a monitor.\\n\\nThe main body of the screenshot shows a section titled \"Learn about RV,\" which is presumably an abbreviation for a specific topic within the context of vaccines or COVID-19, as indicated by the small image below the title. The text on this part of the screen is not clearly legible due to the resolution and size of the screenshot.\\n\\nTo the right, there\\'s a section with a headline that says \"LEARN ABOUT RV,\" followed by a subheadline which seems to be providing information or instructions related to RV, but the text is too small to read clearly. This section includes an icon depicting a human body with an atom representing a cell, surrounded by a circle that might represent the concept of \"cellular response\" in the context of RV and vaccines.\\n\\nBelow this section, there\\'s a call-to-action button that reads \"LEARN MORE,\" which is likely meant to encourage users to click and find more detailed information about RV or its relationship with COVID-19.\\n\\nThe overall design suggests an informational website that aims to educate users about vaccines, specifically focusing on the topic of RV in relation to COVID-19. The use of a real person interacting with the content implies an approachable and human element to the learning process. ', ' The image appears to be a screenshot of a website, focusing on the section dedicated to patient safety. The website has a dark background with white text and some images.\\n\\nOn the right side of the screen, there is a large photo of a young child who seems to be outdoors with their hair styled in a way that it\\'s blonde and long. Below this image, there is a menu or navigation bar with links such as \"Prescription Safety,\" \"Real Patient Stories,\" \"Resources,\" and \"Contact Us.\"\\n\\nThe main content area of the website displays information about prescription safety in different languages, with English selected by default. The English text is too small to read clearly due to the resolution of the image. However, there are bullet points that presumably outline safety tips or guidelines for prescription medication.\\n\\nAt the top left corner of the screenshot, there\\'s a logo followed by some text that says \"Prescription Safety.\" Below this, in the upper right corner, is a phone number and an email address, indicating contact information for the organization or service the website represents. The overall style of the image suggests it\\'s a professional healthcare-related resource. ', ' The image is an illustration of a microscopic view of the female reproductive system, focusing on the cervix and uterus. At the center of the image, there is a magnified view of a section where the cervix, which is typically at the top, would be visible. Below this central part, the uterus is depicted with three distinct sections labeled as \"Ang-2,\" \"Branch Vain,\" and \"Central Vain.\"\\n\\nThe illustration is educational, aiming to provide a visual representation of these structures within the female reproductive system. The use of color, such as purple for the cervix and uterus, helps distinguish between different parts.\\n\\nIn the bottom part of the image, there is a legend or key explaining the various elements shown in the illustration: \"Ang-2,\" \"Branch Vain,\" and \"Central Vain.\" These labels are associated with the corresponding parts in the diagram, providing context to what each section represents.\\n\\nThe overall layout of the image suggests it is meant for educational purposes, possibly as an informational poster or a teaching aid. The diagram serves to visually explain the complex structure of the female reproductive system on a microscopic level, which might not be easily understood from direct observation alone. ', ' This is a colorful, educational illustration that appears to be explaining the concept of how a person\\'s body reacts to an injection or medical intervention. On the left side, there are three labeled components: \"Vabysmo,\" \"blocks Ang 2,\" and \"VEGF.\" Vabysmo is a blockage of Ang 2, which is a type of angiogenesis inhibitor, preventing the formation of new blood vessels, typically associated with cancer growth. VEGF stands for Vascular Endothelial Growth Factor, a protein that stimulates the growth of new blood vessels and contributes to the maintenance of existing ones.\\n\\nThe central focus of the image is an artistic representation of what appears to be a cell or tissue sample. This sample has been labeled with \"blocks Ang 2,\" suggesting it is being treated with this angiogenesis inhibitor, as indicated by the blocked-out sections on the left. The label \"VEGF\" is also present next to the Vabysmo blockage, indicating that this cell or tissue sample is being affected by the presence of VEGF.\\n\\nThe right side of the image shows a magnified view of what seems to be an eye, possibly depicting the eye\\'s retina. This part of the image is labeled with \"Vabysmo blocks Ang 2,\" which might suggest that this particular cell or tissue sample within the eye has been treated in a similar manner to block angiogenesis.\\n\\nThe text at the bottom reads \"Blocks angiogenesis VEGF,\" which reinforces the concept of how Vabysmo works by inhibiting the action of angiogenesis and VEGF, possibly preventing or reducing the growth of new blood vessels in areas where it is not desirable. This could be referring to conditions such as cancer or other diseases where excessive angiogenesis can contribute to their progression.\\n\\nOverall, the image is designed to simplify complex biological processes for an audience that may not have a background in medicine or biology. It uses color coding and labels to guide the viewer through the concept of how a drug can affect cellular responses in different parts of the body. ', ' The image presents a close-up view of a human eye, which is the central focus. This eye is encased in a clear orbital socket and is affixed to the surrounding skull by a suture, as indicated by the labels \"reduced fluid\" and \"sutured\". \\n\\nThe eyeball is characterized by a blue iris, through which the dilated pupil can be seen. The iris, pupil, and other internal structures are clearly visible against the white background of the image.\\n\\nSurrounding the eye is a detailed diagram representing the brain\\'s perception of the world. This diagram is annotated with labels like \"reduced fluid\" and \"swelling\", suggesting some sort of medical or biological context to the image. The diagram is not fully visible, but it seems to be providing a scientific explanation related to the eye.\\n\\nThe image appears to be educational in nature, possibly from a medical or biology textbook. It\\'s designed to illustrate anatomical details and their corresponding terms. However, without additional context, the exact purpose of this image remains unclear. ', \" The image shows a screenshot of a webpage with a predominantly white background and text in various colors. At the top, there is a banner with a photo of two people, possibly taken outdoors due to the presence of trees and natural lighting. The photo features one person wearing a hat, looking down, while the other person is facing the camera directly.\\n\\nThe main body of the webpage contains multiple sections, each with its own heading and content. There are blurred images or icons placed at different intervals along the page, but the details of these images are not clear due to the low resolution. The text on the page is too small to read in detail, but it appears to be structured into paragraphs.\\n\\nThe style of the image suggests that this might be a screenshot from a computer monitor displaying a webpage. The content of the webpage includes various types of text and images, but without a higher resolution or clearer view, it's difficult to provide specific details about the text or the nature of the images. \", ' The image is a screenshot of a webpage. At the top, there is a header with text in various shades of purple that reads \"IMPORTANT SAFETY INFORMATION.\" Below this headline is a navigation bar with menu items such as \"WHOLESALE,\" \"Retail,\" \"Distribution,\" and \"Pricing.\"\\n\\nFurther down the page, there is a large section with a light background featuring an image of two individuals in what appears to be a park setting. The person on the left is wearing a green jacket and has short hair, while the person on the right is wearing a dark jacket and has longer hair. They are both looking towards something or someone off-screen.\\n\\nThe bottom section of the webpage contains text that provides information about the company and its products, likely related to medical supplies and safety equipment. There are several bullet points in black font against a white background, with titles such as \"WHOLESALE,\" \"Retail,\" \"Distribution,\" and \"Pricing.\" Each point is followed by additional details. The text appears to be well-organized, with clear headings and paragraphs providing information about the company\\'s offerings.\\n\\nThe overall style of the webpage is modern and professional, with a color scheme that includes shades of blue, purple, and white. There is also an \"Important Safety Information\" section with its own subheading \"WHAT YOU NEED TO KNOW,\" followed by additional bullet points in black font against a white background.\\n\\nThe website\\'s address at the bottom of the page is \"www.safeinfo.com,\" suggesting that this is the domain for which the webpage is designed to provide information. The design suggests that the purpose of the site is to inform potential customers or users about safety-related products and services offered by the company. ', ' The image appears to be a screenshot of a webpage. At the top, there is a navigation bar with links for \"Home,\" \"About Us,\" \"Privacy Policy,\" \"Terms of Service,\" and \"Contact Us.\" Below this, on the left side, there\\'s a section titled \"Patient Brochure,\" which seems to be part of an interactive brochure or portal. On the right, there\\'s another section with two individuals engaged in what looks like a conversation or presentation, possibly related to a health-related service or product.\\n\\nThe main body of the image features a large banner or promotional section with text that reads \"OPEN UP YOUR WORLD WITH VYBSYM.\" Below this headline is a tagline that says \"Your Trusted Partner in Medical Marijuana.\" This suggests that the content is related to medical marijuana and its benefits.\\n\\nThe design of the webpage uses a color scheme of shades of blue, green, and white. The overall impression is that of a professional website providing information on medical marijuana, likely targeting potential patients or customers. ', ' The image appears to be a screenshot of a digital document, possibly an informational guide or brochure. It is structured with text and images against a white background.\\n\\nAt the top of the document, there\\'s a header that reads \"PATIENT BROCHURE,\" suggesting that this resource is intended for patients, although the specific context or purpose is not provided. The design uses a combination of shades to create a visually appealing layout.\\n\\nThe main body of the document features a large circular image in the center with three individuals and the text \"OPEN UP YOUR WORLD WITH VESIMA.\" This could indicate a theme related to travel or personal wellness, as suggested by the open book graphic that resembles a globe inside the circle.\\n\\nTo the left of this central image, there is a smaller inset photo showing two individuals outdoors with a mountainous backdrop. They appear to be enjoying a hike or outdoor activity.\\n\\nOn the right side of the document, there\\'s another text that says \"PATIENT BROCHURE,\" reinforcing the purpose of the document. Below this, additional text reads \"OPEN UP YOUR WORLD WITH VESIMA.\" This reinforces the theme and likely refers to a product or service called VESIMA.\\n\\nThe overall style of the image is modern and clean, with an emphasis on text and images that seem to relate to health and wellness in the context of outdoor activities or travel. The use of circular shapes and the globe graphic suggest a connection between physical health and exploration or discovery. ', ' The image shows a logo with graphical elements, predominantly in shades of blue and purple. The logo features the word \"VABYSMOIT\" in uppercase letters, with the \\'O\\' in \"MOIT\" replaced by an abstract graphic resembling a wave or ribbon. The style of the image is modern and corporate, and it appears to be designed for a company or organization named \"VABYSMOIT.\" ', ' This image displays a screenshot of a webpage with a blue header that includes the text \"worldwide\" and a subtitle below it. The main content area has a headline in bold text which reads, \"THE RIGHT FOR YOU.\" There is an accompanying photograph showing two individuals standing outdoors; one person appears to be speaking while the other listens. Both people are dressed in casual attire.\\n\\nIn the lower right corner of the image, there\\'s a logo or icon that resembles a cross with the word \"worldwide\" beneath it. This logo is associated with a phone number displayed below it: \"+216 37 45\". The background of the webpage features a gradient from light to dark gray.\\n\\nThe overall style of the image suggests it\\'s a digital screenshot, possibly from a mobile device given the layout and dimensions of the elements. The design is simple with a focus on providing information to viewers. ', \" The image presents a monochromatic, wireframe model of a room. Dominating the space is a large hole in the center of the room, revealing a darker area beyond it. This void is surrounded by a grid of black lines and dots, giving the impression that the room has been digitally cut out and replaced with this wireframe structure. \\n\\nOn the left side of the room, there's a small, white dot located near the bottom of the image. The dot seems to be floating in space within the confines of the wireframe model. Its precise location suggests it could represent a point of interest or importance within the context of this image. \\n\\nThe absence of color and the stark contrast between the dark interior and the white dot create a striking visual. Despite the simplicity of the elements, the image conveys a sense of mystery and intrigue about what lies beyond the hole in the room and where the small dot is leading to. \", ' The image displays a logo with the text \"BYSMO\" prominently at the top. The logo is graphic and features an abstract design resembling a stylized mountain peak, which appears to be composed of three color blocks: one in purple, one in yellow, and one in green, creating a layered effect that gives the impression of depth or elevation. Below this graphical element, there\\'s a small text \"ELECTROVISION INJECTIONS\" aligned to the right.\\n\\nIn the lower left corner, there is a small rectangular emblem with a purple background and an arrow-like shape in white. The style of the image suggests it could be related to a medical or health industry logo, given the mention of \"electrovision injections.\" The color scheme includes shades of purple, yellow, green, and gray. ', ' The image shows a screenshot of a webpage with a focus on safety information. At the top, there\\'s a header with a dark background and white text that reads \"Important Safety Information.\" Below this, there\\'s a section titled \"What is Weatherbay?\" followed by a description in smaller font. The main body of the page features an informative paragraph in bold black font on a light blue background. It explains that the information provided is important and relevant to everyone, regardless of their role or department within the company.\\n\\nThe footer of the webpage has a section with multiple questions such as \"What are Weatherbay\\'s values?\" followed by bullet points with answers. The first question says, \"Why is safety important to Weatherbay?\" and provides two reasons: \"To protect our employees\" and \"To ensure high quality products.\"\\n\\nThe design of the webpage is clean and professional, utilizing a color scheme that includes shades of blue and white for readability against the light background. The overall impression is one of a well-organized, safety-focused company website where safety is clearly prioritized. ', ' The image you\\'ve provided appears to be a screenshot of a website with a focus on learning and treatment related to AMD (Age-Related Macular Degeneration). The main section of the website features an educational video about AMD, emphasizing that there is a cause and treatment for this condition.\\n\\nThe text in the image reads: \"Learning what causes wet AMD. Your eye doctor will diagnose it.\" This suggests that the content on the website aims to educate viewers about the causes of wet AMD (specifically, neovascular AMD), as well as the role of an ophthalmologist in diagnosis.\\n\\nThe video thumbnail depicts a person wearing a red shirt and a black hat, standing outdoors with trees in the background. There is no text or additional information provided about this individual. The focus seems to be on the content rather than the person.\\n\\nIn the lower right corner of the image, there\\'s a small part of an article visible, which might suggest that the website also includes written content related to AMD. However, due to the resolution and size of the screenshot, the details of the article are not clear.\\n\\nThe overall design of the website suggests it is educational in nature, aiming to provide information about AMD to a general audience. The use of a video as the central feature indicates an effort to engage viewers with multimedia content. ', ' The image you\\'ve provided appears to be a scientific diagram or illustration, possibly related to cellular biology or anatomy. It shows a cross-sectional view of what seems to be a structure within a cell, which could be a microorganism or a subcellular organelle given the presence of organelles such as mitochondria and vacuoles.\\n\\nAt the center, there is a circular structure that is likely to represent the nucleus, characterized by its spherical shape and central position in the cell. Surrounding the nucleus are various organelles and structures which could be part of a bacterial cell given their arrangement and function:\\n\\n- To the left of the nucleus, there appears to be a structure that resembles a mitochondrion, with its elongated, tubular shape and double membrane.\\n- Adjacent to the mitochondrion is an organelle that looks like a vacuole, with its rounded, bulbous shape and lack of membrane enclosing it.\\n- On the right side of the image, there\\'s another mitochondrion, similar in shape to the first one, also surrounded by a double membrane.\\n- In between these two mitochondria, there is an elongated structure that could be part of the cell wall or plasma membrane, which encloses the entire cellular structure and provides protection and regulation of substances.\\n- There are also smaller, spherical structures scattered around the image. These might represent other organelles such as ribosomes or cytoskeletal elements like periplasmin or peptidoglycan layers in bacterial cells.\\n\\nThe color coding suggests that different parts of the cell have different functions or components:\\n\\n- The purple structures could be proteins or enzymes involved in metabolism or gene expression, such as ribosomes or DNA-associated proteins.\\n- The blue and green colors might represent different types of lipids, carbohydrates, or other cellular components.\\n\\nThe text \"ANGL2\" could refer to a specific protein or enzyme that plays a role in this cellular structure, possibly related to its function in energy production or intracellular signaling pathways.\\n\\nWithout more context or information about the image, it\\'s challenging to provide a definitive explanation of what is depicted here. However, it is clear that this image is intended to convey complex cellular biology and the interactions between different organelles within a eukaryotic or prokaryotic cell. ', ' The image is a logo for \"EVIDI\". The logo features the name \"EVIDI\" in lowercase letters with a stylized color scheme. The first part of the word, \"Ev\", has a blue and pink hue, while the rest of the name, \"IDI\", is depicted in white text against a solid purple background. In front of the \"DI\", there is a small orange circle containing three green dots arranged vertically. To the left of the logo, there is additional text that reads \"Risiko di riduzione del vantaggio con il trattamento,\" which translates to \"Risk of reduction of the advantage with treatment.\" The style of the image is corporate and clean, likely intended for branding or signage purposes. ', ' The image appears to be a logo or emblem, likely representing an organization or event. It features a graphic element with colorful bubbles that are connected in a linear pattern, giving the impression of a path or progression. Within this arrangement, there is a white space where text would typically be placed, but it\\'s currently blank.\\n\\nTo the right of the bubble arrangement, there is a stylized representation of a tree or plant with its branches extending outward in a natural growth pattern. The tree is colored in shades of blue and green, suggesting foliage.\\n\\nAbove the graphic elements, there is text in Hungarian that reads \"EVYSDI,\" which seems to be the name of the entity or the event this logo represents. Below this, there are two lines of text; the upper line says \"FÜZMÉNYEK VÍGJÁRAD,\" translating to \"Exhibitions in a continuous run,\" and the lower line reads \"EVYSDI ISSZEPÉLYEZI A KÖZVÉDELEK MEGJAVITASÁT,\" which can be translated as \"EVYSDI supports the development of public services.\"\\n\\nThe overall style of the image is clean and modern, with a color palette that includes pastel hues for the bubbles and a more realistic representation for the tree. The text uses a sans-serif font, contributing to the contemporary aesthetic of the logo. The design seems to suggest a connection between exhibitions or events and their impact on public services, possibly indicating an initiative or organization dedicated to supporting continuous improvement in these areas. ', \" The image you've provided is a close-up of what appears to be a carpeted floor in an indoor space. The carpet has a subtle pattern, and the color of the carpet blends with that of the wall, creating a seamless transition between the two surfaces. The lighting in the room is soft and ambient, casting gentle shadows and highlighting the texture of the carpet fibers. There are no visible objects or distinctive features that would allow for more specific descriptions about the contents of the image. The focus is on the floor itself, providing a view that suggests a well-maintained interior space. \", ' The image is a black and white photograph of a scientific diagram. It displays the chemical structure of a molecule, which appears to be an organic compound. The molecular structure is represented by a series of lines connecting various atoms, suggesting the bonds between them.\\n\\nAt the top of the molecule, there is a nitrogen atom with two bonds leading away from it, indicating that this atom serves as a functional group, commonly referred to as a \"nitrogen heteroatom.\" Below this nitrogen atom, there are other atoms including carbons and possibly additional nitrogens or other heteroatoms. The structure includes rings of atoms, which suggests the molecule may contain aromatic rings such as benzene rings, which are common in organic chemistry.\\n\\nThe image also shows a label with the atomic number 13, representing a carbon atom with 13 valence electrons. Additionally, the image includes an organic chemist\\'s notation for the nitrogen-containing ring, denoted by \"NH\" indicating an amino group, and \"CH\" indicating a methylene group (two carbon atoms bonded to each other).\\n\\nAt the bottom of the molecule, there is a three-dimensional depiction of a molecular structure with a covalent bond between two atoms, one of which could be an oxygen atom given its location next to a double-bond system. This three-dimensional model provides a visual representation of how the molecule might exist in three dimensions.\\n\\nOverall, the image is likely used for educational or scientific purposes, such as in a textbook, academic paper, or presentation on organic chemistry, specifically focusing on the synthesis and properties of organic compounds. ', ' The image displays a gray textured background with a central, darker-gray element that appears to be a cylinder or pipe. On this central shape, there are two pieces of information depicted in white text against the darker gray: \"Rainwater Collection\" at the top and \"5 Gallons\" at the bottom, indicating a quantity of rainwater collected. The style of the image is simple and functional, resembling an informational graphic that might be used in educational settings or for informing users about water collection practices. ']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "# import os\n",
    "# import ollama\n",
    "# from tqdm import tqdm\n",
    "# import base64\n",
    "# from PIL import Image\n",
    "# from io import BytesIO\n",
    "\n",
    "# # Initialize an empty list to store the results\n",
    "# img_summaries = []\n",
    "\n",
    "\n",
    "# # Iterate over all image strings in the list with a tqdm progress bar\n",
    "# for image_string in tqdm(image_elements, desc=\"Processing images\"):\n",
    "#     # Decode the image string using utf-8 encoders\n",
    "#     img_data = base64.b64decode(image_string)\n",
    "#     img = Image.open(BytesIO(img_data))\n",
    "    \n",
    "#     # Save the image to a temporary file\n",
    "#     img.save(\"temp.jpg\")\n",
    "    \n",
    "#     # Call the chat function with the image file\n",
    "#     res = ollama.chat(\n",
    "#         model=\"llava\",\n",
    "#         messages=[\n",
    "#             {\n",
    "#                 'role':'user',\n",
    "#                 'content':'Describe elaboratively about this image and text labels on it :',\n",
    "#                 'images':[\"temp.jpg\"]\n",
    "#             }\n",
    "#         ]\n",
    "#     )\n",
    "    \n",
    "#     # Append the result to the image_summary list\n",
    "#     img_summaries.append(res['message']['content'])\n",
    "\n",
    "# # Print the image_summary list\n",
    "# print(img_summaries)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# documents = []\n",
    "# retrieve_contents = []\n",
    "\n",
    "# for e, s in zip(text_elements, text_summaries):\n",
    "#     i = str(uuid.uuid4())\n",
    "#     doc = Document(\n",
    "#         page_content = s,\n",
    "#         metadata = {\n",
    "#             'id': i,\n",
    "#             'type': 'text',\n",
    "#             'original_content': e\n",
    "#         }\n",
    "#     )\n",
    "#     retrieve_contents.append((i, e))\n",
    "#     documents.append(doc)\n",
    "\n",
    "# for e, s in zip(table_elements, table_summaries):\n",
    "#     doc = Document(\n",
    "#         page_content = s,\n",
    "#         metadata = {\n",
    "#             'id': i,\n",
    "#             'type': 'table',\n",
    "#             'original_content': e\n",
    "#         }\n",
    "#     )\n",
    "#     retrieve_contents.append((i, e))\n",
    "#     documents.append(doc)\n",
    "\n",
    "# for e, s in zip(image_elements, img_summaries):\n",
    "#     doc = Document(\n",
    "#         page_content = s,\n",
    "#         metadata = {\n",
    "#             'id': i,\n",
    "#             'type': 'image',\n",
    "#             'original_content': e\n",
    "#         }\n",
    "#     )\n",
    "#     retrieve_contents.append((i, s))\n",
    "#     documents.append(doc)\n",
    "\n",
    "# vectorstore = FAISS.from_documents(documents=documents, embedding=embeddings.OllamaEmbeddings(model='nomic-embed-text'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "# vectorstore.save_local(\"5drug_faiss\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings = embeddings.OllamaEmbeddings(model='nomic-embed-text')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "db = FAISS.load_local(\"5drug_faiss\", embeddings,allow_dangerous_deserialization=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt_template = \"\"\"\n",
    "You are a data scientist and an expert in analyzing images and tables and text.\n",
    "Answer the question based only on the following context, which can include text, images and tables:\n",
    "{context}\n",
    "Question: {question}\n",
    "Don't answer if you are not sure and decline to answer and say \"Sorry, I don't have much information about it.\"\n",
    "Just return the helpful answer in as much as detailed possible.\n",
    "Answer:\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "qa_chain = LLMChain(llm=ChatOllama(model=\"mistral\", temperature=0),\n",
    "                        prompt=PromptTemplate.from_template(prompt_template))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content=' The image depicts a scientific illustration and a schematic representation of the molecular structure of a biomolecule, in this case, HER2.\\n\\nStarting with the top left, labeled \"HER2\", we see a detailed 3D model of the HER2 protein, which is a receptor tyrosine kinase (RTK) that plays a key role in the pathophysiology of several cancers. The HER2 molecule is composed of an extracellular domain (ECD), a transmembrane domain (TMD), and an intracellular kinase domain (KD).\\n\\nThe extracellular domain is shown in green, indicating the color for this part of the protein. The transmembrane domain is depicted as the darker green regions, while the intracellular kinase domain is represented by the purple area, showing the different colors used to illustrate the molecular structure.\\n\\nOn the bottom right of the image, there is a schematic diagram with text labels that explain the process of HER2-mediated signaling. The diagram shows HER2 as a dimer (two units linked together), which can then bind to other molecules such as EGFR (depicted in red) and Akt (in purple).\\n\\nThe process starts with ligand binding, where an external signal activates the HER2 receptors. Following this, HER2 undergoes a conformational change that leads to dimerization. The dimer then transphosphorylates each other\\'s intracellular domains, resulting in the activation of downstream signaling pathways such as the PI3K/AKT pathway and MAPK/ERK pathway. This activation ultimately leads to cell proliferation, survival, and resistance to chemotherapy.\\n\\nThe text labels on the diagram are as follows:\\n- \"HER2\" – indicating the name of the protein.\\n- \"Ligand binding\" – showing where the initial interaction occurs.\\n- \"Conformational change leading to dimerization.\"\\n- \"Transphosphorylation\" – illustrating the activation process.\\n- \"PI3K/AKT pathway\" and \"MAPK/ERK pathway\" – indicating the downstream signaling pathways activated by HER2.\\n\\nThis image is educational, likely used in a medical or biology textbook or lecture to explain the molecular mechanisms of HER2 function and its role in cancer development and progression. ', metadata={'id': '1bb44fc8-4e29-48c5-99a0-851a4564a760', 'type': 'image', 'original_content': '/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0aHBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCACLATQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwBKKKKACiiigAqKW4igaNZJArSNtQHuaWWeGAZllRB/tMBWKNStn1qWYlpUjjCxFELcnkn+lNK5E5qNkbQniM7QCRfNUbinfFSVg3epWxu7S5RJkdJNrM0ZGUIOfrWrDqFpccR3EZPpnB/I0NCjUTbVyzRRRSNAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqvc3kdqwVwxJUtgY6D6ms/zria7KeY6hWKyBTw4z1U44x3/H61JNYQSNvA2NtKlgASQfXP8AOqsZOba900kdZEV0OVYZB9RTqyZYPs8GbQeU4IG5DgAdyR0PFT6ZcPMkiuxOwgAtnLe/0Pb8aTRSnrZl+ikJCjJIAHc1Tm1OCIqF3S57oCR+fT8KRTaW5doqKK5hn4jkBbup4YfUHkVLQNO4UUUUAFFFFABUEku8yQQyqtwqhuRnGen8qnrMvS9jfJfhS0DL5c+P4RnhqaJm7K403t3p7Z1AI8BOBNED8p/2hTxNeagQYP8ARrU/8tGHzt9B2FRwxDVT9ruubbnyYe2P7x9/5UumCWOz8mQOBG7Km7qVzxVGSbbt0JYtPs4HL+X50p6ySncf1qF/Mt9W89Iy0c6hH2j7pHQn2xVyloK5V00KVwZrnUII9jCGFvNZyMAtjgD86szwQ3S4niST3I5/On0UBbe5T8i5swDZSlkH/LGY5GPY9RSLrEt25gsbcfaFGX844VO3brUuoPKlhMYVJkIwMDkZOM1C2mxJbRrA3lSxcpKBzn39QaNCHzJ2jsaFvJMiIl68InckKIycN9M1YrCsrh9X1CGRwqi0B3bTnc5449uM1u1LVjWnLmV1sFFFFIsKKKKACiiigAooooAKKKKACiiigAooooAKgu7j7PAzhHZsHG1c447+lT1Dc20d1EY5AcdiCQR+VAne2hWt8LAECMuz5SGHOfX3qKWbaaS1kijUQMds/wDGhJJz65PrT5YNxqzHoLDLupskxivY5BDK2MoxXHORn156fzp8UWwZNQpHb3t+CqB0QZkJHU9ACPpn9KA10LOozIlrsfIEhA64OMjP6VEWS1jSONcKvAAq5cxGW2dEwGxlT6Ecj9az/NdIl+2QyLJnHyruB4J7ewpIqd73ElkiguIbsjDltp5AyDx3/D8q16zYo7iW8jYxFLdORuxknHp+P+e+hJJHEheR1RR3Y4FJjh1HUVQg1WCV0DMiK6llLP15xj8sf5FX6Vi1JPYKKKKBhWbdA3t+lmP9RGBJP7/3V/rWkTgZPSszTAfscly337mQvz6dh+VNET1sg/s+3jn8yEPEM52o5Ck/TpVmignFUSklsBOKaWpjNURegTZPvpQ1Vt9PV6AuWKqT6etzKzSTzGM9Yg+FqwrU+gbSe5QuYlsTFeQLtEA2ui/xJ3/LrWujrIiuhBVhkEdxVZlDoVYZUjBHtUOjuRbPbE5MDmPPt2/TFJ7BHSVu5o0UUVJqFFFFABRRRQAUUUmQCBnk9KAFooooAKKKKACiiigAooqMzxBnUypuQZYbhlR7+lAFG4015Z2dJFUMwZ92TvweAfYYps9zPBJHGbRmZzgFWBB4zx3/AEqSbUN0saQBiGVjvKYHA4xnGeufwp0dzb3aQCcFJCAy5yvJHY/iarUx9275WQobi/tcCLyVkXDM5yffAFT2dibZ97MGfaVLLxv5zk+/X86swiJYlSHbsT5QFOcY7VSviLi6jtVmKEKXfaecdh/P/Jo3HZJXerLguYTN5IlXzMZ25qRkVxhlDD3GazDFa7tnlJ024xxin6cxglktHmEhADoSecdwf0/Ok0NTd7Mm1BnWBdieYS2PLBwX4PGe3r+FVrSFgu+c+Y4PyO/3gMe/TvSz3Lm/X92fLRSudy9S2M9fb681NK2FpoTs3cakEKEbRwF2gE5AGc1RuFntpGNuJNuDsjTOxePvemc9u9SiYl8VZebyoDIQDjHUgfrTI0aLykMgIOQRkH1orItNQeGDy3jiyjMo/fAcAkDrRU2ZqqkbCXmqyy2k5tLV5INjAzs20dOoHeo4r+4tbeFbqyaOBUUCRGDAD1IHSnXGqQSadcW06G1uPLZRGw4PHGD0obVLZraKKIfaZWjA8pRnt0PpVJeRi5a35jRVg6hlIIIyCKaxpV4UZGOOg7Uj0GhA5qB2qdxVdxTIkND81KjVXCnNToKCUWUNTDpUCVOOlI1RTnuLs3BhtYFO3G6STIUfT1qnbNqEGo3YjWCRztZ15GeO3/16tz3c9rOxkgeWBsbWiGSvrkVSt9SA1O5ljt55S4RVVU54HOfSmZSaurs3bS4N1biRonibJDI3UEVPUNq1w0Aa5REkJJ2qc4HYfWpqzZ0x2CiiigYUUUUAVZpL9ZSIba2ePsz3DKT+AQ/zqlfm9e1Zri1s41T5lkF225G7Efu+v8+la9RyQxyshkQMY23LnsfWgCHT5LqWxie9iWK4I+ZVORVqiigAooooAoteTPdyQRRqETrI3Iz6frUImvbS3ydtywPIAOenr/8AWptrvVJonfMokYkZ55Oc9B61JDvUsXOAO5qzC7epfhkE0KSDoyg1lG3kuLgSMymFZC0R/iHzZOfUHt6CliknttKZw4y7sUZgSACSc8Adf6/hT7By1qF3KyoAqsoIBGPeklYbfNZMnkEbcOqsPcZpk8a3Fu0Qxg449faoZ3YdKdbsT1pivfQXTY5IJmjl+UMg8tQ2QoBPHueRz/hS36m3nS7SNpCRsdRnp2P8x+NVby4ljvYtr7Nr/KPJLZypz06+mK21JKgkYOKT0dyopNcvYyy9rkSGePpn7wqTT8z3Mtw0RTACpkdff+X+TVs2sBnE/lL5g74/z61HLepE8y7c+UgY5bGfYe+P6UXBRs7shvoYIZY7xo0AUkO20d+h/MD86UOs6HbkH0Iwfyq1NElzDjgj7ykjIz2OO9VIrCW1yYpRJuxuEnH5EdB7UJg4u+mw0W/zZxSXFzBaxN5vIA5AGeucfnimRz3jTKvlR4Z3UfP02/8A6j+YqX+zZHlFxJOBMOBhMqBzxj8TzTJ1a91E1naRRWqAxx7iNxwo6mirMaLFGsaDCqAoHsKKg2SSVgdFkXa6hh6EVl6YcWpgIw8DtE3vg8H8sVrVl3YNnqC3AH7icBJT/dYfdP8ASmiJ6WkW6aw4qvcaha2z7JZQH/ugZP5Cp45FljWRDlWGQcYqhXTdiN1qFkq0VphSgTRW2U9VqXZTlSgSQKtSUgGKjuLmK1jDykhSccKT/KgrZXZKSFUljgDkmqukLvje4x/rpGk57DoP0qtc3kV9GlrayBzOcMV/hXuTWvbRLFEqqMKBgD2oeiFH3padCaiiioNgooooAKKKKACiiigAooooAKKKRmVBliAOnNAFaWxSS489XZJfUcj8qgWwlnjdLyUshP3UAXPTv9asG+iIYRB5HHVFXBH1zjH41nre3n2sYQHMpBjL9F2/T6HOe9UrmUnBGvHGsUaxqMKowBWStyLWR7bZ8kJxuzgbeMAepGQKvDUIRhZQ8Uh6Iy5J+mM5/Cllsra5YSOpb0wxAB9cevvSWm45e98JE8QbmkIWCJ5GztRSxx6Cmz288fkqlyShkAJZMkcHGSMcZwKS2tJLi3ja5mZlx9wDbuHYnvVXJ1vaw20m+1XwLIFWNSUIOQ/OCR9OPzqzd3IhcI7tErLlZFAJLf3cEGpYLWK3JMSkA9BkkL9B2/CoJ0FxcMsgDRRAAA93Pf8AAY/Op3ZVmo+ZFC81yJEuWKshCmOM7QeAckjnv0B/OmNYIDL5SxqJFAIKA4PqPwqyAI0AHQeppjS4NUS0uo37PHCN8WYNo6x8D8R0NMt76fen2k4aQgRoq4DA45J9R1xU6SA1G9onzPGMTdVZiTtPXjPQewoDXdF4RRq5dUUMc5IHPPX+Q/Kn1Fby+fbxy42lhkj0PcVLUGqCiiigYVQ1d8WJgChpLhhEgPqe/wCHWr9RS28czRtIuTG25TnoaaJkm1ZGNZxLptwbe5VfMflLj/np7ZPQ+1TxTSS6vKqsTBHEFYdt+f8AClvI9Q1BWtjaxQwk8yO4c49QB0NRx21xpIKxp9otc5yo/eAn1HeqMLNaLZGhRiq9vfW1zxFKC3dTw35U+5uUtIDLJnHQAdSfSg0urXJcCiq1xeC1t0mmidVJAbGDsz61NJLHFHvkkVV9SaAuiSstdQNs9zHNukmEv7uMdWU9MVIb+S5BWwiL9jK4wg/xpP7JlY+elw32wc+a33T7Y9KPUiTb+ErmwntY21BX/wBIXMkqLwrL3WtiK/tJIUcXEShlBwXAIqG2N5KrW95aIiMpDSJJkN+HWrsMKW8KRRjCIMAUmy6cbarYalzbyOFSeJmPQK4JqjLrMMYfapZkLBhnGMOE9PfNadQSWVvNGUeIFTnjJHVgx/UA1JqUm1pUl8todzCPftjfcx4J4GBxx19SKW41hLfT47sxHDuybWYDBAYnnv8AdOPXIq0thbKu0R9O+456Edc56E0CwtRbpb+SDEmdqsSQMgg9fYkfjQA0alaF/L85RICAUPUE+34H6YpF1SxcqFuYzuOBg9en+I/MetKNNtFOVhwdwfIY9QMZ6/n696YmkWSSxOsWBEMImTtHIPT6gUAOTVbJ41bzgMqG2nqM4wMevI49x61cqsun2iyCQQKHAAB+mMf+gj8hVmgAooooAKrX43WpjAyzkKvPQ5yD+GM/hVmszUGlE8eDOBu+TYqkZ2n17/WmtyZuyHW1uYAxdlZ26sFxux3PJyeTzUhlGcUNu8sZ645qk2/fx0qjJuyJ7i2+0EMjhXxjcRkqOuV9D0/KrNgQLURfxRHY3ufX8QQfxqKLdsPrjiq+nCb7fLnzsceZuKkZx7fUdKT2GnaSfc16ia5hSURNIoc9AT/n0qtqLB/KtlmEcjnd15wKhMNrGVQxKceo6/X16mkkXKbT0NC4Zkt3ZSQQOoXcR+HesqFx9qIju5JcvyCAcjaOTgDFTWW20vGgMwKSjdGhP3cdh/ntUty4tbgyyMFgkHJPZh/iP5U1oS3dXFkziqMpbPFXUkWePcoYD/aUqf1pjQ5NMUlcihJqW5YrEpJkC7huMYycfzx9KckeKZcXaw/u1z5rcR5U4LdMZ6UC2WomluGZxG0xTL5DA7fvcYJ71p1DaxeRbRx5ztHJ9amqXuawVlYKKKKRQUUUUAFFFFAFe4sba5/1sKMfXHP51i6hpccVzZxpNMqSSY++flOOMZ710VVNRszeW6hHCTRsHjY9mFUmZVIJrRamdd6QVtJnkvLp1VCcNJkcDuMVLp+l25tIJniVnaNWJf5jyPfpVq9trm8s1gDpGXwJmGenfb/9eraIERUUYVRgD2o5nYSprmvYasSr+HSpKKKk2sFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFV75Q1nIxJBQbwQMkEc1YooE1dGVbXMksphmQLIBl1A+56D3z6+1WPKUnNS/YbXGFhRDkkFBtPPXkVmzafP9qfa85zJHsbcMBe+fp835iqumZNNLXUlvLn7KqKgG+Q4XPr6fjVrT1YW7GRcSl28z65/l0p62VuA26MOWGGL/MSPTmpkRY0VEUKqjAA7Umyoxd7spaimzy7pIy7xnBUE8g/5FQGW2kxIZo14zgsMitaoZLWCSVZXjUuvQkUJhKGt0UrQi5vjJ5RCRLhHP8AHnv9PSrV5B58YyhkCnPl5xuOMdfbOas0UXKUdLMy4o7q3YvcIZAygZTnYBngjv16iiTUbeNwhcbiCcEhcY+uK1KgkgJuBKu0/IVIP5inclwaWhTS9SaNXgR5SwyABgfiTxUSadNuKyoskcmeQceUSSTjPXr168VpWsAtraOLIZlHLYxk96mov2BQv8Q1FKxqpYsQACT3p1FFSaBRRRQAUUUUAFFIyhlKnoRg1X+wW39w/wDfbf40AWaKrfYLb+4f++z/AI0fYLb+4f8Avs/40AWaKrfYbY5+Q8f7Z/xo+wW39w/99n/GgCzRVb7Bbf3D/wB9n/GpYoUhUrGCATnqT/OgCSiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopGZVGWYAe5oAWiimSxJMu1xkZz1IoAfRVb7Bbf3D/323+NH2C2/uH/vs/40AWaKrfYrXBO04Hfef8aPsFt/cP8A323+NAFmiqwsbYk4Q8dfnP8AjR9gtv7h/wC+z/jQBZopqIsaBFGFHTnNOoAKKTcv94dcde9LQAUUUUAFFFFABWSdOube8klsfs8KyS7n+UZYYXg8dOH6Y5I561rUUAZyw6mbF42uVFwXG2QAEheM/wAOPXHHQiohDrSoi/aYWbB3MQOuD22+p/IVrUUAZ9pa3kN00klwWjfJdG2k52qAchRzwfbpVKbRrt4NjTiUFFG19uFw4bA+XkYHfNbtFAGFHo1xHcSzAoA8YQIjbTwqjkhemVPAGOa1bGKSCyhimbdIq4Y7s5P1qxRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU9QtWuhCAqSxo+XhkOFkGCOeD0ODWbeaXqV5HJG0sIiG4RRjogMToOcZ6sv5E+1b1FAGbJ/aENhMXk3y+blTGoJ2ZHAG3r17H/AAggh1p7eJ5LoLIwUsuFG3hc/wAPPO7P4YxWzRQBnRRaqLSfzbmJp2AEe1cBfU9OvOO/Qe9RfZ9Ywh+1rwCGX5eeW5zt642j068VrUUAZM1lfNpot45VDsZPMOR824kjnb784A9qX7LqvQXUe0PuGev384zjpt/U+1atFAGNZ2Wqw3hkkuY/Kkl8yUcEt8ir/dH93tj8amlt9TEztBdLtaUsA+CAvy8dM44bgHuOa06KAM8Raj9i2Gf99vB3Arnb35246+3T3qskWtywqTPErbQw3cHO0dQB65rZooAw203UDJKxnXa8iSgnBYFQoycKAenQAfrxqWRuGtEe6AEz/Myj+DPRfw6VYooAKKKKAP/Z'}),\n",
       " Document(page_content=' The image displays a diagrammatic representation of cellular structures, specifically focusing on the microarchitecture of cells. On the left side of the image is a schematic representation of a typical eukaryotic cell, which includes a nucleus (n), cytoplasm (cy), and cell membrane (m). The nucleus appears to have internal structures, such as chromosomes (ch) and possibly other organelles.\\n\\nThe right side of the image features a zoomed-in view of specific cellular components. This section is labeled \"HE1+,\" which could indicate cells that express protein H (HE1). It shows the following parts:\\n\\n1. Nucleus (n) - The central part of the cell containing DNA and other genetic material.\\n2. Chromatin (ch) - The condensed material found within a nucleus.\\n3. Cytoskeleton (csk) - A network of fibrous proteins that forms in eukaryotic cells.\\n4. Nucleolus (nucl) - A small, dense structure located near the center of the nucleus and contains genetic material.\\n5. Cell membrane (m) - The plasma membrane that encloses all the contents of a cell.\\n\\nBelow these structures is a label \"HE1+,\" which might indicate that the cells express the H protein, although without context, it\\'s unclear what \"HE1+\" refers to in this specific image.\\n\\nIn addition, there is a text box on the left side with a chemical structure diagram (a circular topology), possibly representing a molecule of interest or a pharmaceutical compound being studied. The chemical structure appears to be that of a cyclic peptide.\\n\\nThe overall style of the image is clinical and educational, likely used in a scientific or medical context to illustrate cellular components and molecular structures relevant to cell biology or pharmacology. ', metadata={'id': '1bb44fc8-4e29-48c5-99a0-851a4564a760', 'type': 'image', 'original_content': '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'}),\n",
       " Document(page_content=\" PHESGO is a prescription medicine used in combination with chemotherapy for the treatment of HER2-positive (HER2+) breast cancer. It can be used prior to surgery (neoadjuvant treatment) in adults with locally advanced or early stage HER2+ breast cancer, after surgery (adjuvant treatment) in adults with a high risk of recurrence, and for metastatic HER2+ breast cancer that has not been treated before with anti-HER2 therapy or chemotherapy. HER2+ breast cancer is characterized by excess HER2 receptors on the cells, leading to faster growth and division, causing tumors to form. A HER2 test is required to determine if a patient's breast cancer is HER2+ before starting treatment with PHESGO.\", metadata={'id': '6041215e-8248-4b81-be41-128fec04bed2', 'type': 'text', 'original_content': 'What is PHESGO? PHESGO is a prescription medicine approved for use in combination with chemotherapy for:\\n\\nuse prior to surgery\\n\\n(neoadjuvant treatment) in adults with HER2+, locally advanced, inammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PHESGO should be used as part of a complete treatment regimen for early breast cancer.\\n\\n• use after surgery (adjuvant treatment) in adults with HER2+ early breast cancer that has a high likelihood of coming back.\\n\\nPHESGO is also approved for use in combination with docetaxel in adults who have HER2+ breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.\\n\\nF e e d b a c k\\n\\nYour Privacy Choices\\n\\nWe would like to collect your personal information, some of which may be considered sensitive personal information, such as health data, through cookies and similar technologies in order to support our marketing efforts, personalize the site, and improve its performance. By clicking “Accept All”, you conrm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising. You can personalize your specic preferences by clicking “Your Privacy Choices”.\\n\\nYour Privacy Choices\\n\\nAccept All\\n\\nUS Healthcare Professionals Site\\n\\nSearch\\n\\nPHESGO Patient Support Program\\n\\nPrescribing Information Safety\\n\\nHome\\n\\nAbout HER2+ Breast Cancer\\n\\nAbout PHESGO\\n\\nSide Eects\\n\\nPatient Stories\\n\\nPatient Resources\\n\\nFinancial Support\\n\\nUnderstanding HER2+ breast cancer\\n\\nWhat is HER2-positive (HER2+) breast cancer?\\n\\nAll the cells in the body—healthy and cancerous—have HER2 receptors. But HER2+ breast cancer cells have too many HER2 receptors, which makes them grow and divide faster than other types of cells. This causes tumors to form.\\n\\nNORMAL CELL\\n\\nHER2+ CANCER CELL\\n\\nHow does my doctor know that my breast cancer is HER2+? Your doctor will know that your breast cancer is HER2+ by ordering a HER2 test. This test should be done before any breast cancer treatment is started. PHESGO has been shown to work only in people with HER2+ breast cancer.'}),\n",
       " Document(page_content=\" The text discusses various terms related to breast cancer and its treatment. Here's a summary:\\n\\n* Early breast cancer refers to cancer that is located in the breast or has spread only to nearby lymph nodes.\\n* First-line therapy is the initial treatment given for advanced or metastatic cancer.\\n* HER2 receptor is a protein found on the surface of cells that tells them to grow and divide. Too much HER2 can result in faster cell growth.\\n* HER2-positive (HER2+) breast cancer refers to cancer cells with too many HER2 receptors.\\n* HER2-targeted therapies are treatments that bind to HER2 receptors to fight cancer cells with excessive HER2.\\n* Hormone receptor is a protein on the surface or inside of cells to which hormones attach.\\n* Hyaluronidase is a protein found naturally in most body tissues, and it can be produced in labs for medical use to help drugs move more easily into tissues.\\n* IV (intravenous) is a method of administering drugs by inserting a needle into a vein.\\n* Infusion is the process of putting fluids or drugs into the bloodstream through an intravenous line.\\n* Lymph nodes are small organs that store white blood cells and help remove waste and harmful substances from the body.\\n* Metastatic breast cancer refers to cancer that has spread outside the breast to other parts of the body.\\n* Neoadjuvant treatment is given before surgery to reduce or eliminate cancer cells.\\n* A port is a surgically implanted disc through which blood can be taken and medication can be given without repeated needle sticks.\", metadata={'id': '6ef5d4d1-40c0-48c0-8aab-b4697c591172', 'type': 'text', 'original_content': 'normal cells.\\n\\nE\\n\\nEarly breast cancer When the cancer is located in only the breast or is in the breast and has only spread to\\n\\nnearby lymph nodes, but not to other parts of the body.\\n\\nF\\n\\nFirst-line therapy A treatment that is given rst or as an initial treatment for cancer that is advanced or\\n\\nmetastatic.\\n\\nH\\n\\nHER2 receptor A type of protein that is found on the surface of cells in everyone. This protein tells cells to\\n\\ngrow and divide. Too much HER2 is called “HER2 overexpression” and may result in the cells\\n\\ngrowing and dividing more quickly.\\n\\nHER2-positive (HER2+) HER2 stands for human epidermal growth factor receptor 2. When breast cancer cells have\\n\\ntoo many HER2 receptors, they are called HER2-positive, or HER2+ breast cancer.\\n\\nHER2-targeted therapies A type of targeted cancer treatment that binds to HER2 receptors to ght cancer cells that\\n\\nhave too many HER2 receptors.\\n\\nHormone receptor A protein on the edge or inside of cells to which hormones attach.\\n\\nHyaluronidase A protein naturally found in most tissues of the body. In medicine, hyaluronidase is made in\\n\\nthe laboratory and given with other drugs by injection under the skin to treat certain conditions. Hyaluronidase helps make the uids and connective tissue thinner so the drugs\\n\\ncan move more easily into the tissues.\\n\\nI\\n\\nIV (intravenous) A method of administering a drug by inserting a needle into a vein.\\n\\nInfusion A method of putting uids, including drugs, into the bloodstream. Also called intravenous\\n\\ninfusion.\\n\\nL\\n\\nLymph nodes Small, bean-shaped organs found throughout the body that store white blood cells and help\\n\\nremove cell waste, germs, and other harmful substances from the body.\\n\\nM Metastatic breast cancer Breast cancer that has spread outside the breast to other parts of the body, such as the lungs, liver, or bones.\\n\\nN\\n\\nNeoadjuvant treatment Treatment given before surgery to help reduce or get rid of cancer cells before surgery.\\n\\nPort A surgically implanted disc through which blood can be taken and medication can be given without repeated needle sticks; also called a “port-a-cath.”'})]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "db.similarity_search(\"provide me image of normal cell and HER2+ CANCER CELL\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "def answer(question):\n",
    "    relevant_docs = db.similarity_search(question)\n",
    "    context = \"\"\n",
    "    relevant_images = []\n",
    "    for d in relevant_docs:\n",
    "        if d.metadata['type'] == 'text':\n",
    "            context += '[text]' + d.metadata['original_content']\n",
    "        elif d.metadata['type'] == 'table':\n",
    "            context += '[table]' + d.metadata['original_content']\n",
    "        elif d.metadata['type'] == 'image':\n",
    "            context += '[image]' + d.page_content\n",
    "            relevant_images.append(d.metadata['original_content'])\n",
    "    result = qa_chain.run({'context': context, 'question': question})\n",
    "    return result, relevant_images"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\RAHUL\\Desktop\\chatbot_new\\chatbot\\multimodel\\Lib\\site-packages\\langchain_core\\_api\\deprecation.py:117: LangChainDeprecationWarning: The function `run` was deprecated in LangChain 0.1.0 and will be removed in 0.2.0. Use invoke instead.\n",
      "  warn_deprecated(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Certainly! Here is a simple representation of a normal breast cell and a HER2-positive (HER2+) breast cancer cell:\n",
      "\n",
      "Normal Cell:\n",
      "![Normal Cell](https://i.imgur.com/3jJwZz5.png)\n",
      "\n",
      "HER2+ Cancer Cell:\n",
      "![HER2+ Cancer Cell](https://i.imgur.com/7X6gMvB.png)\n",
      "\n",
      "In the image above, the normal cell on the left has a balanced number of HER2 receptors (green), while the HER2+ cancer cell on the right has an excess of HER2 receptors (green). This overexpression of HER2 receptors allows the cancer cells to grow and divide more rapidly than normal cells.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"provide me image of normal cell and HER2+ CANCER CELL\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/jpeg": "/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0aHBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCACLATQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwBKKKKACiiigAqKW4igaNZJArSNtQHuaWWeGAZllRB/tMBWKNStn1qWYlpUjjCxFELcnkn+lNK5E5qNkbQniM7QCRfNUbinfFSVg3epWxu7S5RJkdJNrM0ZGUIOfrWrDqFpccR3EZPpnB/I0NCjUTbVyzRRRSNAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqvc3kdqwVwxJUtgY6D6ms/zria7KeY6hWKyBTw4z1U44x3/H61JNYQSNvA2NtKlgASQfXP8AOqsZOba900kdZEV0OVYZB9RTqyZYPs8GbQeU4IG5DgAdyR0PFT6ZcPMkiuxOwgAtnLe/0Pb8aTRSnrZl+ikJCjJIAHc1Tm1OCIqF3S57oCR+fT8KRTaW5doqKK5hn4jkBbup4YfUHkVLQNO4UUUUAFFFFABUEku8yQQyqtwqhuRnGen8qnrMvS9jfJfhS0DL5c+P4RnhqaJm7K403t3p7Z1AI8BOBNED8p/2hTxNeagQYP8ARrU/8tGHzt9B2FRwxDVT9ruubbnyYe2P7x9/5UumCWOz8mQOBG7Km7qVzxVGSbbt0JYtPs4HL+X50p6ySncf1qF/Mt9W89Iy0c6hH2j7pHQn2xVyloK5V00KVwZrnUII9jCGFvNZyMAtjgD86szwQ3S4niST3I5/On0UBbe5T8i5swDZSlkH/LGY5GPY9RSLrEt25gsbcfaFGX844VO3brUuoPKlhMYVJkIwMDkZOM1C2mxJbRrA3lSxcpKBzn39QaNCHzJ2jsaFvJMiIl68InckKIycN9M1YrCsrh9X1CGRwqi0B3bTnc5449uM1u1LVjWnLmV1sFFFFIsKKKKACiiigAooooAKKKKACiiigAooooAKgu7j7PAzhHZsHG1c447+lT1Dc20d1EY5AcdiCQR+VAne2hWt8LAECMuz5SGHOfX3qKWbaaS1kijUQMds/wDGhJJz65PrT5YNxqzHoLDLupskxivY5BDK2MoxXHORn156fzp8UWwZNQpHb3t+CqB0QZkJHU9ACPpn9KA10LOozIlrsfIEhA64OMjP6VEWS1jSONcKvAAq5cxGW2dEwGxlT6Ecj9az/NdIl+2QyLJnHyruB4J7ewpIqd73ElkiguIbsjDltp5AyDx3/D8q16zYo7iW8jYxFLdORuxknHp+P+e+hJJHEheR1RR3Y4FJjh1HUVQg1WCV0DMiK6llLP15xj8sf5FX6Vi1JPYKKKKBhWbdA3t+lmP9RGBJP7/3V/rWkTgZPSszTAfscly337mQvz6dh+VNET1sg/s+3jn8yEPEM52o5Ck/TpVmignFUSklsBOKaWpjNURegTZPvpQ1Vt9PV6AuWKqT6etzKzSTzGM9Yg+FqwrU+gbSe5QuYlsTFeQLtEA2ui/xJ3/LrWujrIiuhBVhkEdxVZlDoVYZUjBHtUOjuRbPbE5MDmPPt2/TFJ7BHSVu5o0UUVJqFFFFABRRRQAUUUmQCBnk9KAFooooAKKKKACiiigAooqMzxBnUypuQZYbhlR7+lAFG4015Z2dJFUMwZ92TvweAfYYps9zPBJHGbRmZzgFWBB4zx3/AEqSbUN0saQBiGVjvKYHA4xnGeufwp0dzb3aQCcFJCAy5yvJHY/iarUx9275WQobi/tcCLyVkXDM5yffAFT2dibZ97MGfaVLLxv5zk+/X86swiJYlSHbsT5QFOcY7VSviLi6jtVmKEKXfaecdh/P/Jo3HZJXerLguYTN5IlXzMZ25qRkVxhlDD3GazDFa7tnlJ024xxin6cxglktHmEhADoSecdwf0/Ok0NTd7Mm1BnWBdieYS2PLBwX4PGe3r+FVrSFgu+c+Y4PyO/3gMe/TvSz3Lm/X92fLRSudy9S2M9fb681NK2FpoTs3cakEKEbRwF2gE5AGc1RuFntpGNuJNuDsjTOxePvemc9u9SiYl8VZebyoDIQDjHUgfrTI0aLykMgIOQRkH1orItNQeGDy3jiyjMo/fAcAkDrRU2ZqqkbCXmqyy2k5tLV5INjAzs20dOoHeo4r+4tbeFbqyaOBUUCRGDAD1IHSnXGqQSadcW06G1uPLZRGw4PHGD0obVLZraKKIfaZWjA8pRnt0PpVJeRi5a35jRVg6hlIIIyCKaxpV4UZGOOg7Uj0GhA5qB2qdxVdxTIkND81KjVXCnNToKCUWUNTDpUCVOOlI1RTnuLs3BhtYFO3G6STIUfT1qnbNqEGo3YjWCRztZ15GeO3/16tz3c9rOxkgeWBsbWiGSvrkVSt9SA1O5ljt55S4RVVU54HOfSmZSaurs3bS4N1biRonibJDI3UEVPUNq1w0Aa5REkJJ2qc4HYfWpqzZ0x2CiiigYUUUUAVZpL9ZSIba2ePsz3DKT+AQ/zqlfm9e1Zri1s41T5lkF225G7Efu+v8+la9RyQxyshkQMY23LnsfWgCHT5LqWxie9iWK4I+ZVORVqiigAooooAoteTPdyQRRqETrI3Iz6frUImvbS3ydtywPIAOenr/8AWptrvVJonfMokYkZ55Oc9B61JDvUsXOAO5qzC7epfhkE0KSDoyg1lG3kuLgSMymFZC0R/iHzZOfUHt6CliknttKZw4y7sUZgSACSc8Adf6/hT7By1qF3KyoAqsoIBGPeklYbfNZMnkEbcOqsPcZpk8a3Fu0Qxg449faoZ3YdKdbsT1pivfQXTY5IJmjl+UMg8tQ2QoBPHueRz/hS36m3nS7SNpCRsdRnp2P8x+NVby4ljvYtr7Nr/KPJLZypz06+mK21JKgkYOKT0dyopNcvYyy9rkSGePpn7wqTT8z3Mtw0RTACpkdff+X+TVs2sBnE/lL5g74/z61HLepE8y7c+UgY5bGfYe+P6UXBRs7shvoYIZY7xo0AUkO20d+h/MD86UOs6HbkH0Iwfyq1NElzDjgj7ykjIz2OO9VIrCW1yYpRJuxuEnH5EdB7UJg4u+mw0W/zZxSXFzBaxN5vIA5AGeucfnimRz3jTKvlR4Z3UfP02/8A6j+YqX+zZHlFxJOBMOBhMqBzxj8TzTJ1a91E1naRRWqAxx7iNxwo6mirMaLFGsaDCqAoHsKKg2SSVgdFkXa6hh6EVl6YcWpgIw8DtE3vg8H8sVrVl3YNnqC3AH7icBJT/dYfdP8ASmiJ6WkW6aw4qvcaha2z7JZQH/ugZP5Cp45FljWRDlWGQcYqhXTdiN1qFkq0VphSgTRW2U9VqXZTlSgSQKtSUgGKjuLmK1jDykhSccKT/KgrZXZKSFUljgDkmqukLvje4x/rpGk57DoP0qtc3kV9GlrayBzOcMV/hXuTWvbRLFEqqMKBgD2oeiFH3padCaiiioNgooooAKKKKACiiigAooooAKKKRmVBliAOnNAFaWxSS489XZJfUcj8qgWwlnjdLyUshP3UAXPTv9asG+iIYRB5HHVFXBH1zjH41nre3n2sYQHMpBjL9F2/T6HOe9UrmUnBGvHGsUaxqMKowBWStyLWR7bZ8kJxuzgbeMAepGQKvDUIRhZQ8Uh6Iy5J+mM5/Cllsra5YSOpb0wxAB9cevvSWm45e98JE8QbmkIWCJ5GztRSxx6Cmz288fkqlyShkAJZMkcHGSMcZwKS2tJLi3ja5mZlx9wDbuHYnvVXJ1vaw20m+1XwLIFWNSUIOQ/OCR9OPzqzd3IhcI7tErLlZFAJLf3cEGpYLWK3JMSkA9BkkL9B2/CoJ0FxcMsgDRRAAA93Pf8AAY/Op3ZVmo+ZFC81yJEuWKshCmOM7QeAckjnv0B/OmNYIDL5SxqJFAIKA4PqPwqyAI0AHQeppjS4NUS0uo37PHCN8WYNo6x8D8R0NMt76fen2k4aQgRoq4DA45J9R1xU6SA1G9onzPGMTdVZiTtPXjPQewoDXdF4RRq5dUUMc5IHPPX+Q/Kn1Fby+fbxy42lhkj0PcVLUGqCiiigYVQ1d8WJgChpLhhEgPqe/wCHWr9RS28czRtIuTG25TnoaaJkm1ZGNZxLptwbe5VfMflLj/np7ZPQ+1TxTSS6vKqsTBHEFYdt+f8AClvI9Q1BWtjaxQwk8yO4c49QB0NRx21xpIKxp9otc5yo/eAn1HeqMLNaLZGhRiq9vfW1zxFKC3dTw35U+5uUtIDLJnHQAdSfSg0urXJcCiq1xeC1t0mmidVJAbGDsz61NJLHFHvkkVV9SaAuiSstdQNs9zHNukmEv7uMdWU9MVIb+S5BWwiL9jK4wg/xpP7JlY+elw32wc+a33T7Y9KPUiTb+ErmwntY21BX/wBIXMkqLwrL3WtiK/tJIUcXEShlBwXAIqG2N5KrW95aIiMpDSJJkN+HWrsMKW8KRRjCIMAUmy6cbarYalzbyOFSeJmPQK4JqjLrMMYfapZkLBhnGMOE9PfNadQSWVvNGUeIFTnjJHVgx/UA1JqUm1pUl8todzCPftjfcx4J4GBxx19SKW41hLfT47sxHDuybWYDBAYnnv8AdOPXIq0thbKu0R9O+456Edc56E0CwtRbpb+SDEmdqsSQMgg9fYkfjQA0alaF/L85RICAUPUE+34H6YpF1SxcqFuYzuOBg9en+I/MetKNNtFOVhwdwfIY9QMZ6/n696YmkWSSxOsWBEMImTtHIPT6gUAOTVbJ41bzgMqG2nqM4wMevI49x61cqsun2iyCQQKHAAB+mMf+gj8hVmgAooooAKrX43WpjAyzkKvPQ5yD+GM/hVmszUGlE8eDOBu+TYqkZ2n17/WmtyZuyHW1uYAxdlZ26sFxux3PJyeTzUhlGcUNu8sZ645qk2/fx0qjJuyJ7i2+0EMjhXxjcRkqOuV9D0/KrNgQLURfxRHY3ufX8QQfxqKLdsPrjiq+nCb7fLnzsceZuKkZx7fUdKT2GnaSfc16ia5hSURNIoc9AT/n0qtqLB/KtlmEcjnd15wKhMNrGVQxKceo6/X16mkkXKbT0NC4Zkt3ZSQQOoXcR+HesqFx9qIju5JcvyCAcjaOTgDFTWW20vGgMwKSjdGhP3cdh/ntUty4tbgyyMFgkHJPZh/iP5U1oS3dXFkziqMpbPFXUkWePcoYD/aUqf1pjQ5NMUlcihJqW5YrEpJkC7huMYycfzx9KckeKZcXaw/u1z5rcR5U4LdMZ6UC2WomluGZxG0xTL5DA7fvcYJ71p1DaxeRbRx5ztHJ9amqXuawVlYKKKKRQUUUUAFFFFAFe4sba5/1sKMfXHP51i6hpccVzZxpNMqSSY++flOOMZ710VVNRszeW6hHCTRsHjY9mFUmZVIJrRamdd6QVtJnkvLp1VCcNJkcDuMVLp+l25tIJniVnaNWJf5jyPfpVq9trm8s1gDpGXwJmGenfb/9eraIERUUYVRgD2o5nYSprmvYasSr+HSpKKKk2sFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFV75Q1nIxJBQbwQMkEc1YooE1dGVbXMksphmQLIBl1A+56D3z6+1WPKUnNS/YbXGFhRDkkFBtPPXkVmzafP9qfa85zJHsbcMBe+fp835iqumZNNLXUlvLn7KqKgG+Q4XPr6fjVrT1YW7GRcSl28z65/l0p62VuA26MOWGGL/MSPTmpkRY0VEUKqjAA7Umyoxd7spaimzy7pIy7xnBUE8g/5FQGW2kxIZo14zgsMitaoZLWCSVZXjUuvQkUJhKGt0UrQi5vjJ5RCRLhHP8AHnv9PSrV5B58YyhkCnPl5xuOMdfbOas0UXKUdLMy4o7q3YvcIZAygZTnYBngjv16iiTUbeNwhcbiCcEhcY+uK1KgkgJuBKu0/IVIP5inclwaWhTS9SaNXgR5SwyABgfiTxUSadNuKyoskcmeQceUSSTjPXr168VpWsAtraOLIZlHLYxk96mov2BQv8Q1FKxqpYsQACT3p1FFSaBRRRQAUUUUAFFIyhlKnoRg1X+wW39w/wDfbf40AWaKrfYLb+4f++z/AI0fYLb+4f8Avs/40AWaKrfYbY5+Q8f7Z/xo+wW39w/99n/GgCzRVb7Bbf3D/wB9n/GpYoUhUrGCATnqT/OgCSiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopGZVGWYAe5oAWiimSxJMu1xkZz1IoAfRVb7Bbf3D/323+NH2C2/uH/vs/40AWaKrfYrXBO04Hfef8aPsFt/cP8A323+NAFmiqwsbYk4Q8dfnP8AjR9gtv7h/wC+z/jQBZopqIsaBFGFHTnNOoAKKTcv94dcde9LQAUUUUAFFFFABWSdOube8klsfs8KyS7n+UZYYXg8dOH6Y5I561rUUAZyw6mbF42uVFwXG2QAEheM/wAOPXHHQiohDrSoi/aYWbB3MQOuD22+p/IVrUUAZ9pa3kN00klwWjfJdG2k52qAchRzwfbpVKbRrt4NjTiUFFG19uFw4bA+XkYHfNbtFAGFHo1xHcSzAoA8YQIjbTwqjkhemVPAGOa1bGKSCyhimbdIq4Y7s5P1qxRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU9QtWuhCAqSxo+XhkOFkGCOeD0ODWbeaXqV5HJG0sIiG4RRjogMToOcZ6sv5E+1b1FAGbJ/aENhMXk3y+blTGoJ2ZHAG3r17H/AAggh1p7eJ5LoLIwUsuFG3hc/wAPPO7P4YxWzRQBnRRaqLSfzbmJp2AEe1cBfU9OvOO/Qe9RfZ9Ywh+1rwCGX5eeW5zt642j068VrUUAZM1lfNpot45VDsZPMOR824kjnb784A9qX7LqvQXUe0PuGev384zjpt/U+1atFAGNZ2Wqw3hkkuY/Kkl8yUcEt8ir/dH93tj8amlt9TEztBdLtaUsA+CAvy8dM44bgHuOa06KAM8Raj9i2Gf99vB3Arnb35246+3T3qskWtywqTPErbQw3cHO0dQB65rZooAw203UDJKxnXa8iSgnBYFQoycKAenQAfrxqWRuGtEe6AEz/Myj+DPRfw6VYooAKKKKAP/Z",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display.display(display.Image(base64.b64decode(relevant_images[0])))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " I apologize for any confusion earlier. Unfortunately, I cannot provide an image of PHESGO versus PERJETA and Herceptin directly here. However, I can describe the differences between them in terms of administration:\n",
      "\n",
      "1. PHESGO: It is a single injection that combines both PERJETA (pertuzumab) and Herceptin (trastuzumab) along with hyaluronidase. The injection is given under the skin, typically taking around 5 minutes for the initial dose and about 8 minutes for subsequent doses.\n",
      "2. PERJETA: It is an intravenous (IV) infusion that is administered through a needle in a vein, usually taking between 60 to 150 minutes per infusion session.\n",
      "3. Herceptin: It is also an IV infusion and is given in the same manner as PERJETA, with similar administration time.\n",
      "\n",
      "The image you might be looking for would likely show the physical appearance of each medication, such as a vial or syringe label. However, I cannot provide that information directly here. You may want to check the product packaging or consult your healthcare provider for more detailed visual information.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"provide me the image of phesgo vs perjeta and herceptin\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "ename": "IndexError",
     "evalue": "list index out of range",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[27], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m display\u001b[38;5;241m.\u001b[39mdisplay(display\u001b[38;5;241m.\u001b[39mImage(base64\u001b[38;5;241m.\u001b[39mb64decode(\u001b[43mrelevant_images\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m0\u001b[39;49m\u001b[43m]\u001b[49m)))\n",
      "\u001b[1;31mIndexError\u001b[0m: list index out of range"
     ]
    }
   ],
   "source": [
    "display.display(display.Image(base64.b64decode(relevant_images[0])))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " I'd be happy to help explain the difference between a normal breast cell and a HER2-positive (HER2+) breast cancer cell, but unfortunately, I cannot provide you with actual images here. However, I can describe what each looks like in general terms based on scientific research.\n",
      "\n",
      "A normal breast cell is a type of epithelial cell that forms the milk-producing glands and ducts in the breast. These cells have a relatively flat shape and are tightly packed together with well-defined borders. They grow and divide slowly, and they have a well-organized nucleus with evenly distributed chromatin (the material inside the nucleus).\n",
      "\n",
      "In contrast, HER2+ breast cancer cells have an abnormal appearance due to the overexpression of the HER2 protein on their surface. These cells can be larger and more rounded than normal cells, with irregular borders and a more dispersed nucleus. They grow and divide much faster than normal cells, leading to the formation of tumors. The excessive HER2 protein on the cell surface causes the cells to send incorrect signals that promote uncontrolled growth and division.\n",
      "\n",
      "I hope this explanation helps clarify the difference between normal breast cells and HER2+ breast cancer cells. If you have any further questions, please don't hesitate to ask!\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"provide me image of normal cell and HER2+ CANCER CELL\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/jpeg": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display.display(display.Image(base64.b64decode(relevant_images[0])))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " 1. Phesgo is a combination of pertuzumab, trastuzumab, and hyaluronidase. It is used for the treatment of HER2-positive breast cancer.\n",
      "2. Ocrevus (ocrelizumab) is a monoclonal antibody used to treat relapsing forms of multiple sclerosis.\n",
      "3. Vabysmo (pegfilgrastim-bmez) is a long-acting form of filgrastim, which is used to reduce the duration of neutropenia following myelosuppressive chemotherapy.\n",
      "4. Tecentriq (atezolizumab) is a monoclonal antibody used for the treatment of various types of advanced cancers, including non-small cell lung cancer and urothelial carcinoma.\n",
      "5. Evrysdi (risdiplam) is a recombinant form of the human serine protease inhibitor, alfa-1 antitrypsin, used for the treatment of spinal muscular atrophy in pediatric and adult patients.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"i want to ensure that which of these following drungs are not given in the context 1.phesgo 2.ocrevus 3.vabysmo 4.tecentriq 5.evrysdi\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "ename": "IndexError",
     "evalue": "list index out of range",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[13], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m display\u001b[38;5;241m.\u001b[39mdisplay(display\u001b[38;5;241m.\u001b[39mImage(base64\u001b[38;5;241m.\u001b[39mb64decode(\u001b[43mrelevant_images\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m0\u001b[39;49m\u001b[43m]\u001b[49m)))\n",
      "\u001b[1;31mIndexError\u001b[0m: list index out of range"
     ]
    }
   ],
   "source": [
    "display.display(display.Image(base64.b64decode(relevant_images[0])))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Risdiplam is a synthetic small molecule with a molecular formula of C22H23N7O and a chemical structure that includes a pyridine ring, a urea moiety, and several alkyl and ether groups. The exact structure of risdiplam is as follows:\n",
      "\n",
      "[Chemical Structure Image]\n",
      "\n",
      "Risdiplam acts as a SMN2 splicing modifier, enhancing the inclusion of exon 7 in SMN2 pre-mRNA and increasing the production of full-length SMN protein. This leads to improved motor neuron survival and function in patients with SMA.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"The molecular formula of risdiplam is C22H23N7O and the chemical structure is shown below\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/jpeg": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display.display(display.Image(base64.b64decode(relevant_images[0])))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Based on the context provided, here is a summary of the efficacy of EVRYSDI in patients with Later-Onset SMA (Type 2 or Type 3) at Month 12 of treatment (Study 2 Part 2), presented in a tabular format:\n",
      "\n",
      "| Endpoint          | Proportion of Patients with Later-Onset SMA (N = 180) |\n",
      "|-------------------|-----------------------------------------------------|\n",
      "| Change from Baseline in MFM32 Total Score | 57.8% (EVRYSDI group) vs. 14.6% (placebo group) achieved a clinically meaningful and statistically significant difference (p < 0.001) |\n",
      "| Sitting without support for at least 5 seconds (BSID-III, Item 22) | 32.8% (baseline) vs. 60.3% (Month 12) in the EVRYSDI group |\n",
      "| Alive without permanent ventilation | 87.1% in the EVRYSDI group |\n",
      "\n",
      "Additionally, the figure shows the mean change from baseline in total MFM32 score over 12 months for both the EVRYSDI and placebo groups. The results suggest that patients treated with EVRYSDI experienced a greater improvement in motor function compared to those in the placebo group.\n",
      "\n",
      "It is important to note that Study 3 focuses on investigating the efficacy, safety, pharmacokinetics, and pharmacodynamics of EVRYSDI in infants up to 6 weeks of age with pre-symptomatic SMA. The data from this study was not included in the tabular summary above.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"Summary of Efficacy in Patients with Later-Onset SMA at Month 12 of Treatment (Study 2 Part 2) in a tabular format\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " The figure represents the mean change from baseline in total Motor Function Measure 32 (MFM32) score over 12 months for patients with spinal muscular atrophy (SMA) Type 2 treated with EVRYSDI or placebo in Study 2 Part 2.\n",
      "\n",
      "The x-axis shows the time points labeled as 'Months' and marked by letters A, B, C, and D. The y-axis represents the change from baseline in total MFM32 score, expressed as a percentage of the maximum possible score for the scale (i.e., sum of the 32 item scores divided by 96 and multiplied by 100).\n",
      "\n",
      "The blue line labeled 'Placebo' shows the mean change from baseline in total MFM32 score over 12 months for patients receiving placebo treatment. The orange dashed line labeled 'EVRYSDI' represents the mean change from baseline in total MFM32 score over 12 months for patients treated with EVRYSDI.\n",
      "\n",
      "The vertical dashed lines at points A, B, C, and D may indicate significant changes in the mean change from baseline in total MFM32 score over time. The text box on the top left corner of the graph shows that at baseline or before any intervention, the vehicle-treated group had an average value for the measured parameter (total MFM32 score) of 31.2%, with a sample size of 76 observations.\n",
      "\n",
      "The bottom of the image contains a legend explaining the symbols used to represent the placebo and treated groups and the standard error bars associated with each group's data points. The graph also includes a note indicating that it is 'Probability specified' and specifies a '2-tailed analysis'. This suggests that statistical tests were conducted to determine whether the difference in means between groups was significant at a given probability level (often 5% or 10%).\n",
      "\n",
      "In summary, the figure compares the mean change from baseline in total Motor Function Measure 32 score over 12 months for patients with SMA Type 2 receiving either EVRYSDI or placebo treatment. The blue line labeled 'Placebo' shows the mean change from baseline in total MFM32 score over 12 months for patients receiving placebo treatment. The orange dashed line labeled 'EVRYSDI' represents the mean change from baseline in total MFM32 score over 12 months for patients treated with EVRYSDI. Statistical tests were conducted to determine whether the observed differences between groups were significant at a specified probability level (often 5% or 10%).\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"describe the figure of Mean Change from Baseline in Total MFM32 Score Over 12 Months (Study 2 Part 2)\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/jpeg": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display.display(display.Image(base64.b64decode(relevant_images[0])))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Yes, here is some information about each of these drugs:\n",
      "\n",
      "1. Phesgo: Phesgo is a prescription medicine approved for use in combination with chemotherapy for the treatment of HER2-positive breast cancer in adults. It contains pertuzumab (an anti-HER2 monoclonal antibody), trastuzumab (a humanized anti-HER2 monoclonal antibody), hyaluronidase, and pertuzumab and trastuzumab mixed solution for injection.\n",
      "2. Ocrevus: Ocrevus is a prescription medicine used to treat patients with relapsing forms of multiple sclerosis. It contains ocrelizumab, a humanized IgG1 monoclonal antibody that binds to CD20 cells and reduces their ability to function.\n",
      "3. Vabysmo: I'm sorry, I don't have enough information about this drug. It could be a new or experimental medicine.\n",
      "4. Tecentriq: Tecentriq is a prescription medicine used for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose disease has progressed on or after platinum-containing chemotherapy. It contains tesirumab, a humanized IgG1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1) and blocks its interactions with other proteins.\n",
      "5. Evrysdi: Evrysdi is a prescription medicine used for the treatment of primary immunodeficiency in infants and children, and for adults who weigh less than 60 kg. It contains evolocimab, a humanized IgG1 monoclonal antibody that binds to neotectin, a component of the complement system, and prevents it from activating and causing inflammation.\n",
      "\n",
      "These drugs belong to different therapeutic areas: Phesgo is an anticancer medicine; Ocrevus, Tecentriq, and Evrysdi are immunomodulatory agents.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"can you see these five drugs in the given context 1.phesgo 2.ocrevus 3.vabysmo 4.tecentriq 5.evrysdi\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " The most common side effects of Evrysdi include fever, diarrhea, rash, runny nose, sneezing, sore throat (upper respiratory infection), lung infection (lower respiratory infection), constipation, vomiting, and cough. These side effects may vary depending on the type of SMA being treated. For more detailed information about the possible side effects of EVRYSDI, please consult the full Prescribing Information provided by your healthcare provider or visit the FDA website for more up-to-date information. I'd be happy to help answer any other questions you might have!\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"What are the possible side effects of EVRYSDI\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " EVRYSDI should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C). It should not be frozen. If necessary, EVRYSDI can be kept at room temperature up to 104°F (up to 40°C) for a combined total of 5 days. The total combined time out of refrigeration should not be more than 5 days. Keep EVRYSDI in an upright position in the original amber bottle to protect from light. Any unused portion of EVRYSDI should be discarded 64 days after it is mixed by the pharmacist or if it has been kept at room temperature for more than a total combined time of 5 days. Please see the Discard After date written on the bottle label. (See the Instructions for Use that comes with EVRYSDI).\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"How should I store EVRYSDI refrigerator?\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Evrysdi is a prescription medicine that contains the active ingredient called risdiplam. It comes as a liquid suspension for oral use. The other ingredients in Evrysdi include sodium citrate, citric acid monohydrate, xanthan gum, and water for injection.\n",
      "\n",
      "It's important to note that this information is subject to change, so it's always best to consult the full prescribing information or speak with your healthcare provider for the most up-to-date and accurate information regarding Evrysdi.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"What are the ingredients in EVRYSDI?\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Ocrevus (ocrelizumab) is a prescription medicine used for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome and relapsing-remitting disease, in adults. It is also approved for the treatment of active secondary progressive MS in adults.\n",
      "\n",
      "The recommended dosage regimen for ocrevus is 600 mg given as an intravenous infusion every 6 months (24 weeks apart). The first infusion is typically given as a 300 mg dose followed by a 300 mg dose 2 weeks later.\n",
      "\n",
      "Kesimpta (ofatumumab) is another prescription medicine used for the treatment of relapsing forms of MS, including clinically isolated syndrome and relapsing-remitting disease, in adults. It is given as a subcutaneous injection every 4 weeks.\n",
      "\n",
      "Mavenclad (cladribine) is approved for the treatment of relapsing MS in adults and is given as an oral medication with a dosing regimen of two tablets on days 1, 2, 3, 5, 6, 8, 9, 11, and 12, followed by one tablet daily on days 14 to 27. After this initial treatment course, mavenclad is given as a single tablet daily for 48 weeks every other year.\n",
      "\n",
      "Aubagio (teriflunomide) is approved for the treatment of relapsing MS in adults and is given as an oral medication with a dosing regimen of 14 mg once daily.\n",
      "\n",
      "Tecfidera (dimethyl fumarate) is approved for the treatment of relapsing forms of MS, including clinically isolated syndrome and relapsing-remitting disease, in adults. It is given as an oral medication with a dosing regimen of 120 mg three times daily or 240 mg twice daily.\n",
      "\n",
      "Tysabri (natalizumab) is approved for the treatment of relapsing MS and active secondary progressive MS in adults. It is given as an intravenous infusion every 4 weeks.\n",
      "\n",
      "It's important to note that each of these medications has its own unique safety profile, and patients should discuss with their healthcare provider which medication is right for them based on their individual medical history and current condition.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"what is the dosing frequency of ocrevus,kesimpta,mavenclad,aubagio,tecfidera,tysabri\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Here is a comparison of the dosing frequencies for the mentioned MS medications:\n",
      "\n",
      "1. OCREVUS (ocrelizumab):\n",
      "   - Infusion given twice a year, with the first dose split between 2 treatments in the first year.\n",
      "\n",
      "2. KESIMPTA (mavacamten):\n",
      "   - One oral tablet taken every day.\n",
      "\n",
      "3. MAVENCLAD (cladribine):\n",
      "   - Two courses per year, each lasting for approximately 14 days with a 10-week washout period between courses.\n",
      "\n",
      "4. AUBAGIO (teriflunomide):\n",
      "   - One oral tablet taken every day.\n",
      "\n",
      "5. TECFIDERA (dimethyl fumarate):\n",
      "   - Two tablets taken orally, three times a day.\n",
      "\n",
      "6. TYSABRI (natalizumab):\n",
      "   - Infusion given every 4 weeks.\n",
      "\n",
      "Please note that the dosing frequency may vary depending on individual circumstances and treatment plans. Always consult with your healthcare provider for accurate information regarding your specific treatment plan.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"provide me the image of dosing frequency of ocrevus,kesimpta,mavenclad,aubagio,tecfidera,tysabri\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "ename": "IndexError",
     "evalue": "list index out of range",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[19], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m display\u001b[38;5;241m.\u001b[39mdisplay(display\u001b[38;5;241m.\u001b[39mImage(base64\u001b[38;5;241m.\u001b[39mb64decode(\u001b[43mrelevant_images\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m0\u001b[39;49m\u001b[43m]\u001b[49m)))\n",
      "\u001b[1;31mIndexError\u001b[0m: list index out of range"
     ]
    }
   ],
   "source": [
    "display.display(display.Image(base64.b64decode(relevant_images[0])))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " I'm sorry for any confusion, but based on the context provided, there isn't an image of Mean Change in Visual Acuity from Baseline to Year 2 (Week 100) in BALATON presented in the text. The text only includes images and information up to Week 24. If you have access to additional data or figures that include the requested information, please let me know and I'll be happy to help interpret them.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"provide me the image of Mean Change in Visual Acuity from Baseline to Year 2 (Week 100) in balaton\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/jpeg": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display.display(display.Image(base64.b64decode(relevant_images[0])))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Based on the context provided, there is an image of a line graph that shows the mean change from baseline in total MFM32 score over 12 months for two groups: EVRYSDI (N = 120) and Placebo (N = 60). The graph includes three lines: Baseline, Vehicle, and Treatment. The vertical dashed lines at points 'A', 'B', 'C', and 'D' may indicate significant changes in the measurement over time.\n",
      "\n",
      "The text box on the top left corner of the graph indicates that at baseline or before any intervention, the vehicle-treated group had an average value for the measured parameter of 31.2%, with a sample size of 76. The line graph shows the mean change from this baseline over 12 months for both groups.\n",
      "\n",
      "The line graph suggests that the EVRYSDI group experienced a greater improvement in total MFM32 score compared to the Placebo group over the 12-month period. Specifically, the EVRYSDI group shows an overall upward trend in mean change from baseline, while the Placebo group shows a slight downward trend or no significant change.\n",
      "\n",
      "The line graph also includes error bars representing the standard error of the mean for each group, indicating the variability in the data around the mean values. The shaded area below the lines represents the 95% confidence interval for the mean change from baseline in total MFM32 score over 12 months for both groups.\n",
      "\n",
      "Overall, this line graph provides a visual representation of the mean change from baseline in total MFM32 score over 12 months for two groups and highlights the potential difference in treatment effect between EVRYSDI and Placebo.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"provide me the image of Mean Change from Baseline in Total MFM32 Score Over 12 Months\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/jpeg": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display.display(display.Image(base64.b64decode(relevant_images[1])))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Evrysdi is a prescription medicine used to treat spinal muscular atrophy (SMA) in children and adults. SMA is a rare genetic motor neuron disorder that causes progressive muscle weakness and loss of movement. There are different types or levels of SMA, depending on the age when symptoms begin and the severity of physical signs and symptoms. Evrysdi is indicated for all types of SMA, from infantile-onset to later-onset forms. It works by increasing the amount of a protein called survival motor neuron (SMN) in the body, which helps preserve motor neurons and improve muscle function. The most common side effects include fever, diarrhea, rash, runny nose, sneezing, sore throat, lung infection, constipation, vomiting, cough, and upper respiratory infection for infantile-onset SMA patients; and fever, diarrhea, and rash for later-onset SMA patients. It is important to note that Evrysdi may harm an unborn baby if taken during pregnancy, so women who can become pregnant should use birth control while on treatment and for at least one month after stopping it. Additionally, men taking Evrysdi may have a reduced ability to produce children (fertility).\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"give me a brief introduction about evrydi indication\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " OCREVUS is a prescription medication indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is also indicated for the treatment of primary progressive MS in adults. It is important to note that it is not known if OCREVUS is safe and effective in children.\n",
      "\n",
      "If you experience any side effects while taking OCREVUS, you are advised to call your doctor for medical advice. You can also report side effects to the FDA at 1-800-FDA-1088 or to Genentech at (888) 835-2555. For more information, go to www.OCREVUS.com or call 1-844-627-3887.\n",
      "\n",
      "The full prescribing information for OCREVUS includes warnings and precautions such as infusion reactions, infections, progressive multifocal leukoencephalopathy (PML), reduction in immunoglobulins, malignancies, and immune-mediated colitis. It is important to read the full prescribing information before taking this medication.\n",
      "\n",
      "OCREVUS is available in various dosage forms and strengths. The recommended dosage and dose administration are outlined in the prescribing information. If you miss a dose or experience infusion reactions, there are specific instructions for how to handle these situations.\n",
      "\n",
      "It is important to note that OCREVUS may interact with immunosuppressive or immune-modulating therapies and vaccinations. It is also important to consider the medication's use in specific populations such as pregnant women, breastfeeding mothers, and elderly individuals.\n",
      "\n",
      "The prescribing information includes information on the mechanism of action, pharmacodynamics, and pharmacokinetics of OCREVUS. Clinical studies have shown that OCREVUS is effective in reducing the frequency of relapses in patients with relapsing forms of MS and slowing disease progression in patients with primary progressive MS.\n",
      "\n",
      "Common side effects of OCREVUS include infusion reactions, infections, and reduction in immunoglobulins. It is important to report any serious or unusual side effects to your doctor.\n",
      "\n",
      "It is essential to follow the instructions provided by your healthcare provider regarding the use of OCREVUS and to report any side effects or concerns promptly.\n"
     ]
    }
   ],
   "source": [
    "result, relevant_images = answer(\"multiple sclerosis treatment\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "multimodel",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
